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The OptiFilt Approach to Biopharmaceutical Filter Testing: Scale-Up to Tangential
Flow Filtration with Fouling
Abstract
Ultrafiltration (UF) membranes are required in the biopharmaceutical industry to concentrate or purify the
final biologic product, thereby ensuring patient safety and fulfilling regulatory requirements. It is crucial
that biotechnology clients select the optimal operating parameters for each filtration step. Unsuccessful
filtrations might fail to purify a near-finished drug product, thereby wasting product and incurring financial
loss. In less extreme cases, failure to optimize filtration steps will lead to slowed filtration steps,
potentially causing bottlenecks and reduced throughput. Overall, efficient, effective filtration is crucial to
the financial success of biopharmaceutical companies.
Generally, these companies pre-test filtration processes using commercially available filter test rigs.
Although commonly used, these filters are geometrically and mechanically simplistic and therefore
provide an incomplete picture of filter behavior. Results from these simple filters do not appropriately
represent the behavior of complex industrial filters. As a consequence, filtration tests are inherently
flawed and industrial processes are not optimized.
OptiFilt will solve this problem by providing more accurate filtration analysis services to biotechnology
client companies. Using proprietary computational models and experimental analysis, OptiFilt will
determine unknown hindered convective and diffusive coefficients of client-supplied test UF material.
OptiFilt scientists will determine the unknown properties by fitting the parameters to a MATLAB model for
dead-end flow with fouling. The results from this MATLAB model will be supplied to a tangential flow
filtration COMSOL model which more appropriately describes industrial filter behavior. Overall, this
process will provide more accurate predictions of filter behavior, thereby allowing our clients to more
effectively optimize their filter operating parameters.
We project that OptiFilt filtration analysis services will help our clients reduce filtration time and increase
throughput by 50%. As a result, clients will enjoy increased profitability. OptiFilt, then, will provide
biotechnology clients with a crucial advantage in these competitive times.
OptiFilt will function as a start-up company, beginning its R&D stage in 2012 and seeking investments in
2012 and 2013. Financial analyses have confirmed that this is a profitable and relatively secure venture,
even in the case of events which could adversely affect the business.
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Dear Dr. Lazzara, Dr. Seider, and Professor Fabiano:
We are pleased to present our completed Senior Design report: The OptiFilt Approach to
Biopharmaceutical Filter Testing: Scale-up for Tangential Flow Filtration with Fouling. This
project solves a problem commonly seen by present-day biopharmaceutical companies. As
explained in our Abstract, it is crucial that companies effectively optimize operating conditions
for industrial filter cartridges.
However, currently in industry, there is a disconnect between instruments used for testing
and the industrial filters used in scaled-up bioprocesses. Generally, industrial filters have
tangential flow filtration, complex geometries, and membrane fouling. In contrast, available test
rigs generally assume normal flow filtration; simple, dead-end geometries; and minimal
membrane fouling. For these reasons, test rigs do not appropriately represent industrial filter
behavior.
Our project provides a more thorough approach to filter testing by using two models of
filter behavior: a simple, dead-end flow model in MATLAB and a more complex tangential flow
model in COMSOL. For a client-supplied test ultrafiltration (UF) filter, a modified test-rig
instrument will be used to collect real-time concentration data in the retentate and in the filtrate.
These data will be imported to our MATLAB model. Using this model, MATLAB will compute
the particular hindered convective and diffusive coefficients describing the test filters. These
parameters will then be supplied to the COMSOL model, which will predict filtration results in
an industrial filter. More accurate predictions will allow clients to optimize operating
conditions—such as applied transmembrane pressure or fluid flow rate—in order to cut filtration
time and increase throughput.

The OptiFilt service is unlike any analysis available to biotechnology companies today.
We are confident that the Company will attract clients by providing superior analyses and
helping clients increase throughput and profitability. Additionally, although this project focuses
on UF, the concept is applicable to viral, sterile, and depth filtration processes as well—all
potential targets for OptiFilt. Financial analyses confirm that even in worst-case scenarios, our
business model is relatively low-risk, and in all except a few worst-case scenarios, OptiFilt stock
issuances offer a very lucrative investment opportunity.
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Abstract
Ultrafiltration (UF) membranes are required in the biopharmaceutical industry to
concentrate or purify the final biologic product, thereby ensuring patient safety and fulfilling
regulatory requirements. It is crucial that biotechnology clients select the optimal operating
parameters for each filtration step. Unsuccessful filtrations might fail to purify a near-finished
drug product, thereby wasting product and incurring financial loss. In less extreme cases, failure
to optimize filtration steps will lead to slowed filtration steps, potentially causing bottlenecks and
reduced throughput. Overall, efficient, effective filtration is crucial to the financial success of
biopharmaceutical companies.
Generally, these companies pre-test filtration processes using commercially available
filter test rigs. Although commonly used, these filters are geometrically and mechanically
simplistic and therefore provide an incomplete picture of filter behavior. Results from these
simple filters do not appropriately represent the behavior of complex industrial filters. As a
consequence, filtration tests are inherently flawed and industrial processes are not optimized.
OptiFilt will solve this problem by providing more accurate filtration analysis services to
biotechnology client companies. Using proprietary computational models and experimental
analysis, OptiFilt will determine unknown hindered convective and diffusive coefficients of
client-supplied test UF material. OptiFilt scientists will determine the unknown properties by
fitting the parameters to a MATLAB model for dead-end flow with fouling. The results from this
MATLAB model will be supplied to a tangential flow filtration COMSOL model which more
appropriately describes industrial filter behavior. Overall, this process will provide more accurate
predictions of filter behavior, thereby allowing our clients to more effectively optimize their
filter operating parameters.
We project that OptiFilt filtration analysis services will help our clients reduce filtration
time and increase throughput by 50%. As a result, clients will enjoy increased profitability.
OptiFilt, then, will provide biotechnology clients with a crucial advantage in these competitive
times.
OptiFilt will function as a start-up company, beginning its R&D stage in 2012 and
seeking investments in 2012 and 2013. Financial analyses have confirmed that this is a profitable
and relatively secure venture, even in the case of events which could adversely affect the
business.
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Chapter 1:

Introduction
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I.

Filtration and Bioprocesses

Membranes and filters play a key role in the production of small-molecule drugs and
biologics.1 The U.S. Food and Drug Administration (FDA), along with its international
counterparts, strictly regulates what quantities and types of impurities are permissible in final
drugs and biologic products (the Code of Federal Regulations governing drug impurities are
included in the Appendix). The filtration process itself is also tightly controlled. All
manufacturing processes must be pre-approved to maximize quality and minimize risks and
hazards; any deviations from pre-approved processes, including the re-filtering of impure or
poorly separated materials is dangerous and often illegal. As such, the ability to predict filtration
conditions is an important step in any biopharmaceutical process. Given the context of this
project, this section will focus on the production of biologic drugs rather than small organic
molecules.
A representative process flow diagram for biologics manufacturing is shown in Figure 11. Filtration is used at several points in downstream biopharmaceutical manufacturing2 to remove
impurities from the final protein product. The type of filter used depends not only on the product,
but also on the impurity of interest. As Figure1-1shows, soon after drugs are produced (via
fermentation or other biochemical steps), they undergo centrifugation to remove the largest
process impurities. Centrifugation is followed by the first filtration step, depth filtration
(sometimes called pre-filtration). Depth filtration consists of several filters in series in which
most biomass and cellular debris is removed. Removing these larger particles prior to finer
filtration steps prevents unnecessary damage to finer filters further in the downstream process.
1

Biologic drugs are those with large, generally protein, active ingredients which are derived from biochemical or
biological processes. In contrast, small molecule drugs are derived purely from chemical processes.
2
In pharmaceutics, a ‘downstream’ process refers to that portion of the larger manufacturing process which occurs
after the drug (or biologic) is produced (the ‘upstream’ process) biochemically. ‘Downstream’ goals include
separation, purification, and packaging of the final drug product.

3

Figure 1 - 1 Representative biologic production process [1-1].

Following depth filtration, undesired proteins are removed from the stream via
chromatography. The product stream is sent through a polish filter to remove any bacteria
introduced to the process during chromatography. A second series of depth filters follows polish
filtration. In this case, the depth filters’ pore size is small enough to restrict the flow of the
protein product through the membrane; the goal in this step is to remove impurities which are
smaller than the drug product (media components from fermentation, acetic acid, buffers, etc.).
The next steps in this representative process include virus inactivation and ion chromatography.
The latter, like filtration, helps to remove impurities from the process stream.
Chromatography is followed by sterile filtration. As the name implies, sterile filtration
ensures the sterility of the final protein product by removing any remaining bacteria. This
4

representative protein product stream undergoes multiple rounds of sterile filtration, which can
be separated by holding periods depending on the product, its impurities, and the scheduling
requirements. Viral filtration is subsequently performed to remove any remaining viruses from
the product stream. Again, multiple rounds of viral filtrations often take place.
Ultrafiltration (UF) is used throughout the process to concentrate the product stream and
further isolate the protein product. For example, this representative process employs UF between
sterile and viral filtration steps to increase the efficiency of steps further downstream. This type
of filtration is also used in the final purification and isolation steps; the goal in these final steps is
to achieve as pure and concentrated a protein product as possible.
In UF steps, an applied pressure forces the product stream against a semipermeable
membrane, thereby removing water and small molecules and concentrating the larger protein
molecules. This type of filtration is the focus of this project.

II.

Types of Filters and Filtration

Even a single chemical process, such as the representative bioprocess shown in Figure 12, contains variety of filters and filtration types. When describing a filtration process, a key
defining characteristic is the type of flow involved. The simplest flow set up is normal or deadend flow, in which fluid flows perpendicular to the membrane surface. Because all fluid is
flowing normal to the membrane, dead-end flow is the most likely to cause a buildup of solute
caking on the membrane surface.
In contrast, in cross-flow filtration, fluid flows parallel to the membrane surface. In this
case, parallel-flowing fluid is able to wash away a portion of the solute cake as it builds; in this
way, cross-flow filtration results in significantly less solute caking than does dead-end flow. The
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caking of solute or impurities on the membrane surface almost always leads to reduced
throughput through the membrane, in addition to premature filter wear. Therefore, cross-flow
filtration is often favorable in industry because is lessens the effects of caking on the filtration
process.
This project primarily concerns UF membranes, although the basic framework is
applicable to a wide range of viral, sterile, and depth filters as well. Generally, for UF
membranes, target solutes range in diameter from 0.001 to 0.1 µm, or have molecular weight cutoffs3 (MWCO) on the order of 1,000 to 10,000 Da. In an UF process such as the ones studied in
this project, the membrane pores are small enough so that the target protein product cannot pass
through the membrane. As solvent and smaller impurities pass into the filtrate, the target protein
is concentrated on the retentate side of the membrane.
In industrial-scale bioprocesses, UF steps usually take place after sterile, viral, and
microfiltration steps take place. The earlier steps in the process help remove large impurities
which would lead to premature fouling if introduced to an UF process. As explained previously,
sterile and viral filters remove bacteria and viruses, respectively, from the product process
stream. As opposed to UF processes, in which the product to be purified remains on the retentate
side of the membrane, sterile and viral filters contain pores which are large enough to allow the
target product to pass through the membrane. Instead, large impurities (bacteria and biomass for
sterile filters, or viruses for viral filters) are held on the retentate side.
Microfiltration functions similarly. In microfiltration processes, pores are large enough to
allow the target product to pass through the membrane. However, these pores are small enough
to prevent the passage of larger particles such as fat globules, cell debris, and colloids. Here, the
size cutoff ranges from 0.04 to 10 µm, significantly larger than that for UF. Again, a
3

The MWCO of a filter is the largest possible molecular weight which can pass through that filter.
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microfiltration step is generally included prior to UF steps in order to prevent premature fouling
and wear of UF membranes.

III.

Relevant Industrial Applications

In the biopharmaceutical industry, UF devices come in a variety of geometries and
materials. Generally, for the aforementioned reasons, these devices employ a cross-flow
configuration rather than normal flow, and their geometries are designed such that the filter
maximizes filter surface area, and therefore process throughput, without requiring an
unreasonably large total filter volume. In other words, industrial filters’ geometries pack a large
membrane surface area into a relatively small total volume. As a consequence, geometries are
complex and difficult to model with normal-flow assumptions. Typical UF devices used in the
biopharmaceutical industry are illustrated in Figure 8-2.

Figure 1 - 2 Typical UF devices used in the biopharmaceutical industry [1-2].

IV.

Key Parameters and Equations

Figure 1-3 shows a typical normal-flow UF process in cross-section. Although this image
shows fluid flowing from left to right, of course, vertical and other orientations are common as
7

well. Here, an applied transmembrane pressure ∆PTM forces solvent, which contains the orange
solute molecules shown, through the membrane of thickness δ. In this case, the molecular weight
cutoff (MWCO) of the membrane is large enough to allow the passage of solute molecules into
the filtrate side of the membrane.

Figure 1 - 3 Pseudo-steady state concentration profile for a normal-flow UF process.

As solute particles flow to the filtrate side, the solute concentration in the filtrate (Cf),
begins to build. The solute concentration in the retentate changes as is dictated by a) the mass
transfer out of the retentate side, and b) the loss of solvent volume on the retentate side, Vr. Note
that we have two possible solute concentration values on this side of the membrane. As flow runs
against the membrane surface, a portion of solute particles flow through the membrane, while
others are retained at the membrane surface. These retained solute particles lead to a buildup of
solute close to the membrane. As a result, the concentration on the retentate side of the
membrane is higher closer to the membrane surface. Although there is an experimentally
8

measurable or apparent Cr, there is a higher concentration at the upstream surface of the
memrane, the upstream or intrinsic Cr,u. This phenomenon is referred to as concentration
polarization.
The dimensionless sieving coefficients describe membrane behavior by comparing the
concentrations on either side of the membrane. Because retentate-side concentration has two
possible values, there are two possible values for the sieving coefficient. First, the measurable or
apparent sieving coefficient is an experimentally-determinable value which compares Cf to Cr.
The apparent sieving coefficient is given


      , (1-1)


In contrast, the intrinsic sieving coefficient compares   



and therefore cannot be

determined directly from experimental data. The sieving coefficient is given




 

 , (1-2)

Because cannot be determined experimentally, we must compute it from
experimentally-determined  values. To relate these two variables, we use the equation
 



 
    

, (1-3)

where vf and kc are the fluid velocity through the membrane and the mass transfer
coefficient of the system, respectively. The mass transfer coefficient is computed as
!

 "#$$% &' (&) (1-4)

where µ and D are the viscosity of the solvent and the diffusivity of the solute,
respectively. In contrast, in our models, vf changes with time and is described by
*+   ,- ./ 0 1.2 (1-5)
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where Lp is the hydraulic permeability constant; σ is the osmotic reflective coefficient,
and ∆π is the osmotic pressure across the membrane. The hydraulic permeability constant is
essentially a measure of how able solvent is to pass through the membrane. In our simplest
models, we have assumed that Lp is constant; however, as the membrane cakes, this actually
decrease for the composite membrane.
The osmotic pressure drop changes with time with or without membrane caking. As Cf
builds relative to Cr,u, the osmotic pressure builds in the direction opposite that of the applied
pressure (toward the retentate), in an ‘attempt’ to reestablish equal concentrations of solute on
either side of the membrane. Experimental data have shown numerous relations between ∆π, Cf,
and Cr,u; these relations are specific to the solute and solvents used. In our models, we have
assumed


.3  "$#456 789 :;#;<<= >  0 <@ , (1-6)
?

to accurately determine osmotic pressure.
OptiFilt relies on a few other relationships to describe the behavior of UF membranes.
First, an overall material balance restricts Cf, Cr, and Vr such that
A
AB



 C  >  D EF 0 


AC
AB

 <-6

By the same idea, the total rate of volume change in the retentate is determined by the
fluid velocity through the membrane, such that
AC
AB

  0EF D  (1-8)

Finally, the structure of the Company’s filtration analysis service requires that we
determine > and >’ mathematically as well as experimentally. To this end, we compute > from
known physical properties of the membrane, using the relation
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HIJ
J KLMNK

>  HI

(1-9)

where O is the partition coefficient across the membrane, P F is the convective coefficient
of the membrane, and Pe is a dimensionless number described by
Q7  

HIJ R S
HIT U

# (1-10)

where Kd is the diffusive coefficient of the membrane studied.

IV.

Membrane Fouling

Previously described models assume no membrane caking or fouling; that is, they assume
that any buildup of solute particles on the membrane surface have a negligible impact on fluid
velocity and hydraulic permeability. In reality, this is never the case. As filtration proceeds,
solute builds up either on the membrane surface or within the membrane pores. These
phenomena effectively reduce the pore size of the membrane, thereby slowing fluid flow and the
filtration process.
A variety of models describe the membrane fouling. As is discussed in further detail in
Chapter 5, the cake-adsorption model was selected in this project because it most appropriately
describes fouling in biopharmaceutical filters. Mathematically, this model uses experimental data
to fit a relation between the hydraulic permeability and time. The changing hydraulic
permeability slows fluid flow and, when introduced to the existing models, provides a more
accurate picture of membrane behavior in real systems. The equations and parameters used for
this model are detailed in Chapter 4.
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Chapter 2:

The OptiFilt Approach

12

I.

Market Analysis

Therapeutic monoclonal antibodies command a market of more than $30 billion annually. Much
research has been invested in the development of therapeutic monoclonal antibodies for the treatment of
various cancers, autoimmune diseases, inflammatory conditions, and infectious diseases that are
characterized by elevated expression of a target protein at a cell surface. The proven safety of and efficacy
of mAbs as a drug class has driven faster developmental and regulatory timelines and the search for more
efficient pipeline of the drugs from their discovery to the market [3-1]. Within the past twenty years, the
United States Food and Drug Administration has approved numerous monoclonal antibodies for
therapeutic use (as shown in Figure 3-1) and hundreds are currently undergoing clinical trials [3-2]. Thus,
on an industrial scale, there is a large market for the efficient production of therapeutic mAbs that can
meet the level of purity required by FDA regulations. The high demand for mAbs has focused attention
on the need for advanced purification techniques and systems to increase the speed, robustness, and
scalabilty of the downstream processes required for mAb manufacturing. The driving force behind mAb
process technology development is improved productivity – achieved by enhancing the ease of operation,
reproducibility, quality control, and process validation.
Therapeutic mAbs are also among the most expensive drugs to produce. Due to a large potential
market consisting of over 500,000 patients, expensive large-scale production capacity is required in order
to produce 10–100 kg/year of each mAb. The high cost of manufacture is further reflected in the cost of
treatment; the annual cost per patient can reach $35,000 for antibodies treating cancer conditions due to
their use for chronic conditions and their relatively low potency resulting in the need for high doses
(grams per patient per year rather than milligrams) [3-3]. The large financial burden associated with the
manufacture of mAbs negatively affects the ability of pharmaceutical companies to manufacture mAbs at
the necessary scale to meet the demand. This problem came to
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Antibody
Trade Name
Company
Muromonab – CD3 Orthoclone OKT3 Centocor (Johnson & Johnson)
Abciximab
ReoPro
Centocor (Johnson & Johnson)
Rituximab

Rituxan

Genentech

CD20
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1997

Daclizumab

Zenapax

Roche

CD25

Humanized

1997

Trastuzumab

Herceptin

Genentech

HER-2

Humanized

1998

Infliximab
Basiliximab

remicade
Simulect

Centocor (Johnson & Johnson)
Novartis

Chimeric
Chimeric

1998
1998

Palivizumab

Synagis

Medimmune

TNFα
CD25
RSV F
protein

Therapeutic Indication
Transplant Rejection
High Risk Angioplasty
Non-Hodgkin’s Lymphoma
Chronic lymphocytic Leukemia
Rheumatoid Arthritis
Transplant Rejection
Breast Cancer
Metastatic Gastric or
Gastroesophagel Junction
Adenocarcinoma
Transplant Rejection
Transplant Rejection

Humanized

1998

Respiratory Syncytial Virus

Alemtuzumab

Campath

Genzyme

CD52

Humanized

2001

Adalimumab

Humira

Abbot

TNFα

Human

2002

Zevalin

Biogen Idec

CD20

Bexxar

Corixa, GlaxoSmithKline

CD20

Xolair

Genentech, Novartis

IgE

Bevacizumab

Avastin

Genentech

VEGF

Humanized

2003

Cetuximab

Erbitux

Imclone, Merck

EGFR

Chimeric

2004

Natalizumab

Tysabri

Biogen Idec

VLA-4

Humanized

2004

Ranibizumab

Lucentis

Genentech

VEGF-A

Panitumumab

Vectibix

Amgen

Eculizumab

Soliris

Alexion Pharmaceuticals

Certolizumab

Cimzia

UCB

Ibritumomab
Tiuxetan
Tositumomab and
Iodine 131
Omalizumab

Target
CD3
GPIIb/IIIa

Type
Murine
Chimeric

Year Approved
1989
1994

B-cell chronic lymphocytic
leukemia
Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Crohn's Disease
Plaque Psoriasis

2002

Non-Hodgkin’s Lymphoma

Murine

2003

Non-Hodgkin’s Lymphoma

Humanized

2003

Asthma
Metastatic Colorectal Cancer
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
Metatastic Renal Cell Carcinoma
Head and Neck Cancer
Colorectal Cancer
Multiple Sclerosis
Crohn's Disease

Humanized
Antibody
Fragment
Human

EGFR
Complement
Humanized
C5
Humanized
TNFα
Antibody
Fragment
CD20
Human

Neovascular Age-Related
Macular Degeneration

2006
2006
2007

Metastatic Colorectal Carcinoma
Paroxysmal Nocturnal
Hemoglobinuria
Chrohn's Disease

2008

Ofatumumab

Arzerra

Genmab, GlaxoSmithKline

CanaKinumab

Ilaris

Novartis

IL - 1β

Human

2009

Golimumab

Simponi

Centocor (Johnson & Johnson)

TNFα

Human

2009

Ustekinumab

Stelara

Centocor (Johnson & Johnson)

Human

2009

Plaque Psoriasis

Tocilizumab

Actemra
Prolia
Xgeva

Rheumatoid Arthritis
Postmenopausal Osteoporosis
Prevention of SREs

Denosumab

2009

Rheumatoid Arthritis

Roche

IL - 11
IL - 23
IL - 6

Humanized

2010

Amgen

RANKL

Human

2010

Chronic lymphocytic Leukemia
Cryopyrin-associated Periodic
Syndromes
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis

Figure 3-1: Therapeutic monoclonal antibodies approved by the FDA. [3-2]
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mainstream attention in 2000 when demand for the antibody Enbrel® exceeded capacity because its
manufacturer, Immunex, did not have the money to build a large enough scale facility to manufacture the
drug in sufficiently large quantities [3-4]. These concerns have increased the pressure to drive down
manufacturing costs of mAbs by an order of magnitude from $1000’s per grams to $100’s per gram [3-3].
The pharmaceutical industry is volatile and high-risk as companies invest billions of dollars into
finding the next billion-dollar drug. Most FDA-approved mAbs are produced in a batch/fed batch culture
of mammalian cells followed by purification steps using chromatography with intermediate sterile, viral,
and ultrafiltration steps in order to remove cell debris, bacteria, viruses, and other contaminants [3-3].
One way to decrease the financial burden of mAb manufacturing is to optimize these filtration steps in
order to conserve the antibodies, increase throughput, lower pressure drops, and decrease operation time
and its associated energy and labor costs. However, the high cost of manufacturing monoclonal antibodies
prevents the use of industrial scale equipment to optimize the filtration process [3-5]. Thus, it is necessary
to develop small scale filtration processes which can reliably predict manufacturing scale performance,
requiring the use of smaller quantities of mAbs and thereby reducing the cost of production and process
characterization [3-6].
Consequently, OptiFilt has a great opportunity to provide in-house testing of filtration processes.
Although such testing services already exist, OptiFilt would be the first to provide important features such
as high throughput, parallel testing, real-time data collection, and information on the fouling mechanism
of the membrane all within the same system. It is this abundance of features and the resulting convenience
that make our testing services more attractive. Our potential clients include smaller manufacturers of
mAbs which may not have employed a filtration scientist, but wish to optimize their filtration process to
reduce their operating costs. Furthermore, these clients may not currently employ a person with
experience using software to model membrane filtration processes. The cost to hire someone with such
expertise or to train a current employee may be too much for a small manufacturer.
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II.

Competitive Analysis
a. SciLog
SciLog manufactures and sells the FilterTec Plus 3-Filter Testing Station, which provides parallel

testing, real-time monitoring, and an automated software interface to perform filterability studies on up to
three filters simultaneously. As shown in Figure 3-7, the sample solution being studied is pumped through
a test filter at constant pressure, typically between 10-20 psi. Using an electronic scale, the cumulative
solution weight (or volume) exiting the dead-end filtration device is recorded as a function of time [3-8].
A single run typically takes about ten minutes [3-9].

Figure 3-2: Sci Log Filter Tec Plus 3-Filter testing Station [3-8] [3-9]
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Assuming a fouling mechanism of a gradual “pore plugging” model, a linear plot of the time
divided by the cumulative solution weight versus the time is obtained. The inverse of the slope of this line
is Vmax, the maximum amount of fluid that will pass through the filter before it is completely plugged [37]. The system also monitors the pressure, feed rate, and collection rate of the operation of the filters,
allowing the user to determine the optimal parameters to give the highest Vmax value for a given filter
and mAb solution.The solution is distributed through the system using the FilterTec Smart Pump, which
maintains the selected backpressure at a constant value by modulating the pump output. Built –in alarms
can also be programmed for each run, allowing walk-away operation and thereby increasig productivity.
TheFilterTec Plus is compatible with a wide variety of 47mm disk test filters. Its operation also offers
much flexibilty – the system can be run at constant pressure or pump rate, in serial or parallel
configuration, or with a programmable continuous changing of pump rate or pressure with time [3-10].
Sci Log also provides an automated software interface with the test rig, Sci Doc, which is implemented
within Microsoft Excel and allows real-time process analysis with graphing of data and documentation of
process parameters (see Figure 3-2).

Figure 3-3: SciDoc , the software asscociated with the FilterTec Plus Multi-filter Capacity testing System [3-9]

Easily fit on a laboratory bench, the FilterTec Plus testing station costs $16, 795 and requires no
other purchases besides test filters.
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b. Millipore
Millipore Corporation provides Vmax Filtration System Optimization, a client service that
performs Vmax testing for the design and optimization of filtration systems used in the production of
pharmaceutical fluid (Figure 3-4). Requiring only small volume of process fluid, the Vmax test can be
performed in about an hour and meaningful results can be gained after only 10 minutes , ensuring its
cost-effectiveness while maintaining its accuracy for scale-up to the industrial level.

Figure 3-4: Millipore Vmax Testing setup [2-7]

The versatility of the service is an important factor – Millipore Validation Specialists are
trained to analyze entire filter trains using this technology. As previously explained, the cumulative
volume is recorded as a function of time at a specified differential pressure (usually 5-10 psi) and
used to calculate the value of Vmax by assuming fouling on the membrane occurs through the gradual
pore blocking mechanism typically exhibited during the filtration of biological fluids [3-11]. Vmax
testing can accurately predict throughput for dead-end filters in less than ten minutes (Figure 3-5).
Millipore will evaluate filters of various media compositions and pore sizes with a wide range of
process fluids
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.
Figure 3-5: Vmax Filtration System Optimization offered by Millipore. Notice the time saved by Millipore’s proprietary
technique. [3-12]

Millipore has also developed Pmax, a sizing
technique for filters operated at a constant flux (see Figure
3-6). The filter resistance to flow - the pressure across the
membrane as a function of throughput – is plotted versus the
throughput of the filter. From this function, the filter sizing
is then calculated within the Pmax sizing spreadsheet. This
method is independent of the fouling model. However, it
requires longer testing times and larger sample volumes than
Vmax testing [3-11].
Figure 3-6: Millipore Pmax testing Setup [3-12]
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To collect and analyze the results of Vmax and Pmax testing, Millipore has developed
proprietary Vmax software (Figure 3-7). This software enables the validation specialists to
recommended filter sizing, filter configuration, and operating conditions for optimization of the entire
filter train.

Figure 3-7: Software associated with millipore’s optimization package. [3-12]

For new processes, Millipore offers its validation and optimization services free of charge for the
first time. For the optimization of validation testing of existing processes, the prices vary depending on
the size of the process, the cost of travel to the site, the time required to optimize the service, and the level
of service need. This typically costs $1,000 to $1,500 per day depending on the level of service needs. For
example, consultation or training could be less costly than troubleshooting and programming. At a large
scale, 3-5 days would be needed depending on the complexity of the system, for a site test, adding up to
about $7,500 to optimize an entire filtration process.

c. OptiFilt – Overview of Science and Software
As previously mentioned, OptiFilt will provide filtration testing services using laboratory scale dead-end
filters to client companies and recommend optimal operating conditions for scale-up to other filter
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geometries used at the industrial scale. For the purposes of illustration, this report will focus on scale up
to a tangential flow ultrafiltration membrane module. Using the FilterTec Plus Multi-capacity Testing
Station as a base, the testing rig will monitor conditions such as pressure, filtrate and permeate volume,
filtrate and permeate velocity as a function of time. Refractometers will measure the index of refraction
of the filtrate and permeate, which can then be used to calculate the bulk concentration of the filtrate and
permeate of each filter as a function of time. In order to determine the operating parameters for optimal
performance of the filter, parameters such as the pH, solute concentration, and applied pressure will be
varied and tested in parallel to conserve sample. Chapter 7 includes a more detailed explanation of this
instrumentation. The data collected will then be imported and analyzed using a one-dimensional model of
the mass transfer involved in dead-end membrane filtration which is implemented in MATLAB.

i. MATLAB Model
Briefly, parameters such as the initial sample volume, initial sample concentration, mass transfer
coefficient, initial hydraulic permeability, and the cross-sectional area of the membrane will be inputted
into the model. The model with then solve a differential-algebraic system of equations describing the
mass transfer across the dead-end filter , and produce plots showing how the concentration and volume of
the filtrate and volume, the osmotic pressure across the membrane, and other parameters change as a
function of time. Chapter 3 will discuss the mass transfer equations for the normal flow filter in more
detail. Most importantly, the MATLAB model utilizes simulated annealing, which fits an estimate of the
unknown intrinsic properties of the membrane to the data. Chapter 5 will discuss the MATLAB model
and simulated annealing in further depth. The determined values for the intrinsic properties will then be
used to model the industrial crossflow filter in COMSOL.

ii. COMSOL Model
A finite element solver, COMSOL Multiphysics was used to simulate the mass transfer and fluid
mechanics with the industrial filter. A simplified two-dimensional model of tangential flow filtration was
drawn within its interface. The Navier-Stokes Equation modeled the flow of the mAb solution within the
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channel of the filter, the Brinkman Equations modeled its flow within the membrane, and a species
balance modeled the convection and diffusion of the mAbs within both the channel and membrane. The
appropriate boundary conditions were then set – operation by a constant applied pressure was assumed
and the flux through the membrane was calculated using the intrinsic properties of the membrane
determined using MATLAB. Chapter 6 will further discuss the COMSOL model.

d. Pricing Analysis
As Chapter 8 will further explain, OptiFilt plans to charge $150,000 to perform filterability trials
for client biotechnology companies. This price is much more expensive than the cost of purchasing a
FilterTec Plus 3-Filter Testing Station directly from Sci Log or utilizing Millipore’s testing services.
Although each utilizex Vmax testing, the service provided by OptiFilt is superior to that of Millipore and
Sci Log for several different reasons. Our testing rig is able to test membranes in parallel, allowing us to
provide our clients with results more quickly. Furthermore, our testing rig includes refractometers to
provide information on the concentrations of the filtrate and permeate during filtration. Vmax testing, on
the other hand, only predicts the total throughput of the filter. Furthermore, the MATLAB model will take
in account numerous modes of membrane fouling, while Vmax testing is only applicable when fouling
occurs according to the gradual pore-plugging model. In addtion, although Millipore and Sci Log offer
their product and serives for much cheaper, the service provided by Optifilt is more useful because it is
able to scale up to any geometry. Whereas a company that utilizes different filtration processes would
have to buy multiple test rigs from Sci Log or utilize Millipore’s service multiple times for different
geometries, the MATLAB model can be easily scaled up to the chosen geometry drawn within the
COMSOL interface. In addition, many industrial filters are operate at flows within the transitional
regime. The COMSOL model is able to accurately model complex flow characteristics both at steadystate and transiently.
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Our decision to provide testing services rather than to sell the testing rig has two main advantages
for the survival of our company and the convenience of our client. For our company’s benefit, providing a
service ensures us a stream of recurring revenue as biotechnology companies will have to request and pay
for our service when developing a new process or streamlining an older one. If we chose to sell the test
rigs, demand could decrease as the market becomes saturated with our equipment. From the perspective
of our prospective clients, although they would be paying more money by using our service multiple
times rather than purchasing the filter station for themselves, they would access the expertise of a
company that focuses completely on membrane filtration. Furthermore, because a biotechnology
company would likely work to optimize a process a few times per year, they avoid having the filter
station taking up space within their facility and remaining unused for most of the year.
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Chapter 3:

Concept Stage
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I.

The OptiFilt Approach
OptiFilt aims to deliver high-throughput testing of membrane filtration conditions in parallel in

order to improve the ability to identify optimal operating parameters for the ultrafiltration of mAb
solutions at a laboratory scale for use in increasing the efficiency of the production of mAbs at the
industrial scale. This project consists of four main goals: designing the instrumentation and physical
specifications of the testing rigs and determining its cost, developing software that can accurately model
mass transfer properties of the normal flow filtration setup within MATLAB, modeling the mass transfer
and fluid mechanics of the filtration with the tangential flow setup, and providing a feasible plan for a
start-up company which receives samples of mAb solutions from clients and identifies conditions for
efficient filtration.
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a. Project Charter
Project Name

The OptiFilt Approach

Project Champion
Project Leaders
Specific Goals

Dr. Matthew Lazzara
Elizabeth Blake, Jennielle Jobson, Nikhil Shankar
Design a high-throughput dead-end ultrafiltration
system and the software necessary to test filtration
conditions in parallel to identify optimal operating
parameters for the tangential flow filtration of
mAbs
In Scope:
• Design of the test rig and its equipment
• Develop analytic models to characterize
laboratory-scale dead-end filtration in
MATLAB and industrial-scale cross-flow
ultrafiltration in COMSOL
• Provide in-house testing of filtration
processes using protein solutions and
membranes provided by clients
• Develop a working business model
• Test rig must utilize parallel testing of
membrane in real time
Out of Scope:
• Expansion of testing to sterile and viral
filtration membranes
• Detailed instrumentation of the test rig
• Integration of the filtration process into
manufacturing process of mAbs
• Market assessment and competition
analysis
• Technical feasibility assessment
• Financial and sensitivity analyses over the
course of 8 years
• Manufacturing capability assessment
• Product life-cycle assessment
• Construction of the test rig, process
development, and implementation of the
analytical models within 12 months
• Scale-up operations within 2 years
• Full scale production in years 4-7
• Continue with the company, liquidate
assets, or sell the company after the
conclusion of the eight year

Project Scope

Deliverables

Timeline

Table 2.1 OptiFilt’s Project Charter
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b. Technology Readiness Assessment
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Chapter 4:

Dynamic, Dead-End Flow
Test Rig Models
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I.

Assumptions of the Test Rig Model

The test rig is intended to improve UF performance on an industrial scale, and to lessen
the chance of UF failure and associated financial burden. As such, the model needs to emulate
reality as closely as possible to be generally applicable, while still remaining highly customizable
to the demands of the company.
A set of interdependent differential and algebraic equations were derived to define the
time-dependent behavior of flux, > and >. These were solved simultaneously in MATLAB
R2010a both in the complete absence of fouling and the presence of cake-adsorption fouling.
While the standard (pore-plugging) model is generally sufficiently accurate [4-2], the cakeadsorption model is considered the most relevant for to mAb filtration fouling [4-1] and is
therefore used in this model. Should a company prefer another type of fouling evolution, the
modifications are quite simple. However, some other fouling models result in decreasing pore
radius, or increasing membrane thickness, and the model operator should take care to consider
that these values are now variable. In the cake-adsorption fouling model for mAb, resistance
builds up because of topical cake formation of (relatively) small thicknesses, compared to the
filter [4-8]. When cake fouling appreciably affects membrane thickness, flux decreases
markedly, the membrane rapidly approaches capacity, and the filter is washed. Therefore,
membrane thickness is assumed constant during the span of functional operation. Nevertheless, it
would technically be an improvement to this model if membrane thickness were recorded as
variable. The cake-adsorption model also assumes that caked foulants are incompressible, though
this is not always true. In the case of mAb deposition, however, and for most other proteins, this
is a safe assumption [4-1].
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It was decided that the UF model would run under constant trans-membrane pressure
(pressure), rather than constant flow rate (flux), as the former is the most common type of
laboratory filtration performed today [4-3]. If filtration is indeed desired at constant flux, the
model can be adjusted to accommodate the change by replacing the flux relationship with one of
pressure and by changing the empirical equations for fouling into their new constant-flux form.
The most recently developed fouling models were designed to be able to predict the membrane
capacity in one mode of operation when data from the other mode was fit to the correlation [4-8].
This has not always been the case; the two modes of operation have long been considered vastly
different, and only in 2006 were hybrid fouling models created. Today, fortunately, changing
from constant flux to constant pressure operation, upon request by the company, is
straightforward.
The extent of CP is reflected in the model by the difference between > and >. The model
equations used as correlations for > and >are standard in membrane science; the true sieving
coefficient is a function of the products ΦKc and ΦKd, and apparent sieving coefficient is a
function of the true one. These algebraic relationships are always true [4-7].
The sieving coefficients are also dependent on kc. Many different theoretical equations
and correlations exist for the specific kc of various materials and flows. Thus, an appropriate
estimation for kc should be obtained and entered into the model prior to simulation. This model
uses the kc correlation for the general case of a CSTR that provides ideal mixing, or constant C∞,
and whose base is replaced by a standard UF membrane [4-7]. This approximation vastly
simplifies calculation. This kc equation (a function of µ and U) is generally valid for most
solutions but it would be ideal to use a more specific correlation if one is known.
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Electrostatic effects are highly dependent on solution composition, and are not the
dominant contribution to flux decay in membrane dynamics [4-10]. Most solutions do have
charged species, but if molar concentrations are high, these effects are overwhelmed. It is
possible, of course, that a certain protein (e.g. albumin) or membrane polymer possesses enough
charge at particular solution conditions to significantly affect fouling beyond that predicted by
classic pore or thickness adsorption. In this case, repulsion or attraction yields decay in flux that,
nevertheless, may still be properly fit to a Kc and Kd pair. If electrostatic effects are suspected,
either upon inspection of the protein to separate or because of optimization failure, the technician
may utilize an available approximation to the Poisson-Boltzmann equation, or other available
theoretical model [4-10], to consider them in this model [4-11].
∆π always acts in opposition to the driving pressure applied to the UF system, and
increasingly slows filtration over time. While ∆π is a colligative property, equations that properly
predict its magnitude vary significantly based on the type of protein in the system, temperature,
charge, and other properties. For a specific solution to be filtered, the natural osmotic pressure
across a semipermeable membrane should be determined by experiment (or extracted from
literature), fit to equation, and entered into the model. For this model, the ∆π correlation was
found experimentally for constant solution pH and substance charge [4-9] and the resulting
equation was used to model osmotic effects in the simulation. It is never desirable to use the
Morse correlation for dilute solutions to approximate ∆π, as the osmotic effects in relevant
concentration regimes are not linear.
The remaining variables (viscosity, diffusivity, membrane length and cross-sectional
area, applied pressure, osmotic reflection coefficient, starting permeability, initial volumes and
concentrations) are case-dependent and can freely be adjusted based on a company’s
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specifications. These are all held constant. The model operator should find accurate values
(usually readily tabulated in literature) to eliminate constants as any potential source of error. A
restriction with this model is its limitation to only one dominant solute in the sample. The model
will accommodate as many solutes as desired, as long as there are no solute-solute interactions,
and as long as any solute beyond the first contributes negligibly to the gel-based CP at the
membrane boundary.
Once the general model successfully predicted results for a sample set of mAb filtration
data, the code was overhauled to function as an optimization algorithm. The new model accepts
empirical results (which should be collected from a bench-scale experiment) detailing the
behavior of > and > over time. Then, using a simulated annealing (SA) algorithm, the model
performs a two-parameter fit, selecting the optimal ΦKc and ΦKd that yield results that minimize
the sum of squares of the residuals (SSR) between data and simulation. In trial runs, this method
of optimization took between 3 seconds and 7 minutes on an Intel Core i5 CPU, depending on
the proximity of the initial guess to the true global minimum. Thus, this method, while
potentially fairly lengthy, is quite exhaustive and thorough. If no global minimum is found, or if
the minimum is too large, the model operator should try other suspected fouling models to see if
fit can be improved. ΦKc and ΦKd are strong decaying exponential functions of membrane
radius, so a fouling model that assumes material deposition within pores would not fit a constant
ΦKc and ΦKd. Rather, the SA algorithm would fit constants in a generic function ΦKc = exp(Ar)
and ΦKd = exp(Br), where r is pore radius and A and B are presumably negative [4-7]. If all
suspected fouling models also fail, the technician should consider electrostatic effects, or
consider introducing a minute time delay to account for this model’s intrinsic assumption of
instant reaction to filtrate conditions at the retentate-membrane boundary.
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SA relies on several variables which must be carefully selected by the technician,
specifically: the lower and upper bound of search space, maximum error tolerance, and
temperature (step size) profile. In recent years, adaptive simulated annealing (ASA) has gained
popularity as an algorithm which self-modifies these parameters as optimization progresses. In
this manner, ASA allows far more leniency in parameter selection. However, these parameters
can quite easily be determined by the technician prior to running a simulation for a company.
Additionally, while ASA is a more automated process, it results in longer processing times.
There is therefore no particular need to modify the model to use ASA instead of SA. Both
algorithms always require that the technician provide an initial starting point.
UF is a highly scalable process, but the geometry of flow is extraordinarily different
between the testing-rig and industrial-rig scale. A given UF membrane is fully defined by Kc and
Kd, the particular hindered convective and diffusive coefficients of that filter [4-6]. (Models for
Φ are readily available, and once the products ΦKc and ΦKd are found by SA, Kc and Kd can
easily be extracted.) However, the MATLAB model functions over the breadth of very simple,
dead-end flow, and a basic square membrane. In an industrial setting, companies typically prefer
crossflow over dead-end flow, as less fouling occurs and the membrane can easily be washed
after use [4-5], and utilize more complicated geometry, such as cylindrical tubes. Crossflow and
more complex geometries create more difficult flow conditions, introducing internal eddies, dead
flow, and position-dependent Reynolds number regimes. Therefore, for the purpose of accurate
scalability, the optimal Kc and Kd from the MATLAB model are imported into COMSOL, where
the desired flow geometry is emulated. In COMSOL, boundary conditions of the UF membranes
are well-defined by these fit parameters. Time- and space- dependent flow and concentration
patterns can then be extracted from the simulation results, and analyzed by a technician. If the
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profiles are undesirable, or fouling is extensive, filtration variables (e.g. pressure, membrane
MWCO) and/or geometry can be freely adjusted, and new results obtained.

II.

Model without fouling

The first model was designed under the highly simplified assumption of no fouling. This
model is defined by a differential algebraic equation (DAE) system, consisting of two ODEs and
five algebraic relationships, which were derived, drawn from literature, or fit from experimental
data. The equations are described below.

AC

AB

A
AB

  0EF D for Vr ≥ 0, (1-8)



 C  > D EF 0 


AC
AB

 for Cr ≥ 0, (4-1)

In these equations, Vr is retentate volume, Ac is cross-sectional area, vf is filtration
velocity, Cr is retentate concentration, and> is the apparent sieving coefficient. Recall that
Equation 1-8 implies that loss of volume in the retentate side of the testing rig is based solely on
filtrate flux, which is a realistic statement. Equation 4-1 is a mass balance.

D  VM .QWX 0 Y.3 for vf ≥ 0, (1-5)
Here, Lp is the hydraulic permeability, .QWX is pressure, Y is the osmotic reflection
coefficient, and .3 is the osmotic pressure. Pressure is the driving force for membrane filtration,
and flux is directly proportional to the net pressure [4-12], where the constant of proportionality
is Lp. Because of the tendency for Cr,u to increase over time (due to CP), the trans-membrane
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concentration gradient and osmotic pressure will increase over the course of filtration. This
opposes flow. Y is a factor that corrects for real-world deviation from the ideal semi-permeable
membrane. Though assumed constant in this model, Y may be variable, in which case it is
exclusively a function of > (which is itself a function of Cr,u) because such boundary
concentration buildup has the potential to alter the membrane’s ability to effectively exclude
solute. One reference uses Y  < 0 >, which can be inserted into the model with fouling for
trials where > is on the order of 10-1 or greater [4-7].

Q7  

HIJ R S
HIT U

for Pe ≥ 0, (1-10)

O is the partition coefficient, Z is membrane thickness, U is diffusivity, and Kc and Kd
are, respectively, defining convective and diffusive coefficients of the membrane. The Peclét
number, Pe, is the dimensionless ratio of the convective elements of flow to the diffusive
elements of flow. It is an integral aspect of CP and general membrane dynamics. No sufficiently
accurate models exist for the products OP F and OP [ for most membrane materials (though there
are models for straight-pore membranes) [4-7], which necessitates the optimization-based nature
of this model.
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for 0 ≤> ≤ 1, (1-9)
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0 ≤> ≤ 1, (4-2)

Equations 1-9 and 4-2 define > and > according to accepted models [4-7].


.3  "$#456 789 :;#;<<=^_    0 <@ 
24 mm Hg≤.3≤ 3840 mm Hg (1-6)

The osmotic pressure equation above is empirically defined as a best-fit equation to
experimental pressure measurements from [4-9].
This model utilizes a simultaneous equation solver to produce time-dependent results.
MATLAB offers a multistep solver function called ode15s, designed for stiff ODE solutions
and general DAEs, which uses the numerical differentiation formulae as algorithms. DAE
solvers, ode15s included, require both initial conditions for the ODEs and good guesses for the
algebraic equations. If these guesses are inadequate, or mathematically inconsistent, the solver
simply terminates. A consistent set of initial guesses can be approximated by the model
technician, or the function fmincon can be used. fmincon minimizes the normalized sum of
the five algebraic equations above given filtration conditions set by the company.

a. Results
Model results for a standard run (with realistic values for all relevant constants, provided
below) are shown below in Figure 4-1(a) through (g). Hydraulic permeability values were
identified from Biomax UF membrane product sheets as approximately 3 LMH/psi, or 1.612 x
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10-8 m/s mm Hg [4-13]; remaining constants are from Millipore product sheets detailing
appropriate usage of the company’s UF membranes [4-14].
The results from the no-fouling model can be
divided into two regimes: where osmotic effects are
negligible, and where they are significant.
Figure 4-1(a) shows how the volume of 5 mL
filtrate decreases linearly for the first part of the
(a)

simulation, which, upon inspection of Equation 1-8,
must be caused by a constant or near-constant
filtration flux. As Figure 4-1(c) shows, this is indeed
the case, up until approximately 120 seconds.
Therefore, 0 ≤ t ≤ ~120 sec is mostly pressuredependent, in that mainly the applied trans-membrane
pressure affects results. During this time span, ∆π

(b)

increases to 30 mm Hg, but while the applied ∆PTM
during this trial was 100 mm Hg, trans-membrane
pressure still dominates. Figures 4-1(d) and (e) show
how > and > increase relatively slowly in this first
regime. In the absence of osmotic effects and fouling,
the membrane is functionally a much more permeable
membrane, both to solute and solvent. While solute

(c)

flows through the membrane at a steady pace, solvent
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does so as well, and though filtration is occurring
(and mass is transferring), concentrations change only
gradually. Then, since > 



 

and > 





, both

exhibit little change.
Following this, Cr,u at the membrane boundary

(d)

continues to increase until osmotic effects become
significant, and the system also becomes
concentration-dependent. In this regime, in spite of
increasing osmotic flow, CP increases as the
simulation continues due to practical limitations of
(e)

mass flow within the membrane. Particles cannot
flow through the pores instantly, causing mass
buildup. Additionally, because of the significant
osmotic pressure, some solvent flows back through
the membrane from the filtrate to the retentate,
dramatically concentrating filtrate product and
decreasing net pressure and velocity. Though both >

(f)

and > now quickly increase, > does so faster than >
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implying the presence of CP in the model. As flux is
lessened, filtrate volume decreases more gradually,
tending to zero asymptotically. In the presence of
very limited volume, the remaining mAb mass
becomes very highly concentrated (as shown in
(g)
Fig 4-1: Membrane and flow dynamics in
the fouling-free model. MATLAB stops
the trial at 158 seconds.

Constants used as real-world approximations
∆PTM =100 mm Hg
µ = 10 cP
σ=1
Lp =1.612x10E-8 m/s mm Hg
U =10E-8 m2/s
Ac = 5 cm2
OP F =0.01
OP [ =0.02
L = 1 mm

Figure 4-1(b)). Figure 4-1(g) shows, however, that the
remaining mass of mAb on the retentate side of the
membrane is decreasing, as expected. Figure 4-1(g)
also shows that mass is filtered at a faster rate when
filtration becomes concentration-dependent, which is
due primarily to the very high Cr,u associated with this

regime. Therefore, although solvent flow decreases, solute transfer increases and the majority of
filtration occurs near the end of the trial. As OptiFilt trials aim for minimal transfer of product
mass through the UF membrane, significant undesired activity occurs in the concentrationdependent regime in this idealized, fouling-free model. If this behavior was actually observed in
real experimental runs, companies would run UF purification only to the second regime, and then
cease trials to prevent product loss.
Filtration nears completion when osmotic pressure approaches applied pressure, as all
filtration activity stops as flux nears zero. There is consistently a minute amount of mass
remaining on the retentate side after the simulation stops.
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b. Limiting cases
To ensure that the model predicted trends that agreed closely with reality, the limiting
cases of > and > ≈ 0 (complete impermeability to solute) and > and > ≈ 1 (complete
permeability to solute) were tested. It is important to recall that constant sieving coefficients do
not imply constant concentrations, only constant concentration ratios.
For > = 0.01 and > = 0.02, one expects that because of the minimally permeable
membrane, mAb proteins will filter through the membrane only until the osmotic pressure equals
the applied pressure, at which point filtration (but not transport) will stop. One also expects that
overall mass transfer will be small. This bounded model is fundamentally different from the
previous model because it restricts the behavior of Cr,u, and limits the degree of CP that can exist.
In limiting Cr,u, osmotic pressure increases proportionally to the degree of filtration, and only
gradually approaches applied pressure. As discussed earlier, Cr,u increases exponentially in the
normal model because of increasing Cr and ever-flowing forward filtration rate. These conditions
create a type of feedback loop which leads to the unexpected result of faster mass filtration at
longer times. As Cr,u is not permitted this exponential growth when so bounded by > and >, the
behavior of osmotic pressure should be much more controlled, and exponential increases in
concentration should not be seen at long times. Rather, all concentrations are expected constant
prior to model termination.

40

(a)

(b)

(c)

(d)

Fig 4-2: Membrane and flow dynamics in the fouling-free model under the constraints of > = 0.01 and > = 0.02,
otherwise same constants as above. Notice the presence of a third regime where filtration slows down again,
beginning at t = 145 s.

Figures 4-2(a) through (d) show the results of a simulation under these constraints.
Beyond the prior two regimes discussed in the unconstrained model, there now exists a final
third regime in which filtration slows and the feedback loop is broken by > and > constraints. As
expected, overall mass transfer is small, with only 1.7 µg passing through the membrane.
Because volume is non-zero at long times (since slowing effects of the third regime stop the
feedback before Vr = 0), final retentate concentration increases from 10 g/m3 to 64 g/m3, instead
of tending to infinity as before. Finally, of special note is the behavior of osmotic pressure and
velocity, which more clearly support the existence of a third regime. While flux and ∆π
approached final values quickly in Figures 4-1(c) and (f), their graphs here have a point of
41

inflexion where function slope begins to tend gradually to zero as the variables tend toward zero
flux and 100 mm Hg, respectively. Therefore, the results for an impermeable membrane seem to
agree with expected membrane behavior under this condition.
For > = 0.98 and > = 0.99, the maximally permeable membrane, solute and solvent
particles flow freely through the membrane at all times and at all filtrate and retentate
concentrations. Since particles flow through the pores so quickly, slower flux on the retentate
side (causing CP) is minimal. Thus, the membrane is scarcely an impediment to mass transfer at
all. As Cr,u never increases to critically large values, simulation results under this constraint
should solely emulate the behavior of the pressure-dependent first regime.

(b)

(a)

(c)

(d)
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Fig 4-3: Membrane and flow dynamics in the fouling-free model under the constraints of > = 0.98 and > = 0.99,
otherwise same constants as above. Functional response is constant throughout; one regime only.

Figures 4-3(a) through (d) show the simulation results under these conditions. Figure 43(d) shows the expected constant rate of decrease of retentate mass, in agreement with the
constant rate of decrease of retentate volume (not shown). Note from Figure 4-3(b) and (c) that
filtrate velocity and osmotic pressure are functionally constant throughout the entire trial, as
observed in the pressure-dependent region of the normal model. Figure 4-3(a) shows a small
increase in concentration, from 10 g/m3 to 10.58 g/m3, because the membrane was modeled as
nearly perfectly permeable, with > ≠ 1. (This was done to avoid computational discontinuities
associated with extreme values.) All of the results from this scenario fundamentally emulate the
responses of the variables in the first regime of the unbounded model, as predicted, and it can be
said with some certainty that the model without fouling is successful at predicting fouling-free
membrane dynamics.

III.

Model with fouling

To add fouling, the foregoing equations were reused, and Equation 4-3, defined below,
was added to the model. Fouling models define the dimensionless ratio of current flux to
maximum (initial) flux in constant-pressure operation, or alternatively, define the ratio of current
pressure to initial pressure in constant-flow operation. For either type of operation, the fouling
equations can be manipulated to express fouling as a ratio of current Lp to initial Lp. This can
then be inserted into the model quite easily. Fouling will always lead to decreasing hydraulic
permeability over time, though this rate of decrease is a function of many variables, and the type
of fouling model chosen has significant effects on the model results [4-8].
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For 1.0 kg/m3 BSA trials, varying pressure to 2, 5, 10, and 20 psi, through 0.2 µm track-etched polycarbonate
membrane, Ka and Kc were selected at 5.03 x 106 s/m2 and 3.36 x 10-4 s-1, respectively. Analogous values for Ka
and Kc in the case of mAb filtration were not available in literature, and so were tentatively approximated as
above in the design of this model. [4-8]

In Equation 4-3, Lp,0 is initial hydraulic permeability, .3k is initial osmotic pressure, and
t is time. Equation 4-3 is for the cake-adsorption model, with Ka and Kc fit to the type of solution
being filtered. To properly utilize any fouling model, a technician must first find acceptable
values for these parameters. Doing so is straightforward. While holding all other variables
constant, the technician should record four or five time-dependent profiles of flux (taken over a
range of pressures) from experimental trials. Osmotic contributions to each case should be
predicted by Equation 1-6 or similar correlation, to isolate the effect of decreasing permeability
on flux. Then, using simulated annealing in a manner not unlike how the algorithm is used to
extract OP F and OP [ , Ka and Kc should be selected as the pair that minimizes the SSR between
l

equation ( = f(∆PTM), as above) and reality [4-8]. Other fouling models like intermediatel
b

adsorption or complete-adsorption have at most two fit parameters, with some having only one
[4-8]. Following determination of constants, Equation 4-3 may be inserted into the model with
fouling, which is then capable of predicting membrane behavior of any variable at any provided
trans-membrane pressure.
The late-stage increased rate of filtration found in the first model was valid for a nonfouling, ideal case, and is therefore unlikely in actual filtration systems. However, under certain
conditions and assumptions of fouling, the simulation terminates before system variables are
equilibrated due to Vr = 0. In early termination, it is possible for fouling to not sufficiently
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impede the natural Cr,u buildup, in which case the idealized filtration behavior may occur. In
normal cases, fouling plays too great a role in flux decay for the aforementioned feedback loop
to occur, and late-stage filtration is slow, not fast. Knowledge of the filtration conditions that
cause either behavior and/or allow equilibration of concentrations is, of course, valuable to the
customer company.
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e. Results using identical conditions as in the fouling-free model
To run the simulation and obtain results, a similar ode15s and fmincon solution was
used. To ensure that the effects of fouling on all variables could be readily identified, all
simulation conditions were kept identical to the non-fouling model (though this resulted in the
model terminating before equilibration, i.e., zero flux). No other changes were made, for the
purpose of obtaining comparable results.
Figures 5-4(a) through (h) show the results
from the model with fouling. Here, there are no clear
“regimes” of operation, as the trends of system
variables change dramatically with small changes in
(a)

constants (which can be seen by comparing Figure 54 to Figure 5-5).
Fouling causes Vr to decrease non-linearly
with time throughout the range of time constraints, as
(b)

expected, due to the decreasing hydraulic
permeability caused by the cake-adsorption fouling
effects, shown in Figure 5-4(h). Under the conditions
of this trial, Vr does equal zero at long times,
effectively ending the simulation. For various

(c)

permutations of constants (permeability, pressure)
and initial conditions, one often finds that the model
terminates simulation with a more plausible non-zero
final retentate volume, as shown in Figure 5-5 (with
(d)
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constants and ICs shown). For instance, if initial Vr is
increased in the trial of Figure 5-4, hydraulic
permeability decreases too quickly for all of the
volume in the retentate to be filtered. Osmotic
(e)

pressure is consistently increasing, so there comes a
time when ∆π = ∆PTM and remaining volume on the
filtrate-side is simply under no net driving force for
fluid filtration.

(f)

When using this model, it is also important to
take into account the variability of Z and/or r, if the
selected fouling model and operation conditions
appreciably affect these terms over the trial. This is

(g)

easily done by adding another equation defining the
nature of pore decrease or thickness increase, with
such equations being pulled from supplementary
information about the fouling model. For mAb
fouling modeled by the cake-adsorption fouling

(h)

model, Z and r do not change appreciably, so such
equations were not used in this model.
With fouling, filtration took approximately

Fig 5-4: Membrane and flow dynamics in
the complete model. MATLAB stops the
trial at 541 seconds, compared to 158
seconds in the fouling-free model.

three times as long to complete, with “completion”
defined as the time when either Vr or vf decreased to
0.5% of its initial value, whichever occurred first.
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Constants used as real-world approximations
µ = 10 cP

∆PTM =100 mm Hg

σ=1

U =10E-8 m2/s

OP

OP F

Additionally, overall mass transfer was greatly
decreased, with only 2 µg of mAb successfully
passing through to filtrate (compared with nearly 48 µg in the fouling-free model). Furthermore,
> and > are significantly smaller than they were in the absence of fouling, suggesting that only
minor filtration has occurred.
Osmotic pressure increases at long times to approach applied pressure, but the simulation
ends before ∆π = ∆PTM, as shown in Figure 5-4(f). Both > and > increase as the simulation
progresses, implying the presence of increasing amounts of mAb mass in the filtrate as time goes
on. These trends are entirely expected [5-6]. Companies must provide a threshold for acceptable
amount of product loss in the filtrate, and a guideline as to what degree of concentration they
desire in retentate product.

f. Results using conditions that permit equilibration
To obtain a more complete analysis of the membrane, conditions were varied so that the
simulation would terminate only after reaching equilibrium (i.e., after satisfying the vf criterion
for completion, such that net flow is nearly zero). These trial results are not directly analogous to
the results from the fouling-free model, but they are more realistic, in that they are expected to be
observed in practice.
Figure 4-5 shows the behavior of several
variables when the model reaches zero net pressure.
The major and most significant change is for Lp, which
is decreased by two orders of magnitude. These
(a)
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conditions lead to much longer simulation time scales,
of about 45 min. In this case, the simulation ends
because of vf approaching zero, not Vr doing so as in
(b)

Figure 4-4. Vr now terminates at about 88% of its
initial value.
Non-zero steady-state Vr is expected (and
required) in real filtration since solutes of greater

(c)

molecular weight than the MWCO will remain on the
retentate side [4-3] and because cross-flow filtration,
which is preferred over dead-end flow, physically
requires the presence of some volume for flow. For

(d)

these reasons, zero Vr is simply nonphysical.

One also notes that over the scope of this trial, > and >
Fig 4-5: Membrane and flow dynamics in
the complete model, with lower
permeability than in Fig 4-4.
Constants used as real-world approximations
∆PTM =100 mm Hg
µ = 10 cP
U =1.12E-8 m2/s
σ=1
Ac = 5 cm2
OP F =0.01
OP [ =0.02
L = 1 mm
Lp = 4.48E-10m/s mm Hg

are generally larger than they were in Figure 4-4. This
tremendous improvement in apparent membrane
permeability when shifting Lp in a direction that should
lead to poorer throughput clearly suggests that the

previous trial terminated before the system reached equilibrium. Since permeability never
reaches zero (only approaches it), there is consistently an available avenue for equilibrating
concentrations. It therefore seems appropriate to redefine “completion” as the time for vf to
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decrease to 0.5% of its initial value, where systems that exhibit the Vr condition are nonphysical,
and modified to exclusively satisfy the vf criterion.
In further support of this constraint for the model, Figure 4-5(d) shows the rate of mass
transfer. Instead of faster filtration at longer times, mAb transfers quickly early on and more
slowly as fouling increases and permeability decays. This behavior is observed in physical
models and indicates promising model results.

g. Limiting cases
The limiting cases of near-zero and near-unity > and > were analyzed in the model with
fouling as well. The results again suggest internal consistency.
For > and > ≈ 0, plots for Vr, vf, and Lp should be comparable to those of Figure 4-5. In
the case of no fouling, this limit resulted in large values of ∆π which eventually approached
∆PTM and stopped flux. However, for these parameters, and with fouling, the minimally
permeable membrane no longer relies on osmotic pressure to implicitly define the time span of a
trial. For both free and restricted > and > , the system still undergoes the same degree of fouling,
and in the latter case, this fouling replaces osmotic pressure as the principal retarding force of the
model. Therefore, the plot of ∆π is expected to vary only slightly from initial values, reflecting
slight CP. Finally, mAb filtrate mass should be minimal, since the membrane is nearly
impermeable.
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(a)

(b)

(d)

(c)

Fig 4-6: Membrane and flow dynamics in the complete model under the constraints of > = 0.01 and > =
0.02, otherwise same constants as above.

Figure 4-6(a) through (d) show this predicted behavior. Vr is unaffected by this change,
as is vf, osmotic pressure increases only minimally, and a mere 0.12 µg of mAb is filtered.
At the other extreme, > and > near unity, predicted trends again vary from those
expected for the fouling-free model; and once again, this is because Lp is unaffected by > and > .
Since osmotic pressure does not change in the perfectly permeable membrane (see Figure 43(c)), only hydraulic permeability affects the decrease in flux. Therefore, Vr and vf should be the
same as before, osmotic pressure should remain constant, and the decrease in retentate mass
should be larger than in the unconstrained case.

(a)

(b)
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(c)

(d)

Fig 4-7: Membrane and flow dynamics in the complete model under the constraints of > = 0.98 and > =
0.99, otherwise same constants as above. Results as expected.

Potentially useful for a customer is the knowledge of theoretical minimum and maximum
filtrate mass. Given conditions set by the company or determined by the model technician, > and
> can be set to a very small value, and then a very large one, to determine the range of possible
extents of filtration (with the lower bound typically being zero, if > and > are sufficiently small).
For instance, under these conditions, the impermeable membrane, unconstrained membrane, and
fully permeable membrane predict 0.12 µg, 0.8 µg, and 5.2 µg of mAb filtrate, respectively. If
the minimum of 0.12 µg (Figure 4-7(d)) is an unacceptable loss of product, optimization for
those conditions can be skipped, and a new set of conditions chosen, to save time and effort.
The results from these limiting-cases tests confirm that the model with fouling appears to
be a fully functional extension of the previous, valid, fouling-free model.

III.

Simulated Annealing

In the previous results, approximations were made for OP F and OP [ , in which Kc and Kd
are fundamental properties of a membrane that do not change with flow geometry or
composition, or membrane size or orientation [4-6]. A key element of scalability, in addition to
determining the scale-up factor, is identifying these parameters for the specific membrane in use.
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Membranes are imperfect, in that pores may be of slightly varying radii or that pores may be
unevenly distributed throughout the membrane. UF membranes are rated on their capacity and
MWCO, not on their degree of physical ideality. Therefore, determining Kc and Kd is
extraordinarily difficult from first principles, as any equation would need incorporate factors that
account for uneven pore radii, etc. Alternatively, it is simpler to collect real experimental data,
insert the conditions of that trial into a model, and have the model vary the terms OP F and OP [
until a suitable fit is achieved, whereupon these products can be divided by O which is
determined from models [4-6]. SA is an excellent optimizing algorithm for this purpose, and
more time-effective than exhaustive brute-force, though the latter method may be used if the
absolute best solution is desired. Using SA, the previous model with fouling was reversed in
function, such that it now accepts data and outputs parameters, rather than the other way around.
> and > are used because they encapsulate the important experimental results. > and >
describe fundamental information about CP, membrane capacity, and the time-dependent Cf and
Cr profiles. In addition, the sieving coefficients are dimensionless, so results are widely
applicable to a variety of feed concentrations. Knowing > behavior for a given membrane and
solution, and knowing Cf0, allows predictions of concentration in the retentate and filtrate. For
flow conditions, notice from Equations 4-5 and 4-6 that only OP F and OP [ are undefined and
unknown. Once OP F and OP [ are found, then, > and > can be predicted.
SA was coded in this model to simultaneously optimize > and > , with SSR deviations for
both functions weighted equally in calculating overall fit-experiment discrepancy.
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Fig 4-8: Optimization using SA. Notice that as SSR sum decreases, fit between curves becomes closer,
simply from observation. SA was arbitrarily set to terminate when SSR ≤ 10-10, though OP F and OP [ fits
reasonably well at SSR on the order of 10-5.

Figure 4-8 shows the results from a test run. The experimental sieving coefficient data
was pulled from the complete model with fouling, with OP F = 0.01 and OP [ = 0.02, and this
data was simply imported into the SA model to test code fidelity. A search space was defined
with lower bound of [0, 0], with no higher bound, though the model technician must provide an
initial guess of appropriate magnitude, and if optimization fails, modify the temperature (stepsize) schedule to that smaller magnitude.
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Fig 4-9: Optimization using SA. Process run time was 330 seconds.

Figure 4-9 shows the process of simulated annealing. Optimization was manually stopped
after about 5 minutes to show the progress of the algorithm; it self-terminates with SSR ≤ 10-10
after a much longer length of time, on the order of hours. Figure 4-9 details the same kind of test
fit shown in Figure 4-8, in that the correct OP F and OP [ are 0.01 and 0.02. SA iteratively solves
the DAE system to find OP F = 0.0103 (variable #1 above) and OP [ = 0.0191 (variable #2) after
this length of time, and finds OP F and OP [ to a much higher degree of accuracy if allowed to
self-terminate.
The SA model should be used to fit variables to experimental data, not to simulated data
as done above. In addition to this (successful) test of code fidelity, physical trials should be
performed to confirm the accuracy of this model. This model should only be used commercially
if and when it is successful in performing experimental fit.
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a. Optimal control code
SA ultimately finds Kc and Kd that fit experimental data. The alternative, which is
arguably much more powerful, is to provide desired > and > profiles and have the model
optimize all filtration conditions – membrane length and cross-sectional area, trans-membrane
pressure, initial conditions, choice of solvent, flow geometry, and type of fouling – to find the
cheapest and/or fastest conditions that still, within tolerance, satisfy the > and > goals. All
optimized variables will be subject to practical constraints and other constraints provided by the
customer. Models that perform such multivariable optimization contain “optimal control code”,
and can be highly complex. Such control code would require a dynamic transfer of information
between MATLAB and COMSOL, and could be mediated by specifically designed packages
like MUSCOD-II [4-4] which would employ optimization techniques beyond SA, if necessary.
In such optimal control code, error to minimize is still the SSR between fit and goal for > and > ,
but sources contributing to that error cannot be equally weighted, and the search space and
temperature profiles are markedly different among all variables.
OptiFilt aims to produce > and > profiles for provided conditions, and reliably predict
membrane behavior on an industrial scale. OptiFilt has not yet developed optimal control code
for companies with more freedom in membrane design, and less in the degree of product
filtration, though this may be feasible in the future. Though this is potentially more
computationally intensive, optimal control code is not inherently more difficult to code, merely
more time-consuming.

IV.

Conclusions

The model described and developed in this section was shown to provide results (see
Figures 4-1, 2, 3, 5, 6, 7) which agreed with behavior that would be expected from an
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experimental system. This does not definitively prove the accuracy of the model, but acts in
strong support of its general applicability. This complete model with fouling should be able to
predict > and > profiles for any conditions with a single dominant solute, and without significant
electrostatic dipoles.
Use of the model requires several steps prior to SA optimization, in which parameters are
determined by independent experiment. To begin, the technician must empirically derive a
correlation for the osmotic pressure of the protein to filter. The technician then selects the most
appropriate fouling model based on literature. If not available, he should obtain flux profiles at
different pressures to test each of the four hybrid models (cake-adsorption, intermediateadsorption, complete-adsorption and adsorption) detailed in [4-8]. Controlling for osmotic effects
by using the ∆π correlation, the technician should then attempt to fit each fouling model to the
flux results to find the minimum possible SSR among all models. If this SSR is also acceptably
small, the technician should select this fouling model and the associated fit parameters; if SSR is
still large, electrostatic effects may be present, in which case approximate solutions to the
Poisson-Boltzmann equation should be used. Remaining system conditions should be specified
by the company or chosen by the technician. The model can now be used. > and > profiles
should be recorded for a wide range of pressures, and for each case, the technician should record
fit values of OP F and OP [ (or of constants in the radius-dependent exponential decay ofOP F or
OP [ ). O is then determined by appropriate model [4-6] and Kc and Kd determined for each trial.
If standard deviation is relatively small among obtained values, Kc and Kd should then be
definitively taken as an arithmetic average of all trials. These values are imported into COMSOL
where various permutations of geometry and flow conditions can be tested for the company.
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This process is lengthy, but the potential payoff is in most cases excellent, as detailed in
the economic analysis of Chapter 7. The technician can complete his report by providing
information on the effect of various variables on membrane performance. This effect, after all,
cannot be deduced from simple inspection of the system. DAE systems are remarkably sensitive
to perturbations of initial conditions or associated constants. Small changes may lead to an
unexpectedly large system response. This model should be very helpful in predicting these
effects, for the purpose of optimizing overall membrane performance according to company
constraints.
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Chapter 5:

Industrial Filter Model
Finite Element Method
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I.

Invalid Assumptions from Test Rig Model

On the industrial scale, companies typically use tangential flow rather than normal flow
filters to minimize fouling. Due to the use of tangential flow, several of the assumptions made
when modeling the laboratory scale filter are no longer applicable to the model of the industrial
filter. Because fluid flows through the channel in a direction tangential to that of the flow
through the membrane, the model of the industrial filter must account for at least two
dimensions. In addition, industrial filters typically utilize complicated geometry, such as hollow
fiber and spiral wound membrane modules, introducing the possibility of turbulent flow.
Consequently, an overall mass balance over the filter is no longer sufficient to model the UF
membrane. Due to this complexity, COMSOL Multiphysics, a finite element solver and
simulation package, was used to model the industrial UF membrane.

II.

Rationale for Using COMSOL

The finite element method (FEM) approach implemented in COMSOL Multiphysics was used to
model simplified two-dimensional tangential flow filter. FEMs are a numerical technique designed to find
approximate solutions general partial differential equations (PDE) as well as of integral equations [5-1].
The FEM approach works to either eliminate the differential equation completely for steady state
problems or render the PDE into an approximating system of ordinary differential equations, which are
then numerically integrated using standard techniques such as Euler's method or the Runge-Kutta
methods. FEMs are useful for complex geometries or varying domains because they rely on “mesh
discretization” of a continuous domain into a set of discrete subdomains of a simple sample. Called
elements, these subdomains are typically triangles for 2D geometries and tetrahedrons for 3D geometries.
Because modeling the tangential flow filter involves the coupling of four PDEs (Navier-Stokes,
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Brinkman, and two convection-diffusion equations), arriving at an analytical solution is not feasible.
Consequently, the finite element method was used to simulate the filter instead.

III.

Equations and Assumptions

As explained in Chapter 4, the Navier-Stokes, Brinkman, and Convection-Diffusion equations are
coupled together within COMSOL to calculate the velocity, pressure, and concentration field throughout
the entire filter. It was assumed that the filter was infinite in the z-direction and that the gradients of the
pressure, velocity, and concentration of the protein were negligible in that direction. With these
assumptions, the geometry of a tangential flow filter was simplified to two dimensions. This geometry
was approximated to be equivalent to that of parallel plates, with the bottom plate semi-permeable to fluid
flow. The problem was also assumed to be at steady state, bringing the times derivatives in all the
equation to zero.
Within industry, TFF processes are typically operated at pressures high enough to bring the flow
within the filter to the translational regime. This creates unpredictable flow patterns, such as eddies,
which work to decrease fouling and concentration polarization at the membrane by inducing greater
mixing within the filter. However, for simplification, flow through the channel was assumed to be
laminar. The following equations were used to calculate the maximum velocity and Reynolds number for
flow between parallel plates:
mnop  

 As
0tq 
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(5-1)

(5-2)

where h is half of the distance between the plates.
Industrial filters are typically operated at a pressure drop of 10 psi between the inlet and outlet.
For this pressure drop, Equations 5-1 and 5-2 were solved simultaneously to find the length of the filter
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that would ensure that the Reynolds number remains below 2000 to keep the flow from entering the
transitional regime. It could then be assumed that the Navier-Stokes equation could adequately describe
the flow within a channel of the calculated dimensions. Furthermore, we assumed that the mAb solution
was dilute enough to be incompressible and that its density was equal to that of water. The viscosity of
mAb solutions has been found to increase as the concentration of the solution increases [5-2]. However,
for the purposes of simplification, the viscosity of the fluid within the filter is assumed to be independent
of its concentration. The body force on the fluid was also considered to be zero. With these
simplifications, the Navier-Stoke s equations become:
y z {0|y} ~ y}  ~     0} z  y} (5-3)
y  z }  ; (5-4)
In addition to the same assumptions made for the Navier-Stokes equations, the dilatational
viscosity and source term were also considered to be zero. The Brinkman equations could then be
simplified to:
 
~y
h





z 0 y ~ yW  ~ 9  0  (5-5)
\
y  z }  ; (5-6)

The diffusion coefficient in the convection-diffusion equation was assumed to be isotropic
(uniform in all directions). At steady state, the convection-diffusion equation simplified to:
y z {0(y ~ }  ; (5-6)
Although these assumptions are made for the simple illustration of the utility of the model, more
realistic assumptions can be made according to the needs of our clients. Transitional and turbulent flow
can be simulated within COMSOL using the K-ε and K-ω turbulence models. Expressions for
thermophysical properties, such as the viscosity and density, can also be entered directly into the
COMSOL user interface and applied to the selected subdomains if they are not truly constant.
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IV.

Geometry and Boundary Conditions

As shown in Figure 5-1, both flat sheet and plate and frame membrane modules are composed of
flat sheet membranes attached to rectangular channels. In order to simplify the model for the purposes of
illustration, a single channel was simulated with rectangular coordinates was simulated within the
COMSOL interface.

Figure 5-1: Top – OPTISEP Flat Sheet Membrane Module from SmartFlow Technologies and a cross-sectional view of its
rectangular channels [5-3]. Bottom – A typical plate and frame membrane module and a cross-sectional view of its
rectangular channels [5-4].

Figure 5-2 shows the geometry of the model simulated within COMSOL and its boundary
conditions. It consists of a rectangular channel with a membrane attached to one of its boundaries. The
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channel has a height of 1 mm and a width of 16 mm. The membrane has a height of 0.125 mm. The
Navier-Stokes is applied to the channel and the Brinkman equations to the membrane. The flow through
the channel is driven by the pressure drop of 4 Pa between the inlet (boundary 1) and outlet of the channel
(boundary 7). There are no slip conditions at boundaries 2, 6, and 8, which state that there are no velocity
components perpendicular to these boundaries:
} z   ; (5-7)
Here, n is a unit vector that has a direction perpendicular or normal to a boundary. An outlet
pressure of 0 Pa is specified at boundary 4. The Brinkman and Navier-Stokes equations are coupled at
their common boundary, boundary 3. Here, the boundary condition is continuity:
 y} ~  }  0    0  q yq ~  y W  ~  9q   ; (5-8)
This condition specifies that the pressure and the velocity components on either side of boundary
4 which are perpendicular to the boundary are equal. The viscosity of the solution was set to 10-3 Pa·s, the
density to 1000 kg/m3, the permeability to 10-10 m2, and the porosity to 0.1. From the boundary conditions
and constants, the fluid mechanics of the entire filter is fully specified and can be solved for the velocity
and pressure field.
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Figure 6-2: Depiction of the modeling geometry with its associated boundary conditions – The boundary conditions for the
Navier-Stokes and Brinkman equations are outline in black. The boundary conditions of the two convection-diffusion
equations are shown in red.

Because the concentration across the boundary between the channel and membrane is
discontinuous, two convection-diffusion equations were necessary to accurately model the concentrations
across the entire filter. The inlet concentration was specified to be 10 mol/m3 at boundary 1. Because they
are walls, the boundary conditions at boundaries 2, 5, and 6 were set to be insulated:
y z {0(y ~ }   (5-9)
 z   ; (5-9)
Here, N denotes the vector of the total flux. This condition sets the total flux perperdicular to the
the boundary to a value of zero. At boundaries 4 and 7, because there is no longer any impediment to the
transport of protein, the convective contribution to the mass transport is assumed to be much larger than
the diffusive contribution:
 z 0( z y  ; (5-10)
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Consequently, the diffusive flux can be considered to be negligible at these boundaries. The two
convection-diffusion equations are coupled together at the interface between the channel and the
membrane, boundary 3. Here, the concentration in the channel in channel is related to the concentration in
the membrane by the partition coeffiecient, K:
!

   ! (5-11)


cm is the concentration of the protein within the membrane and cc is the concentration of the
protein within the channel. In addition, at boundary 3, the total flux of the protein exiting the channel
must be equal to the total flux entering the membrane . However, the COMSOL interface does not allow
these boundary conditions to be specified at the same boundary simultaneously: defining the
concentrations according to the partition coefficient K destroys the continuity of the flux. Instead, the stiff
spring method (applicable to PDEs for which the solution changes rapidly) is used to define continuous
flux conditions that also force the concentrations to the desired values [5-5]:
0(! y! ~ F } z   n 0 !  (5-12)
0(n yn ~  } z   ! 0  n  (6-13)
Dc and Dm denote the diffusion coefficients of the mAb within the channel and the membrane,
respectively. M is a (nonphysical) velocity. Equation 5-12 is applied at boundary 3 for the convectiondiffusion equation applied to the channel and equation 5-13 is applied at boundary 3 for the convectiondiffusion equation applied to the membrane. If both sides of equations 5-12 and 5-13 are divided by M, in
the limit of large values of M, the left hand sides of the equations go to zero:
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 n 0 !   ; (5-14)
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 ! 0  n   ; (5-15)

66

This satisfies equation 5-11. Furthermore, the concentration differences on the right hand sides of
equations 5-12 and 5-13 are the same, but reversed compared to each other. This means that the normal
component of the flux exiting one boundary enters the other boundary, giving a continuous flux across
the interfaces. The diffusion coeffiencts within the membrane and the channel were set 10-9 m2/s, the
partition coefficient was set to 0.1, and the stiff spring velocity was set to 10,000 m/s.
The two convection-diffusion equations were coupled to the Navier-Stokes and Brinkman
equations through their convective terms. For the channel, the velocity vector of the convection term was
set to be equal to that of the velocity field calculated by the Navier-Stokes equation. Similarly, within the
membrane, the velocity vector of the convection term was set to be equal to that of the velocity field
calculated by the Brinkman equations. Most importantly, we can account for the mass transfer properties
of the membrane, kc and kd, by multiplying these values by u and v (the velocity in the x- and ydirections) within the domain of the membrane. These kc and kd values will be calculated from the onedimensional MATLAB model using simulated annealing. Using FEM, COMSOL approximated the
velocity, pressure, and concentration fields for the entire model.

V.

Results

The results of the COMSOL model are shown below. Figure 6-3 shows a surface and arrow plot
of the velocity field within the channel and membrane. The velocity of the fluid within the channel
reaches a maximum value of 57 mm/s at about 1 mm into the channel. The velocity of the fluid decreases
along the length of the channel as fluid exits through the membrane. The arrow plot shows that the
velocity profile is parabolic over the length of the entire filter.
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Figure 5-3: Surface and Arrow Plot of the Velocity Profile within the channel and membrane

Figure 6-4 (a) shows the velocity profile at various cross-sections along the length of the filter.
The green line is the velocity profile of the cross-section at the inlet of the channel and orange line is the
velocity profile of the cross-section at the outlet. At the inlet, the flow is not yet parabolic as it has not
completed its adjustment to the no slip condition at the top wall and the membrane boundary at the
bottom wall. After the hydrodynamic entry length, the velocity profile becomes parabolic and remains so
for the entire length of the filter. In the limit of low membrane permeability to water, the flow within the
TFF channel can simplified to that of flow between two parallel plates. Consequently, the fluid within the
channel exhibits a parabolic velocity profile similar to the velocity profile of flow between flat plates.
However, unlike flow between flat plates, as the position within the filter increases in the x-direction, the
velocity of the mAb solution decreases as some of the fluid exits through the membrane and its volume
decreases even though the cross-sectional velocity profile remains parabolic. At the height of the channel,
the velocity is zero at all cross-sections along the filter. This indicates that the no slip condition is indeed
being fulfilled at boundary 4. However, at the Navier-Stokes and Brinkman boundary, the velocity
reaches a nonzero value and remains constant at this value across the membrane. This nonzero value
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decreases with the in the x-direction of the filter as less fluid is passing through the membrane further into
the filter.

Figure 6-4: a) Cross-sectional velocity profile along the length of the filter. b) Line plot of the velocity profile along the length
of the channel

A line plot of the velocity profile along the length of the channel can be seen in Figure 5-4 (b).
Within the hydrodynamic entry length, the velocity of the fluid rapidly increases to its maximum value.
Once fully-developed, the velocity decreases with the length of the filter as the water passes through the
membrane and the volume of fluid decreases. The rate of the decrease in the velocity profile decreases
towards the end of the channel. This occurs because the pressure drop decreases along the length of the
filter. At a given point along the length of the filter, the average transmembrane pressure drop is related to
the pressure drop across the length of the channel by the following equation:
¢/ 

--£¤¥
q

(5-16)

P denotes the pressure at the point along the length of the filter and pout is the outlet pressure.
Therefore, because the pressure drops along the length of the filter, the difference between p and pout also
decreases, giving a lower TMP. As a result, there is less pressure forcing fluid through the membrane as
you move further along the channel in the x-direction, causing the flux of water through the membrane to
decrease and the velocity to decrease along the change at a slower rate.
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Figure 5-5(a) shows a surface plot of the pressure field across the entire filter. Figure 5-5(b)
shows a line plot of the pressure along the length of the channel at the centerline of the channel’s height.
The pressure drop across the channel decreases linearly across the length of the channel, which is to be
expected because the behavior of the flow within the channel should approach that of flow between
parallel plates in the limit of low water permeability.

Figure 5-5: a) Surface plot of the pressure profile within the filter. b) Line plot of the pressure profile along the length of the
channel

Figure 5-6: Cross-sectional pressure profile along the length of the filter

Figure 5-6 shows series of line plots of the pressure profile at different cross-sections along the
length of the filter. For each cross-section, the pressure is constant across the channel and then decreases
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linearly across the membrane. The TMP decreases with increasing length in the x-direction as expected
from Figure 5-4 (b).
As shown in Figure 5-7 (a), the concentration of the mAbs within the channel increases from 10
mol/m3 at the inlet to about 19 mol/m3 at the outlet. The concentration within the center of the channel is
not influenced by the filtration process until about halfway into the channel. The developing diffusion
layer before the membrane can also be clearly seen. The concentration reaches a maximum of 24 mol/m3,
but decreases due to the increased effect of the diffusion of the protein throughout membrane as the
velocity of the fluid decreases, reducing the convective contribution to the total flux. The concentration
within the membrane also increases along its length as a small portion of the mAbs partition into the
domain.

Figure 5-6: a) Surface Plot of the Concentration Field. b) Line plot of the concentration across the length of the channel

Figure 5-7 (b) shows the increase in the concentration of the mAbs within the channel along the
length of the channel along the centerline of the channel. The concentration increases from 10 mol/m3 to
about 18.5 mol/m3. From about 2 to 12 mm into the channel, the concentration increases linearly in the xdirection. However, the rate of increase begins to reach a steady state value close to 19 mol/m3 from 1216 mm into the channel. The TMP decreases along the length of the channel causing the flux rate of water
through the membrane to also decrease. As the water exits the channel through the membrane at a slower
rate, the total volume of fluid begins to decrease more slowly. As a result, the rate at which the mAbs
within the channel concentrates also begins to decrease. The concentration within the center of the
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channel is not influenced by the filtration process until about halfway into the channel. The developing
diffusion layer before the membrane can also be clearly seen.
Figure 5-8 (a) shows how the concentration varies in the x-direction at boundary 4. At the
boundary between the channel and membrane, the concentration is immediately affected by the
permeation of water through the membrane, rising quickly. However, less than 2 mm into the filter, the
rate of increase in the concentration at the boundary begins to slow and then the concentration at the
boundary actually begins to decrease 8 mm into the filter, before the fluid exits that channel at a
concentration of 20 mol/m3. As previously stated, this occurs because the diffusive contribution to the
total flux of the mAbs becomes more significant as the velocity of the fluid decreases within the channel.
Consequently, as you move through the channel in the x-direction, a greater percentage of the channel
experiences an increase in the concentration as the mAbs begin to spread throughout the channel and the
diffusive layer increases.

Figure 5- 7: a) Line plot of the concentration at the channel-membrane boundary across the length of the membrane. b) Line
plot of the concentration at the outlet boundary of the membrane

Similarly, Figure 5-8 (b) shows how the concentration varies in the x-direction at boundary 3.
Figure 5-8 (b) looks exactly the same as Figure 5-8 (a); however, the values of the concentrations are 10
times smaller. This occurs because the flux into the membrane is equal to the flux out of the channel at
boundary 3 and the partition coefficient is 0.1. Thus, at every point along the boundary between the
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membrane and the channel, any changes in concentration in the channel are reflected in the concentration
in the membrane. Moreover, because the mAbs and water move at the same velocity and in the same
directions once in the membrane (there is no internal partition) and because the membrane is so thin, the
concentration immediately diffuses through the membrane in the y-direction and does not change. This
means that the concentration of the fluid at the outlet of the membrane is the same as that directing over
the membrane and we can be confident that the stiff spring method adequately specified the continuous
flux and concentration boundary conditions.

Figure 5-8: Concentration Polarization across the Membrane

Figure 5-9 shows a line plot of the concentration at a representative cross-section of the filter. As seen
in normal flow filtration, the presence of the membrane causes the concentration to increase rapidly
directly before the membrane, followed by a discontinuous drop in concentration. Here, the bulk
concentration in the channel is about 12 mol/m3, the concentration in the channel directly before the
membrane is 24 mol/m3, and the concentration within the membrane is 1 mol/m3. Thus, at this crosssection, θ = 0.04 and θ’ = 0.083. Within COMSOL, average values of the bulk concentration within the
retentate, and concentration within the retentate at the membrane, and the concentration of the filtrate
were calculated by the integrating the values of the concentrations over their respective boundaries.
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Integrating over boundary 4, the average concentration within the filtrate was calculated to be 0.035374
mol/m2. Integrating over boundary 3, the average concentration within the retentate at the membrane was
calculated to be 0.353744 mol/m2. Integrating over boundary 1, the average concentration of the feed was
calculated to be 0.01 mol/m2. Using these values, the θ and θ’ of the system are 0.1 and 3.54, respectively.
Consequently, whereas empirical data is usually necessary to determine θ and θ’, our company can
determine that directly from the industrial model.

VI.

Limiting Cases

In order to illustrate the flexibility and accuracy of the COMSOL model, several limiting cases
will be discussed in the following section. First, the model was tested in the limit of a completely
impermeable membrane to the mAb solute molecules, but permeable to water through the use of an
insulation condition at boundary 3. This sets the normal flux through the membrane and, as a result, the
concentration within the membrane to zero. The velocity and pressure field are not affected by this
change and, as such, are not reproduced. However, as shown in Figures 5-10 (a) and (b), the outlet
concentrations increased by about three moles compared to the previously specified flux, which makes
sense because no protein is being transported the membrane.

Figure 5-9: Surface Plot of Concentration and Velocity
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Figure 5-11 shows the surface plot of the concentration for a membrane that is completely
permeable to mAbs. This was achieved by setting the partition coefficient equal to a value of one.
Because the protein is not being partitioned between the channel and the membrane, the protein is able to
move throughout the entire filter freely. As a result, the concentration within the entire filter is zero.

Figure 5-10: The surface concentration for a completely permeable membrane.

In order to investigate the effect of the diffusion coefficient on the surface concentration, it was
increased by a factor of 100. Figures 6-12 (a) and (b)

Figure 5-11: a) The surface concentration of a species with a much higher diffusion coefficient. b) Line plot of the crosssectional concentration of a species with a much higher diffusion coefficient

Figure 5-12 (a) shows that for a species with a higher diffusion coefficient, the increase in
concentration due to the loss of fluid spread through the system much more quickly. The effect of the
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filtration process affected the concentration of the species at the height of the column directly at the inlet
of the channel. Similarly, because the transport due to diffusion was so high compared to the x-direction,
there was no a gradient in the concentration across the height of the filter. Consequently, as shown in
figure 5-12 (b), there was no longer any concentration polarization due to a greater diffusive flux.
However, the concentration increased to a smaller value – only 16 mol/m3 – by the outlet compared to the
model with a smaller diffusion coefficient. This stems from the fact that the diffusive flux contributes to
the flux out of the channel. As the diffusion coefficient increases, the flux out of the channel also
increases, decreasing the concentration of mAbs within the channel.
Increasing the permeability by a factor of 10 changes the fluid mechanics of the model, which in
turn affects the concentration field. Increasing the flow through the membrane disrupts the previously
parabolic velocity profile. Instead, the parabola begins to lean toward the membrane as more of the fluid
streamlines pass through the membrane. Consequently, the velocity in the x-direction decreases by a
larger amount across the length of the filter but remains at a higher value that the velocity in the previous
filter. This occurs because the TMP doesn’t have to be as high to push fluid though a more permeable
membrane, increasing the overall velocity of the fluid compared to flow through a filter with a less
permeable membrane.

Figure 5-12: a) Velocity field and b) cross-sectional velocity for a membrane with a higher hydraulic permeability
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As more fluid passes through the filter, the channel can no longer be modeled as fluid flow
through parallel plates. Figures 5-14 (a) and (b) show that the pressure drop across the length of the
channel is no longer linear. In fact, there is a steep drop in pressure within the initial 5% of the channel.
This is probably due to the hydrodynamic entry length of the channel. After this, the pressure increases
once again and then decreases once again in a nonlinear manner.

Figure 5-13: a) Surface Pressure and b) pressure drop across the length of a membrane with a lower permeability

As expected, Figures 5-15 (a) and (b) shows that the concentration increases to a higher value as
the permeability increases. Resulting from an increased loss of fluid, the concentration increases to about
35 mol/m3 at the outlet, after reach a maximum concentration of about 60 mol/m3. Because the velocity of
the fluid is higher compared to the less permeable case, the diffusive contribution to the total flux is
lower. This causes there to be less diffusive spreading of the concentration with the channel and the
concentration at the centerline of the channel is only influenced by the filtration process towards the outlet
of the channel.
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Figure 5-14: a) Surface Concentration. b) Line plot of the concentration across the length of the membrane with a lower
permeability

As demonstrated here, using the COMSOL model, OptiFilt will be able to quickly and easily
analyze the effects of varying different parameters affecting the efficiency of TFF. Although this was
demonstrated for a simplified geometry and governing equations, these results are applicable to a wide
range of other geometries, including those involving radial symmetry, and to complicated mechanics,
such turbulent or Forchheimer flow.
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Chapter 6:

Equipment and
Instrumentation
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I.

Test Rig Overview

As explained in Chapter 4, normal-flow fouling models compute Kc and Kd for client UF
membranes by comparing experimental sieving coefficient data to that predicted by our
proprietary MATLAB model. As such, the test rig equipment will need to collect Cf and Cr in real
time; in this way, OptiFilt scientists will compute experimental

and

’ values for use in our

computational models.
We have elected to purchase a simplified filter test rig, such as those commonly used by
biotechnology clients today, and additional monitors which can be attached to the filters such that they
will provide in-line, real-time measurements of Cf and Cr. We have selected refractometers to monitor

these concentrations. The Pharma Refractometer PR-23-AC, purchased for $18,760 each from
K-Patents, can be used in-line with a slow fluid stream and is appropriate for large biologic
solutes (full product specifications are included in the Appendix).
We have selected this refractometer because it is accurate within a refractive index
corresponding to 0.1% of the solute weight, thereby providing as accurate a measurement as
possible of the protein concentration on either side of the test filter. It also meets pharmaceutical
industry guidelines including the Food and Drug Administration’s Code of Federal Regulations
(CFR) and Good Manufacturing Practices (GMP).
For the test rig, we have selected the Filter Tec Plus Multi-Filter Capacity Testing
system, purchased for $16, 795 each from SciLog Bioprocessing Systems (specifications are
included in the Appendix). These systems can perform three normal-flow filtrations at once, at
either constant fluid velocity or constant applied pressure, and parameters can vary from one
filtration to another. Because we want to perform more than three filtration test at a time, we will
purchase three of these systems and perform nine filtrations at once. In this way, our tests will
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collect as much data as possible and our analyses will be more thorough than if three tests had
been conducted.
Two refractometers are needed per individual test filter used—one for the filtrate side,
and one for the retentate side. This means that a total of 18 refractometers are required for the
OptiFilt filtration analysis system—six per three-filter Filter Tec testing system. Intuitively, this
quantity of filters seems excessive; however, given the price we will charge per analysis, as well
as the minimal inventory and rental costs we will incur, a relatively large investment in quality
refractometers is reasonable (see Chapter 7: Financial Analysis).
Figure 6-1 illustrates a rough prototype of a single three-filter test rig. The protein solution to be
filtered, which will be supplied by the client, will run through each of three individual filters. As filtration
proceeds, refractometers will continuously measure the protein concentration in the filtrate and retentate
side of the membranes. These real-time data will be supplied to workstations where experimental
apparent sieving coefficients will be computed.

Figure 6-1: Prototype for a single three-filter test rig. Refractometers will collect concentration data in real time.
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As explained previously, experimental apparent sieving coefficient will be used to calculate the
intrinsic experimental sieving coefficient for the filtration process studied. These data will then be
compared to proprietary MATLAB models; this comparison will allow OptiFilt scientists to determine Kc
and Kd for the specific membrane used. Finally, these Kc and Kd values will be supplied to proprietary
COMSOL models, which will predict industrial-scale filtration results for the filter, solution, and
operating parameters used.
All computational aspects of the analysis will be performed on Inspiron 560s Desktop computers,
purchased for $798 each from Dell. These computers were selected because they appropriately balanced
cost and superior processing capabilities, which will be necessarily in order to efficiently run the
MATLAB and COMSOL models.4 Two PowerConnect 6224 Switches were purchased for $1,300 each
from Dell to ensure that data can be properly shared across OptiFilt computers. In this way, physical
filtration tests and computational analyses can be performed simultaneously, thereby increasing service
throughput.

II.

Test Filters

For all analyses performed, the filters themselves, like the protein solutions to be separated, will
be supplied by clients. Generally, filter manufacturers produce small-scale test filters for this purpose;
these filters are made of the same material as their industrial-scale counterparts. Obviously, these test
filters will be UF membranes, because the proprietary MATLAB and COMSOL models described
previously most appropriately apply to UF behavior. The Filter Tec Plus Multi-Filter Capacity

Testing system can accommodate test filters ranging from 8.0 to 15.0 cm in diameter (as seen in
the Appendix); these values are typical for test filters currently on the market.

4

We have elected to purchase one desktop computer per OptiFilt employee. This means that seven computers will
be purchased in the R&D stage, and three additional computers in the following year (see: Chapter 8, Financial
Analysis).
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III.

Cleaning and Maintenance

In between runs, the test rig will be disinfected with 91% isopropyl alcohol, which can be purchased
inexpensively from local retail pharmacies. WFI will be used to wash out the system following
disinfection. To ensure that no remaining water will affect subsequent filtration tests, three Miniature
Dessicant Air Dryers (one for each test rig system) will be purchased from Twin Tower Engineering for
$599 each. Rigs will be dried thoroughly prior to each new filtration analysis begins. Throughout testing,
pH will be maintained at levels appropriate for the protein products of interest. For the purpose of cost
projections and financial analyses, we have selected a representative buffer kit to be kept in OptiFilt
inventory. The kits, purchased from Invitrogen for $152 each, will contain 100 ml samples of buffer
solution.
Biohazard waste will be stored in 1-gallon biohazard boxes, purchased form Stericycle for $152 each.
Waste will be treated and removed monthly by Clean Harbors. Waste treatment services will be
performed monthly at a cost of $800 per month.

IV.

Space and Other Requirements

As previously explained, the Filter Tec Plus Multi-Filter Capacity Testing system is a

bench-scale apparatus. All physical experiments and data collection will require no more space
than the average desk. Of course, OptiFilt will require also space for its Dell desktop computers,
as well as space in which scientists, computer scientists, and technicians can perform filtration
analyses. The Company will also require a (likely adjacent) office space which management and
sales representatives will use as their ‘home base.’ We estimate that the total space required will
be 1,500 square feet.
In the (albeit small) laboratory space, care will be taken to maintain steady room
temperatures and low humidity levels. We have provided for enough space to carefully store
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disinfectants, WFIs, buffers, and other inventory items, as well as the client-supplied samples
and test filters. Because of these requirements, we have estimated the rental cost of our
laboratory space to be slightly higher than average Cambridge, MA rents (see: Chapter 7,
Financial Analysis).
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Chapter 7:

Financial Analysis
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I.

Market Analysis

As stated previously, OptiFilt will have a service-based, rather than product-based, business
model: the Company will provide filtration testing and analysis services on a fee-per-service
basis. A service-based model has a number of advantages over a product-based model (in which
OptiFilt would sell its test rig instrumentation rather than actual analyses), including: a) clients
will receive more rigorous analyses, conducted by scientists for whom filtration is a full-time
job, and b) this service-based model will provide a recurring revenue stream as clients re-seek
analysis services.
Before forecasting the Company’s profitability, it is crucial to ensure that there exists a
significant, well-funded and stable client base. In this case, OptiFilt’s target clients are
biotechnology companies which manufacture therapeutic proteins. Generally, these companies
are producing proteins a) for immediate human or veterinary use, or b) for clinical trials of drugs
seeking FDA approval. Regardless of their end-products, all client companies intend to
maximize product throughput and minimize process time and consequently, operating costs.
OptiFilt has a large and growing group of potential clients. In the United States alone, there
were 1,452 biotechnology companies in 2006, 336 of which were publicly traded [7-1]. In New
England, in which OptiFilt will be located, there were 60 publicly traded biotechnology
companies at this time [7-2]. Assuming that the portion of public companies is evenly distributed
across the country, approximately 260 biotechnology companies (private or public) existed in
New England as of 2006.
These biotechnology companies are increasingly profitable and well-funded. Between 1994
and 2006, the total number of U.S. biotechnology companies increased only 11%, from 1,311 to
1,452. In the same time period, however, total industry revenues skyrocketed from $11.2 billion
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to $53.5 billion—a 378% increase. Furthermore, although investment in the industry dipped in
the early 2000s, it has increased significantly since the 1990s. In 2007, total biotechnology
financing was $24.8 billion—a 359% increase since 1998 [7-3].Existing biotechnology
companies are becoming more profitable as they produce more new drugs and/or enjoy larger
profit margins on existing products [7-4].
OptiFilt’s success requires not only that client companies exist and are well-funded, but also
that these companies are active, consistently developing new products or continuing to produce
approved products. Despite significant R&D costs, the industry continues to be prolific. As of
2010, over 600 biologic drugs were in development by United States biotechnology companies
[7-5], and over 200 therapeutic proteins and vaccines had been developed by these companies
already [7-6]—in addition to hundreds of diagnostic, agricultural, and environmental products.
Of the 600 products in development, 400 are in clinical trials [7-7]. There is also a growing
market for biosimilars, or generic biologic drug products intended to mimic the therapeutic result
of their brand-name counterparts. The biosimilars market is projected to reach $10 billion by
2017 [7-8].
Given the trends of the past decades, as well as the large number of biologic drugs currently
in development, it is clear that the biotechnology industry fulfills OptiFilt’s requirement of a
sizable, well-funded, and stable client base. Even so, changes in the client industry are possible
and could affect OptiFilt’s future success. These changes are discussed in detail later in the
following chapter (see Chapter 9: Scenario and Sensitivity Analyses).
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II.

Projected Quantities Sold

The first step in our financial analysis is to estimate how many services OptiFilt will provide
at full capacity. The quantity of services sold will be restricted by the smaller of two potential
limiting factors: a) OptiFilt’s manufacturing capabilities, or b) projected demand for filtration
analysis services by biotechnology clients.
It is the most logical to estimate client demand prior to estimating OptiFilt’s capabilities. If
client demand is low, there will be no need to project capabilities with doubled equipment, night
shift workers, and other strategies meant to increase the supply of filtration analysis services.
Client demand is primarily dependent upon a) the number of biotechnology companies in the
U.S. and in New England, b) how frequently these companies design new bioprocesses or
reevaluate existing processes, and c) what portion of the existing biotechnology market OptiFilt
successfully attracts.
As stated previously, there were 1,452 U.S. biotechnology companies as of 2006.
Approximately 260 of these companies were located in New England. Due to the relatively slow
growth rate in number of companies over the past two decades, as well as the recent
macroeconomic recession, we will conservatively assume that an equal number of companies
exist today.
It was also stated previously that as of 2006, there were over 200 therapeutic biologics
available on the U.S. market, 400 biologics in clinical trials, and 600 biologics in any stage of
development. Again, OptiFilt’s analysis services will help client companies to reduce filtration
time and consequently increase throughput. Biotechnology clients will therefore only be
interested in these services if they are producing large quantities of biologic products. For this
reason, we will consider relevant drug products to be those biologics which are either a)
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currently produced for patient use, or b) currently undergoing clinical trials. For our purposes,
then,
";;¦§¨ v©vª¨«ªm©¬ ~ 4;;®®§©¨®§¨«ªm©¬  =;;′¨vv*§©¨«ªm©¬ ′ (7-1)

where ‘relevant products’ are those biologic drugs whose manufacturing processes may be
improved by OptiFilt’s services.
Intuitively, it seems unreasonable that there exist fewer biologic drug products in
development than there are biotechnology companies. However, ‘biotechnology companies’
includes those companies involved in blood and plasma, diagnostic services, genetically
modified foods, and other non-drug activities. Although some of these ‘non-drug’ companies do
produce relevant protein products, it is clear from the company-product discrepancy that a large
portion of total biotechnology companies are not relevant to OptiFilt. For this reason, we will
base our quantity analysis on the number of ‘relevant products’ in the U.S., rather than the
number of biotechnology companies.
Any biotechnologically-produced active ingredient will be produced and sold in a variety
of formulations; these formulations have different dosages and inactive ingredients. Despite this
fact, we are interested in improving the downstream manufacturing process of the active
ingredient only; OptiFilt cannot help clients assemble their final drug products. For this reason,
we make the conservative assumption here that each of the 600 relevant products has only one
corresponding manufacturing process. Under these assumptions, 600 processes exist today which
could benefit from OptiFilt’s filtration analysis services.
To approximate future demand, we must estimate a) at what rate companies reevaluate
existing processes, and b) at what rate the number of relevant processes will change. On the first
point, by the suggestion of our advisor, Dr. Matthew Lazzara, we will assume that a
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biotechnology client company will re-evaluate existing manufacturing processes each year. On
the second, we note that biotechnology R&D processes are very slow, taking 10-15 years on
average [7-9], and that only 132 new biologics were approved between 2000 and 2003 [7-10]
despite the industry’s highest-ever level of financing in 2000 [7-11]. Additionally, although the
biosimilars market is expected to grow in the next decade, especially given its new FDA
approval pathway created by the Patient Protection and Affordable Care Act of 2010, production
of these drugs is nearly as slow as that of their brand-name counterparts. Unlike small-molecule
generics, biosimilars can take up to a decade to develop [7-12]. The time required for new
biologics to be produced, then, exceeds the period of study for this profitability analysis. For this
reason, we conservatively assume here that the rate at which new ‘relevant processes’ are
developed is equal to the rate at which current processes are discontinued. Hence the total
number of relevant processes will be 600 for each year in this study.
OptiFilt’s success hinges upon what portion of these relevant processes’ parent
companies will seek our filtration analysis services. Obviously, fraction depends not only on the
quality of our service, but on how successfully we market the Company and seek new clients.
Again, we assume there are 1,452 biotechnology companies in the U.S., 260 of which are in New
England. Assuming that ‘releveant processes’ are evenly distributed across all biotechnology
companies5, approximately 18% of relevant processes (107 processes) will be New Englandbased.
When projecting our success rate in attracting clients, we note three observations. First,
nearly all relevant processes already involve some type of filter integrity testing; our success
hinges not on introducing a new step in the bioprocess, but on replacing clients’ existing filter

5

We are maintaining our assumption here that a large portion of these biotechnology companies have no relevant
processes at all.
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testing strategies. Second, in an attempt to cut costs and process times, U.S. biopharmaceutical
companies are increasingly outsourcing parts of their research and manufacturing processes to
small, specialized companies like OptiFilt. In fact, outsource spending in the industry grew 15%
from 2001 to 2008 [7-13].
Finally, because OptiFilt’s Cambridge, MA location is also a biotechnology hub, it makes
sense for us to focus much of our marketing and sales efforts locally. In this way, we will access
a large number of potential clients with minimal time and expense. A consequence of this
strategy is that our success in attracting New England clients will be higher than that for other
U.S. potential clients. For these reasons, we project that by the time we reach full capacity, we
will have successfully attracted 35% of New England ‘relevant processes’ as clients and 20% of
non-New England ‘relevant processes’ as clients. This means that at this time, the total demand
for OptiFilt’s services will be
;#$¯ ° <;6 ~ ;#"; ° =;; 0 <;6  ± <$=¬v¨*®v¬&²¨# (7-2)
Of course, OptiFilt’s success is contingent upon the accuracy of our projections here.
Failure to attract this portion of potential clients will reduce company profits and investors’
returns. This issue is discussed in the following chapter.
Before assuming that OptiFilt will provide 136 filtration analyses per year, we must
confirm that this quantity is within our capabilitites at full-capacity. In an attempt to minimize
equipment costs (see: Chapter 6), we will purchase only enough equipment to perform one
filtration analysis at once. Each analysis takes a total of 12.8 hours and is comprised of the steps
shown in Table 7-1. However, OptiFilt employees will be able to provide services at a rate
greater than one service per 12.8 hours, because a) the longest step, Code, can be performed
overnight without supervision, and b) only the Prep, Run, and Clean steps require the test rig

91

instrumentation. As a consequence, multiple samples can be analyzed at once, provided that the
samples’ Prep, Run, and/or Clean steps do not overlap.
Step

Description

Prep

Set up test rig with client filters and samples

Run

Run test filtration and collect data

Code

Run MATLAB and COMSOL analyses

Analyze

Analyze COMSOL results and predict optimal filtration conditions

Clean

Clean and dry test rig

Time
(hr)
0.5
3.3
5.0
3.0
1.0

Total
12.8
Table 7 - 1 Time requirements for one OptiFilt filtration analysis service.

A sample process schedule is given in Figure 1. Under this schedule, one sample (Sample
1) begins at t=0 hours on the first day. It is run through the test rig instrumentation, after which
the rig is cleaned and a second sample is introduced at t=3.8 hours (because we have used
generous time requirements in Table1, we are assuming that there is no lag or break time
between steps). Sample 2’s Prep, Run, and Clean steps are completed at t=9.6 hours.
Simultaneously with Sample 2’s test rig steps, the data from Sample 1’s Run steps are run
through MATLAB and COMSOL analyses, which are completed at t=8.8 hours on Day 1. If we
assume a ten-hour workday, then by the end of Day 1, we will have COMSOL and MATLAB
results for Sample 1 (from Code), and raw experimental data (from Run) for Sample 2.
As mentioned previously, the Code step can be run overnight without supervision. In this
example, Sample 2 will undergo this step in the evening between Days 1 and 2. At the beginning
of Day 2, then, both samples’ analyses are only missing the final Analysis step. These steps take
three hours each and are performed in succession, completing the analyses at t=6 on Day 2.
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Figure 7 - 1 Proposed schedule for two OptiFilt filtration analysis services.

This example illustrates that with a ten-hour workday, OptiFilt will be able to perform
two filtration analysis services in approximately 1.6 working days. Assuming that the Company
operates 52 weeks out of the year, 5 days per week, the Company will have a total of 260 days in

which to perform filtration analyses. In this timespan, OptiFilt will be able to perform a
maximum of

(7-3)

which is much greater than the projected demand for these services. Consequently, client
demand, not OptiFilt’s capabilities, will be the limiting factor in determining what the quntity of
services sold. For the remainder of tthis
his profitability analysis, we will assume that the Company
will provide 136 services per year. The remainder of available operating time will be used for
marketing, sales, and R&D as the company expands into new services (see: Chapter 9, Scenario
and Sensitivity Analyses).
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III.

Pricing

When determining a price for one filtration analysis service, we are primarily concerned with
how biotechnology companies value the service; in other words, we must estimate the price these
clients are willing to pay. It is also important to determine which prices allow OptiFilt to remain
profitable given its costs. However, this point will be ignored in this section, because a) if
OptiFilt’s price requirement is higher than what clients are willing to pay, clients will not
purchase any services, and b) if OptiFilt’s price requirement is lower than what clients are
willing to pay, OptiFilt management would be foolish to price the service lower than what is
warranted by client demand. By this logic, biotechnology clients’ willingness to pay should be
the sole determiner of OptiFilt’s pricing strategy.
Clients’ willingness to pay for filtration analysis services is determined by a number of
factors. First, we consider clients’ existing alternatives to OptiFilt’s services. Next, we consider
the advantages we can offer over these alternatives. Finally, we look at clients’ typical budgets
for outsourcing parts of their manufacturing processes to companies like OptiFilt.
Nearly all ‘relevant processes’ include some type of bench-scale filter testing. Generally,
these tests are performed in-house using diagnostic instruments such as the FilterTec Plus MultiFilter Capacity Testing rig, which OptiFilt will use in its analyses (see Chapter 7:
Instrumentation). This particular system costs $17,8086 and measures three filtrations in parallel;
typically, similar instruments are priced within the $10,000 to $30,000 range [7-14].7 These rigs
are re-usable.

6

The test rig itself costs $16,795; necessary accessories (sensors and software) bring the total system cost to
$17,808. OptiFilt will not require these accessories because we will use refractometers to collect concentration data.
7
Additional costs of in-house filter testing include the costs of test filters; however, these filters will be supplied by
the clients in OptiFilt’s analyses, and so they are ignored here.
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Performing these tests in-house generally does not require large blocks of time; in the
representative biopharmaceutical manufacturing process described earlier in this report, these
tests took 15 minutes and were performed prior to each batch [7-15]. However, these tests cannot
provide the detailed analysis that OptiFilt can provide its clients. The FilterTec System, for
example, can measure filtrate weight and processed volume; however, it does not provide realtime data on solute concentration (and, consequently, intrinsic or apparent sieving
coefficients)—thereby providing an incomplete picture of mass transfer conditions at the filter
surface. By determining ΦKc and ΦKd values for a client-supplied filter material, OptiFilt will
provide information about each filter which an in-house test cannot possibly provide.
Furthermore, these in-house tests generally have no realistic scale-up component; rather, they
assume that test rig results accurately model industrial filter cartridges. As discussed earlier in
this report, industrial filters involve complex geometries and fluid mechanics, and therefore are
governed by a different mathematical model than are the test rig results. By taking a more
realistic approach to this scale-up, OptiFilt will more accurately predict filtration results in
industrial filter cartridges.
Finally, whereas in-house testing is typically performed by a technician with many
competing laboratory duties, OptiFilt’s analyses will be performed by scientists whose focus is
filtration. We project that this expertise will translate superior data analysis and more innovative,
successful solutions for our clients.
OptiFilt’s analysis services will allow client companies to reduce filtration time and
consequently increase product throughput. We project that our analysis will help clients reduce
filtration times by 50%. Using the previously-defined representative mAb process as a
benchmark, we then estimate that OptiFilt Ultra will save clients 727.5 minutes per batch,
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increasing product throughput by 2.69 kg mAb per year. This additional production will add over

Old Process

$3,000,000 to clients’ profits each year (see Table 7-2).
Total Processing Time
UF Processing Time
Filter Integrity Testing Time
Total 'Relevant' Time per Process
Potential Time Savings per Batch

984
1440
15
1455
727.5

hours
minutes
minutes
minutes
minutes

New Process

New Capacity
39.6 batches/yr
Old Capacity
39 batches/yr
Net Gain
0.6 batches/yr
Addl. Yearly Production
2.69 kg mAb/yr
$ 3,030,241 $/yr
Addl. Yearly Revenues
Table 7 - 2 Potential time savings and additional yearly revenues for a typical biotechnology client using OptiFilt services.

The final piece of the pricing puzzle involves estimating client companies’ budgets for
outsourcing. According to PhRMA, it costs $1.2 billion to develop a biologic product from drug
discovery through FDA approval [7-16]. As biopharmaceutical companies are pressured to cut
costs, increasing portions of these R&D budgets are spent on outsourced services. For example,
of the $51.8 billion spent on biopharmaceutical R&D in the U.S. in 2005, $6.6 billion on contract
clinical trials services alone [7-17]. It is clear that potential biotechnology client companies
recognize outsourcing as a means to increase productivity and cut costs, and therefore are likely
willing to invest in contract services like those offered by OptiFilt.
Given the potential savings provided by our filtration analysis services, as well as client
companies’ large budgets for outsourced services, we find it reasonable to price our service at
$150,000 per analysis. This price conservatively estimates what clients are willing to save, as it
less than 50% of potential savings and 0.04% of the total cost to bring a biologic drug to market.
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Revenue Projections

IV.

For the purposes of this profitability analysis, we have split the study period into four stages:
1) R&D, 2) Scale-up, 3) Full Capacity, and 4) Terminal. The R&D stage is a 1-year period in
which OptiFilt will finalize the test rig instrumentation and analysis procedure, and Company
management will seek and obtain initial clients. The next three years comprise a Scale-up stage
in which the Company increases its client base and builds capacity. For the purposes of this
analysis, we assume that OptiFilt will add 25% of its full capacity each year until full capacity is
reached. The following three years comprise the Full Capacity stage, in which OptiFilt is
providing the full 136 services per year, but continues its R&D efforts in order to remain
competitive. At the final Terminal stage, all initial investments have been recovered. At this
point, management will either a) continue OptiFilt’s operations, b) sell the Company, c) liquidate
assets and dissolve the Company. A timeline of the study period is shown in Table 7-3.
Year

2012

Stage Name
Design
Capacity
Revenue

2013

2014

2015

2016

2017

2018

2019

R&D

Scale-up

Scale-up

Scale-up

Full Capacity

Full Capacity

Full Capacity

Terminal

0%

25%

50%

75%

100%

100%

100%

100%

-

$5,101,875

$10,203,750

$15,305,625

$20,407,500

$20,407,500

$20,407,500

$20,407,500

Table 7 - 3 Revenue projections by stage.

V.

Equipment and Recurring Costs

In order to project future profits, we must determine the Company’s expenses at each year in
the period of interest. OptiFilt’s costs fall into five catetories: equipment, inventory, labor, rental,
and sales and research costs. Equipment costs are one-time costs associated with the purchase of
test rig instruments, as well as computers and software licenses. The majority of these costs are
incurred at the beginning of the R&D period (2012), but three additional computers are
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purchased in the following year as scale-up takes place and additional personnel are hired.
Equipment costs are detailed in Table 7-4.
Equipment Costs
R&D Stage:
Item
Filter Tec Plus Multi-Filter Capacity Testing
COMSOL Multiphysics Named Single User License
MATLAB License
Microsoft Office Home & Business 2010
Inspiron 560s Desktop
PowerConnect 6224 Switch
Pharma Refractometer PR-23-AC
Miniature Desiccant Air Dryer

Cost
$ 16,795
$ 9,995
$ 2,100
$ 280
$ 798
$ 1,300
$ 18,760
$ 599

Qty
3
2
2
1
7
2
6
3

Tot. Cost
$ 50,385
$ 19,990
$ 4,200
$ 280
$ 5,586
$ 2,600
$ 112,560
$ 1,797

Vendor
SciLog Bioprocessing Systems
COMSOL
MathWorks
Microsoft
Dell
Dell
K-Patents
Twin Tower Engineering

Start of Sales Stage:
Item
Inspiron 560s Desktop

Cost
Qty
$ 798
3
Table 7 - 4 Equipment costs.

Tot. Cost
$ 2,394

Vendor
Dell

Inventory costs are recurring costs associated with the purchase of non-durable goods, such
as WFI, buffers, and disinfectant. Inventory costs are variable costs; that is, they increase with
production. However, inventory costs are very small relative to the other four cost categories.
For this reason, we can make the approximation that there are only two levels of inventory costs:
the total cost at the R&D stage, and the total cost at the Scale-up, Full Capacity, and Terminal
stages, which require approximately three times the materials that are required during 2012. (For
simplicity, we here refer to the three later stages of the study period as the Sales stage). We are
ignoring here the fact that capacity increases gradually throughout the Scale-up stage, and so
inventory costs will actually increase throughout the Sales stage. Table 7-5 lists inventory costs
for the R&D and Sales stages.
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Inventory Costs
R&D Stage:
Item
WFI
91% isopropyl alcohol
Biohazard Box
Buffer Kit

Cost
$ 110.50
$ 2.99
$ 37.50
$ 152.00

Sales Stage:
Item
WFI
91% isopropyl alcohol
Biohazard Box
Buffer Kit

Cost
$ 110.50
$ 2.99
$ 37.50
$ 152.00

Units
per 5 L bottle
per 32 oz. bottle
per box
per kit
(100 ml samples)

Qty
12
4
4
1

Units
bottles
bottles
boxes
kits

Total Cost
$ 1,326.00
$ 11.96
$ 150.00
$ 152.00

Units
per 5 L bottle
per 32 oz. bottle
per box
per kit
(100 ml samples)
Table 7 - 5 Inventory costs.

Qty
36
12
12
3

Units
bottles
bottles
boxes
kits

Total Cost
$ 3,978.00
$ 35.88
$ 450.00
$ 456.00

Labor costs are salaries paid to management, sales representatives, scientists, and
technicians. During the first year of operation, OptiFilt will have a CEO (who will also serve as a
sales representative), two senior scientists, two laboratory technicians, one computer scientist,
and one filtration expert (a chemical engineer whose specialty is filtration and mass transfer). All
employees’ salaries are based on the average salaries for comparable positions in the Boston
metropolitan area, as published by the U.S. Bureau of Labor Statistics8. Because top-notch
scientists will be key to the OptiFilt’s success, we have elected to pay our senior scientists and
filtration expert at the higher end of this salary range. At the beginning of the Sales stage (2013),
one additional filtration expert will be hired, as well as two sales representatives. Salaries paid in
each stage are outlined in Table 7-6.

8

We have elected to pay full salaries to management and senior scientists during the R&D stage rather than issue
these personnel equity in OptiFilt. Doing so allows OptiFilt to offer the maximum equity share possible to angel
investors in the R&D stage, thereby allowing us to attract as much funding as possible in these early stages.
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Labor Costs
R&D Stage:
Personnel
CEO (also Sales)
Senior Scientists
Laboratory Technician
Computer Scientist
Filtration Expert

Salary
$ 177,980
$ 100,000
$ 60,000
$ 89,070
$ 100,000

Qty
1
2
2
1
1

Tot. Cost
$ 177,980
$ 200,000
$ 120,000
$ 89,070
$ 100,000

Sales Stage:
Personnel
Salary
Qty
CEO
$ 177,980
1
Senior Scientist
$ 100,000
2
$ 60,000
2
Laboratory Technician
Computer Scientists
$ 89,070
1
$ 130,000
2
Sales Representatives
Filtration Expert
$ 100,000
2
Table 7 - 6 Labor costs.

Tot. Cost
$ 177,980
$ 100,000
$ 60,000
$ 89,070
$ 130,000
$ 100,000

Rental costs consist of rent and utilities for OptiFilt’s Cambridge, MA office/lab space.
These costs consist of a) the cost of physical space, b) utilities costs, which include electricity,
Internet, and phone services, c) maintenance costs, and d) waste management services, which
will be provided monthly by Clean Harbors Environmental Services. We assume here that all
rental costs are constant throughout all stages of the study period. Table 7-7 lists these costs.
Rent and utilities costs were estimated based upon average rental costs in the Cambridge area,
and waste management costs are based upon Clean Harbor’s monthly fees.
Rental Costs
Space
Laboratory/Office

Cost/Sq. Ft/mo.
$ 20

Item
Utilities
Maintainence
Waste Management

Cost/mo.
mo./yr
$ 6,000
12
$ 1,000
12
$ 800
12
Table 7 - 7 Rental costs.

Sq. Ft
1000

mo.yr
12

Tot.Cost
$ 240,000

Tot. Cost
$ 72,000
$ 12,000
$ 9,600

Finally, sales and research costs are those costs associated with a) attracting new clients and
b) updating our technology in order to remain competitive. Because these costs are an investment
in the Company’s future, we estimate sales and R&D costs to comprise 3% and 15%,
100

respectively, of OptiFilt’s gross sales in the following fiscal year, which is comparable to sales
budgets for other biotechnology startups [7-18]. Based on the revenue projections shown in
Table 7-3, Sales and R&D costs are projected in Table 7-8.
Year

2012

Stage
Name
Design
Capacity
Revenue

R&D

Sales Costs
R&D Costs

2013

2014

2015

Scale-up

Scale-up

Scale-up

0%

25%

50%

75%

-

$5,101,875

$10,203,750

$153,056
$765,281

$306,113
$1,530,563

$459,169
$2,295,844

2016

2017

2018

2019

Full
Capacity
100%

Full
Capacity
100%

Full
Capacity
100%

Terminal

$15,305,625

$20,407,500

$20,407,500

$20,407,500

$20,407,500

$612,225
$3,061,125

$612,225
$3,061,125

$612,225
$3,061,125

$612,225
$3,061,125

$408,150
$2,040,750

100%

Table 7 - 8 Sales and R&D costs.

VI.

PPE and Depreciation

Depreciation and Property, Plant, and Equipment (PPE) changes must be computed in order
to project OptiFilt’s free cash flows. As is typical for the comparable equipment purchases, a 5year MACRS depreciation schedule was used to maximize tax reductions early in the period of
study. Depreciation for all equipment purchased is detailed in Table 7-9; PPE changes and the
final net PPE for each fiscal year are also shown.
MACRS Tax Schedule
Year
R&D Stage
Equipment Total
Depreciation

20.00%

32.00%

19.20%

11.52%

11.52%

5.76%

2012

2013

2014

2015

2016

2017

2018

2019

$ 197,398
$ (39,480)

All Later Stages
Equipment Total
Depreciation

$ (63,167)

$ (37,900)

$ (22,740)

$ (22,740)

$ (11,370)

$ (479)

$ (766)

$ (460)

$ (276)

$ (276)

$ (138)

$ 160,312
$ (63,646)

$ 96,666
$ (38,666)

$ 58,000
$ (23,200)

$ 34,800
$ (23,016)

$ 11,784
$ (11,646)

$ 138
$ (138)

$ 11,784

$ 138

$ (0)

$ 2,394

Initial Net PPE
Purchased (Sold)
Less: Total Dpcn

$ 197,398
-

$ 197,398
$ 2,394
$ (39,480)

Final Net PPE

$ 197,398

$ 160,312
$ 96,666
$ 58,000
$ 34,800
Table 7 - 9 Depreciation schedule and net PPE.
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VII.

Income Statement

Table 7-10 shows a projected income statement for OptiFilt for the period of interest. Here,
the ‘cost of sales’ includes any costs directly related to providing the filtration analysis services.
These figures include equipment costs, inventory costs, and rental costs. In contrast, ‘operating
costs’ include any costs that are not directly related to providing filtration analysis services;
rather, these costs are incurred in selling, general, and administrative (SG&A) activities of
OptiFilt. Operating costs include labor, sales, and R&D costs.
For each year in the study period, gross profit is calculated as the total revenue less the cost
of sales. For the purpose of determining taxes, OptiFilt’s pre-tax income equals this gross profit,
less operating costs and depreciation. We have assumed here that federal, state, and local taxes
combined will equal 40% of OptiFilt’s pre-tax income. Net income, then, is the remaining 60%
of pre-tax income after taxes have been paid.
Net income is negative in the study period’s first year; consequently, by these accounting
methods, OptiFilt receives a positive tax shied9 from the government in this year. Although tax
shields are not always provided in cases like this, we will assume here that OptiFilt will receive a
tax shield when these negative earnings occur.

9

A tax shield is essentially a ‘negative tax’—in this example, the government pays OptiFilt its negative taxes as
calculated on its income sheet, rather than OptiFilt paying taxes to the government.
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$ (1,376,415)

Net Income

Margins
Gross Margin
Profit Margin
0.00%
0.00%

0%

$ (2,294,025)
$ 917,610

Pre-Tax Income
Taxes (40%)

Capacity

$ (688,638)
$ (1,605,388)
-

Gross Profit
Operating Costs, SG&A
Depreciation

2012

$ (688,638)

R&D

Revenue
Cost of Sales

Year

50%

$ 3,740,113

$ 6,233,521
$ (2,493,409)

$ 9,709,230
$ (3,412,063)
$ (63,646)

$ 10,203,750
$ (494,520)

2014

75%

$ 6,265,223

$ 10,442,039
$ (4,176,815)

$ 14,811,105
$ (4,330,400)
$ (38,666)

$ 15,305,625
$ (494,520)

2015

2016

100%

$ 9,335,628

$ 15,559,380
$ (6,223,752)

$ 19,912,980
$ (4,330,400)
$ (23,200)

$ 20,407,500
$ (494,520)

Sales
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90.26%
95.15%
96.77%
97.58%
24.36%
36.65%
40.93%
45.75%
Table 7 - 10 Projected income statement for OptiFilt.

25%

$ 1,243,054

$ 2,071,757
$ (828,703)

$ 4,604,961
$ (2,493,725)
$ (39,480)

$ 5,101,875
$ (496,914)

2013

97.58%
45.75%

100%

$ 9,335,738

$ 15,559,564
$ (6,223,826)

$ 19,912,980
$ (4,330,400)
$ (23,016)

$ 20,407,500
$ (494,520)

2017

97.58%
45.78%

100%

$ 9,342,561

$ 15,570,934
$ (6,228,374)

$ 19,912,980
$ (4,330,400)
$ (11,646)

$ 20,407,500
$ (494,520)

2018

97.58%
45.81%

100%

$ 9,349,465

$ 15,582,442
$ (6,232,977)

$ 19,912,980
$ (4,330,400)
$ (138)

$ 20,407,500
$ (494,520)

2019

Working Capital

IX.

In order to correctly analyze free cash flow and investors’ returns, we must adjust OptiFilt’s
income statement for cash items. Of primary interest here is working capital, the amount of
capital OptiFilt will need to have on hand for its daily operations. Essentially, working capital is
the portion of profits which is kept on hand as cash in order for the Company to operate.
We have assumed four types of working capital to be relevant here. First, accounts receivable
(A/R) are those payments OptiFilt is owed by clients but has yet to receive. If we assume that
clients will be required to pay within 30 days of contracting our services,
³
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The higher A/R are, the more cash is owed OptiFilt; conversely, this implies that OptiFilt has
less cash on hand. Therefore a positive A/R represents a decrease in working capital.
Second, inventory consists of the non-durable goods OptiFilt must purchase to provide
filtration analysis services. As discussed previously, these items include WFI, buffers, and
disinfectants. If we assume that inventory items are purchased every 30 days,
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Higher inventory implies that OptiFilt has spent cash to purchase these items. Therefore, an
increase in inventory represents a decrease in working capital.
Third, accounts payable (A/P) are bills owed by OptiFilt which have not yet been paid. These
bills include rental, sales, and research costs. Assuming that OptiFilt pays its bills every 30 days,
³
s



´¶B¾o¿¹½¼¹B¹´À ½¼¹B¹·
x_

°

x_

)'¸Aox¹

° $;ª§²¬# (7-6)

Higher A/P implies that OptiFilt is holding more cash as it waits to pay its monthly bills.
Therefore, an increase in A/P effectively increases working capital available to the Company.
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Finally, cash reserves (C/R) consist of the cash kept on hand to pay salaries in the near
future. Assuming that salary for one fiscal quarter (three months) is kept on hand,
^ u 
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° qn¼# ° $¦«# (7-7)

An increase in C/R implies that OptiFilt is setting aside a larger portion of its cash to pay
future salaries; reserving capital in this way effectively reduces working capital. Therefore, an
increase in C/R represents a decrease in working capital.
Table 7-11 lists the change in each working capital component at each point in the study
period, as well as the total working capital change. It is this total change which will allow us to
determine free cash flows from OptiFilt’s net income.
Year

2012

2013

2014

2015

2016

2017

2018

2019

Item
A/R
Inventory
A/P
Cash Reserve

$ 135
$ 40,241
$ 171,763

$ 419,332
$ 404
$ 40,241
$ 164,263

$ 838,664
$ 404
$ 40,241
$ 164,263

$ 1,257,997
$ 404
$ 40,241
$ 164,263

$ 1,677,329
$ 404
$ 40,241
$ 164,263

$ 1,677,329
$ 404
$ 40,241
$ 164,263

$ 1,677,329
$ 404
$ 40,241
$ 164,263

$1,677,329
$ 404
$ 40,241
$ 164,263

WC Change
(+)/- A/R
(+)/- Inventory
(-)/+ A/P
(+)/- C/R

$ (135)
$ 40,241
$ (171,763)

$ (419,332)
$ (270)
$ 7,500

$ (419,332)
-

$ (419,332)
-

$ (419,332)
-

-

-

-

$ (131,656)

$ (412,102)

$ (419,332)

$ (419,332)

$ (419,332)

-

-

-

Total WC
Change

Table 7 - 11 Working capital changes by year.

X.

Free Cash Flow

Unlike net income, free cash flows represent the actual cash received by those holding equity
in OptiFilt. As mentioned previously, net income must be adjusted for cash items, such as
working capital, in order to determine free cash flows. In this analysis, free cash flows are
calculated as
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and are shown in Table 7-12 for each year in the study period.
As shown in Table 7-12, OptiFilt will issue stock twice in the study period: in 2012 and
2013. The earlier investors, hereafter referred to as ‘research stage’ investors, are angel investors
who will provide the capital required for the costs of beginning the Company’s R&D stage.
Based on the costs incurred in this first stage of operation (see: Equipment and Recurring Costs),
research stage investors will provide approximately $970,341 at EOY 2011. Because these
investors are providing capital with minimal evidence of future sales, they will be granted a
higher rate of return granted that the Company is successful.
In the following year, $1,000,000 in capital will be provided by a second group of
investors, hereafter referred to as ‘sales stage’ investors. Sales stage investors are venture
capitalists who will invest in OptiFilt upon evidence of a stronger, more versatile service
prototype and client contracts. The $1,000,000 investment is again based upon equipment and
operating costs, and will allow OptiFilt to operate until profits can cover all operating costs
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$ (171,763)
$ (131,656)

$ (197,398)

$ 970,341
$ (735,129)

(+)/- C/R
Total WC Change

Cash From Investing Activities
(Purchase)/Selling of Equipment

Cash From Financing Activities
Issuance of Common Stock

Free Cash Flow

$ (135)
$ 40,241

-

$ (1,376,415)

WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P

Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation

Net Income

Year

2012

$ 1,868,038

$ 1,000,000

$ (2,394)

$ 7,500
$ (412,102)

$ (419,332)
$ (270)

$ 39,480

$ 1,243,054

$ 3,384,427

-

-

$ (419,332)

$ (419,332)
-

$ 63,646

$ 3,740,113

2014

$ 5,884,557

-

-

$ (419,332)

$ (419,332)
-

$ 38,666

$ 6,265,223

2015
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Table 7 - 12 Projected free cash flows.

2013

$ 8,939,496

-

-

$ (419,332)

$ (419,332)
-

$ 23,200

$ 9,335,628

2016

$ 9,358,754

-

-

-

-

$ 23,016

$ 9,335,738

2017

$ 9,354,206

-

-

-

-

$ 11,646

$ 9,342,561

2018

-

-

-

-

$ 9,349,603

$ 138

$ 9,349,465

2019

XII.

Terminal Value

Net present value and rate of return analyses require that we project a theoretical terminal
value for OptiFilt. The terminal value estimates the present value of all cash flows continuing
past the study period (assuming that Company management decides to move forward with its
operations rather than liquidate or sell the company). Terminal values are calculated using the
perpetuity growth model, which assumes a constant growth rate g for OptiFilt moving forward
and a discount rate r. OptiFilt’s terminal value was determined using the formula
¢v¨¦®§Æ§mv  Ç¨vv^§¬tÇ«Â ° 

È
_È

(7-9)

where r is the discount rate. We have assumed a discount rate of 25%, which is comparable to
rates used in other biotechnology startups [7-19], and a conservative growth rate of 2%. For
comparison, we have calculated the terminal value of OptiFilt at 25% and 30%; these results are
shown in Tables 7-13 and 7-14, respectively.

XIII. NPV Valuation
The terminal value of OptiFilt is represented as the free cash flow value for the year
following the end of the study period. This value allows us to create a more complete picture of
OptiFilt’s valuation by considering growth and profits that extend past the year 2019.
One method of valuing OptiFilt requires determining its net present value (NPV), or the
present value of all future cash flows. The NPV is calculated by discounting the free cash flows
at each year (including the terminal value) to their present value, and then summing these
discounted cash flows to find the NPV. Obviously, the NPV is very sensitive to the discount rate
used. As explained previously, we used a 25% discount rate for these analyses; these results are
108

shown in Table 7-13. For comparison, we also include an NPV analysis using a discount rate of
30%; these results are shown in Table 7-14.
It is important to note that in both Tables 7-13 and 7-14, the 2012 discount rate is 50%
rather than 25 or 30%. This rate is higher because research stage (2011) investors, as noted
previously, are making a riskier investment than sales stage investors. Consequently, research
stage investors require a higher rate of return on their capital. The discount rate chosen for 2012
is comparable to similar discount rates for early-stage investments in biotechnology startups [720].
Also included in the NPV calculation are the present values of all investments made in
OptiFilt. Under OptiFilt’s planned financial structure, stock issuances sell partial ownership in
the Company to angel and venture capital investors; therefore, the NPV decreases with stock
issuances made. Research and sales stage investments are discounted to the year 2012 and
included as negative values in the total NPV.
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Growth
Rate

Investments
Discount
Rate
PV
NPV

Free Cash
Flow
Discount
Rate
PV

T

Year

0%

0%

3%

$ (970,341)
$ 17,866,348

$ (970,341)

-

-

0

2011

$ (800,000)

$ (1,000,000)
25%

$ (490,086)

50%

$ (735,129)

1

2012

$ 1,195,544

$ 1,732,827

25%

$ 3,384,427

3

2014

$ 2,410,315

25%

$ 5,884,557

4

2015

$ 2,929,294
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25%

$ 8,939,496

5

2016

Table 7 - 13 NPV Analysis at 25% discount rate.

25%

$ 1,868,038

2

2013

$ 2,453,341

25%

$ 9,358,754

6

2017

$ 1,961,719

25%

$ 9,354,206

7

2018

$ 1,568,603

25%

$ 9,349,603

8

2019

9

$ 5,875,132

25%

$ 43,773,142

Terminal
Value

Growth Rate

Investments
Discount
Rate
PV
NPV

-

Free Cash
Flow
Discount
Rate
PV

$ (769,231)

$ (970,341)
$ 12,823,384

3%

$ (1,000,000)
30%

$ (490,086)

50%

$ (735,129)

1

2012

$ (970,341)
0%

-

0%

0

2011

T

Year

$ 1,105,348

$ 1,540,476

30%

$ 3,384,427

3

2014

$ 2,060,347

30%

$ 5,884,557

4

2015

$ 2,407,666
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30%

$ 8,939,496

5

2016

Table 7 - 14 NPV Analysis at 30% discount rate.

30%

$ 1,868,038

2

2013

$ 1,938,911

30%

$ 9,358,754

6

2017

$ 1,490,745

30%

$ 9,354,206

7

2018

$ 1,146,163

30%

$ 9,349,603

8

2019

9

$ 3,363,384

30%

$ 35,667,005

Terminal
Value

XIV. Financing
As mentioned previously, OptiFilt will obtain capital through two stock issuances: a
‘research stage’ issuance of $970, 341 at EOY 2011, and a ‘sales stage’ issuance of $1,000,000
at EOY 2012. Both investments will provide capital necessary to purchase equipment and
inventory and pay rental fees, salaries, and sales and research expenses.
Research stage investors are angel group investors or early-stage venture capitalists.
These investors will provide capital to OptiFilt with minimal evidence of future success;
consequently, they are undertaking a relatively risky endeavor. To compensate investors for their
risk, research stage investors will receive a higher rate of return than sales stage investors,
assuming that OptiFilt is successful. Sales stage investors are venture capitalists who will
provide the Company capital after the development of a strong service prototype and preliminary
client list.
In determining the portion of OptiFilt owned by each stage of investors, we discount the
sales stage investment to the present year. To account for the risk inherent in research stage
investments, a discount rate of 50% was here; this valuable is comparable to other biotechnology
startup rates [7-21]. Percentage ownership by each group of investors is outlined in Table 7-15.
Investment
RSCH Stage
Investors
Sales Stage
Investors
Total

Discount Rate

FV
Investment
$ 646,894

Percentage

$ 1,000,000

60.7%

$ 1,646,894
Table 7 - 15 Percentage ownership by investor group.

100.0%

$ 970,341
50%

$ 1,000,000

39.3%

Using these equity shares, we can estimate the dollar amount owned by each investor
group at each year in the study period. For each group, this value equals OptiFilt’s NPV at a
particular year, multiplied by the fraction of the Company that is owned by that group. These
equity percentages are outlined in Table 7-16.
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Year

$ (1,460,427)

-

$ (1,460,427)

Scientists
RSCH Stage
Investors
Sales Stage
Investors
Total

100.0%

100.0%

$ (1,064,882)

$ (646,601)

$ (418,282)

$ (1,064,882)

60.7%

0.0%

$ (1,460,427)

0.0%
39.3%

2013

0.0%
100.0%

2012

NPV @ 25%

Scientists
RSCH Stage
Investors
Sales Stage
Investors
Total

$ 667,944

$ 405,578

$ 262,366

$ 667,944

$ 3,078,259

$ 1,869,130

$ 1,209,129

$ 3,078,259

100.0%

60.7%

0.0%
39.3%

2015

$ 6,007,553

$ 3,647,808

$ 2,359,745
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60.7%

0.0%
39.3%

2017

100.0%
$ 8,460,894

$ 8,460,894

$ 5,137,486

$ 3,323,408

Share Values v. Time

$ 6,007,553

100.0%

60.7%

0.0%
39.3%

2016

Table 7 - 16 Equity percentages by investor group.

100.0%

60.7%

0.0%
39.3%

2014

$ 10,422,613

$ 6,328,649

$ 4,093,965

$ 10,422,613

100.0%

60.7%

0.0%
39.3%

2018

$ 11,991,217

$ 7,281,110

$ 4,710,106

$ 11,991,217

100.0%

60.7%

0.0%
39.3%

2019

$ 17,866,348

$ 10,848,512

$ 7,017,836

$ 17,866,348

100.0%

60.7%

0.0%
39.3%

Terminal

Investors’ rates of return are determined via modified internal rate of return (MIRR)
analysis. Although the internal rate of return (IRR) method is traditionally used to determine
investors’ returns, an IRR approach is inappropriate in this case. An IRR analysis assumes that
all positive cash flows are reinvested at the IRR being calculated. In contrast, OptiFilt will not
reinvest its positive cash flows; it only has two investment stages (at EOY 2011 and 2012).
Therefore, an IRR analysis would exaggerate investors’ returns in this case.
An MIRR analysis more conservatively determines OptiFilt’s investors’ returns. In order
to calculate the MIRR, we must define a reinvestment rate, or the rate of return OptiFilt owners
receive on positive cash flows, and a finance rate, or the rate that OptiFilt will owe its creditors
in the event that negative cash flows are generated. We have assumed a reinvestment rate of
0.15%, which as of April 1, 2011 was the current yield on a six month United States Treasury
bill [7-22]; we assumed that our finance rate equals the prime loan interest rate of 3.25% [723].10
Table 7-17 details this MIRR analysis for OptiFilt. According to the previously
calculated equity percentages, free cash flows for each year in the study period are appropriated
to research and sales stage investor groups. The MIRR(…) function in Microsoft Excel was then
used to determine the MIRR each investor groups’ MIRRs. We project that research stage
investors will receive an MIRR of 41%, while sales stage investors will receive 56%.
Finally, a pro forma income statement is shown in Table 7-18, which includes the
previously computed free cash flows, NPV, and MIRRs. Also included are the projected terminal
values of OptiFilt for discount rates of 25 and 30%.

10

The reinvestment rate chosen here is the risk-free rate, or the rate of return on an investment with negligible risk.
Obviously, biotechnology startups like OptiFilt are inherently riskier than U.S. Treasury bills, and so a higher
reinvestment rate is possible here. We have elected to remain conservative in our profitability analysis and use the
risk-free rate regardless of the riskiness of this venture.
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$ 35,667,005

$ 43,773,142

3.25%
0.50%

Finance Rate
Reinvestment Rate

Terminal Value
(25%)
Terminal Value
(30%)

41%
56%

$ (970,341)
$ (1,000,000)

Investment

RSCH Stage MIRR
Sales Stage MIRR

Cash Flows
RSCH Stage
Sales Stage

Equity Percentage
RSCH Stage
Investors
Sales Stage Investors

Free Cash Flows

Year

$ 1,329,391
$ 2,055,036

60.7%

39.3%

$ 3,384,427

2014

$ 2,311,433
$ 3,573,125

60.7%

39.3%

$ 8,939,496

2016

$ 3,511,401
$ 5,428,094

2017

$ 3,676,085
$ 5,682,670

60.7%

39.3%

$ 9,358,754

Divided Free Cash Flows

60.7%

39.3%

$ 5,884,557

2015
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2018

$ 3,674,298
$ 5,679,908

60.7%

39.3%

$ 9,354,206

Table 7 - 17 MIRR Analysis at 25% discount rate, 3.25% finance rate, and 0.50% reinvestment rat

$ 733,758
$ 1,134,279

60.7%

0.0%

$ (735,129)
-

39.3%

$ 1,868,038

2013

100.0%

$ (735,129)

2012

$ 3,672,490
$ 5,677,113

60.7%

39.3%

$ 9,349,603

2019

$ 17,193,931
$ 26,579,212

60.7%

39.3%

$ 43,773,142

Terminal

NPV at 25%
NPV at 30%

RSCH Stage Investors (39.3%
Equity)
Sales Stage Investors (60.7%
Equity)
$ 17,866,348
$ 12,823,384

$ (1,000,000)

$ (970,341)

0%
Investment

$ (735,129)

Free Cash Flow

% Design Capacity

$ 1,000,000

$ 970,341

-

$ 1,134,279

$ 733,758

50%

$ 3,384,427

-

-

$ (419,332)
$ (419,332)

$ 63,646

$ 10,203,750
$ (494,520)
$ (3,412,063)
$ (63,646)
$ 6,233,21
$ (2,493,409)

2014
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$ 8,939,496

-

-

$ (419,332)
$ (419,332)

$ 23,200

$ 20,407,500
$ (494,520)
$ (4,330,400)
$ (23,200)
$ 15,559,380
$ (6,223,752)

2016

$ 2,055,036

$ 1,329,391

$ 3,573,125

$ 2,311,433

2017

$ 5,428,094

$ 3,511,401

100%

$ 9,358,754

-

-

-

$ 23,016

$ 20,407,500
$ (494,520)
$ (4,330,400)
$ (23,016)
$ 15,559,564
$ (6,223,826)

75%
100%
Divided Free Cash Flows

$ 5,884,557

-

-

$ (419,332)
$ (419,332)

$ 38,666

$ 15,305,625
$ (494,520)
$ (4,330,400)
$ (38,666)
$ 10,442,039
$ (4,176,815)

2015

Table 7 - 18 Projected pro forma for OptiFilt.

$ (735,129)

25%

$ 1,868,038

$ (2,394)

$ (419,332)
$ (270)
$ 7,500
$ (412,102)

$ 39,480

$ 5,101,875
$ (496,914)
$ (2,493,725)
$ (39,480)
$ 2,071,757
$ (828,703)

2013

$ (197,398)

$ (135)
$ 40,241
$ (171,763)
$ (131,656)

-

$ (688,638)
$ (1,605,388)
$ (2,294,025)
$ 917,610

2012

(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities

Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income

$ 5,682,670

$ 3,676,085

100%

$ 9,354,206

-

-

-

$ 11,646

$ 20,407,500
$ (494,520)
$ (4,330,400)
$ (11,646)
$ 15,570,934
$ (6,228,374)

2018

-

-

-

$ 5,679,908

$ 3,674,298

100%

$ 9,349,603

$ 138

$ 20,407,500
$ (494,520)
$ (4,330,400)
$ (138)
$ 15,582,442
$ (6,232,977)

2019

Chapter 8:

Scenario and Sensitivity
Analyses
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I.

Scenario Analysis

Previous financial analyses have made a number of assumptions about OptiFilt’s
operations, sales, and market. Inaccuracies in these assumptions will in turn lead to faulty NPV
and MIRR projections. In an attempt to avoid these errors, we will present financial projections
for several possible scenarios. These scenarios range from the optimistic ‘best-case’ possibilities
to the pessimistic ‘worst-case possibilities.’ Scenarios studied are summarized in Table 8-1.

R&D

R1
R2

R&D Stage takes one year.
R&D Stage takes two years.

Quantities Sold

Q1
Q2
Q3

Capacity builds in 25% increments to 185 services/yr.
Capacity builds in 25% increments to 136 services/yr, as planned.
Capacity builds in 25% increments to 101 services/yr.

Competition

C1
C2
C3

Company maintains market superiority throughout the study period, as planned.
Successful competitors arise at the terminal stage; Company forced to halve prices.
Successful competitors knock out the Company at the terminal stage; sales reach zero.

Growth

G1
G2
G3

Company grows at 3% annually, as planned.
Company size remains constant after the end of the study period.
Company is dissolved or sold at the end of the study period.
Table 8 - 1 Scenarios considered.

Scenarios of interest fall into four categories: R&D, quantities sold, competition, and
company growth. First, previous analyses have assumed that the R&D stage take only one year,
2012, after which OptiFilt will begin providing services to clients. It is possible that scientists
will need more than one year to develop perfect the ComanyX filtration analysis service. This
scenario, labeled R2 in Table 8-1, accounts for the possibility of the R&D stage taking two years
rather than one. In this case, sales would begin in the year 2014 rather than 2013.
Second, in determining the quantity of services sold at full capacity, we have assumed
that we attract 35% of all New England ‘relevant process’ clients (see: Chapter 7, Financial
Analysis) and 20% of all ‘relevant process’ clients elsewhere in the U.S. It is possible that the
Company sales team will be more or less successful in attracting clients. Scenarios Q1 through
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Q3 range from the most optimistic to the most pessimistic of these possibilities. In case Q1,
OptiFilt management is able to attract 35% of New England processes and also 30% of non-New
England processes; full capacity in this case is 185 services per year. Case Q2 is the base case
assumed in previous analyses. Finally, case Q3 assumes that management attracts only 25% of
New England clients, and 15% of non-New England Clients; full capacity in this case is 101
services per year.11
Third, previous analyses have assumed that the Company will sell at the same price after
the study period ends. It is possible that competitors will arise, thereby either a) forcing OptiFilt
to lower its price per service, or b) force OptiFilt out of business altogether. Cases C1 through
C3 cover these scenarios. Case C1 is the case previously assumed, in which minimal competition
arises and OptiFilt is able to maintain its setpoint prices. In case C2, competitors successfully
enter the filtration analysis market, and OptiFilt is forced to halve its prices at the terminal stage.
Case C3 is the worst-case scenario, in which competitors drive OptiFilt out of the market
altogether, and sales stop at the terminal stage.
Finally, previously calculated terminal values are dependent upon the assumed growth
rate past the study period. Case G1 in Table 8-1 is the base case previously assumed, in which
OptiFilt grows at a rate of 5% after the study period ends. Case G2 assumes a zero percent
growth rate; that is, OptiFilt achieves essentially the same cash flows after the study period ends.
In case G3, the Company is dissolved or sold at the end of the study period. Note that cases C3
and G3 are essentially the same; for this reason, only case C3 will be included in subsequent
analyses.

11

In the base case analyses performed previously (see: Quantities Sold), OptiFilt had the means to produce more
than twice the analyses that client demand warranted. For this reason, scenarios Q1 through Q3 are all possible
given the speed at which the Company can provide filtration analysis services.
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Profitability analyses were performed for every combination of the previously defined
scenarios. NPVs were determined at discount rates of 25 and 30%, and the MIRR was
determined for research and sales stage investors. Results are summarized in Table 8-2.
MIRR
RSCH
Sales
Stage
Stage
C1
G1
$ 25,516,587
$ 18,507,527
44.19%
62.13%
G2
$ 24,330,397
$ 17,919,001
43.06%
60.84%
C2
G1
$ 18,888,595
$ 14,492,171
37.02%
53.99%
G2
$ 18,464,244
$ 14,281,630
36.42%
53.31%
C3
G1
$ 12,260,604
$ 10,476,816
11.51%
10.63%
G2
$ 12,598,090
$ 10,644,259
12.71%
12.08%
C1
G1
$ 17,858,534
$ 12,817,578
40.72%
56.34%
G2
$ 17,003,270
$ 12,393,241
39.61%
55.09%
C2
G1
$ 12,986,064
$ 9,865,749
33.54%
48.29%
G2
$ 12,690,854
$ 9,719,281
32.97%
47.64%
C3
G1
$ 8,113,595
$ 6,913,920
10.05%
9.32%
G2
$ 8,378,439
$ 7,045,322
11.19%
10.73%
C1
G1
$ 12,388,496
$ 8,753,329
37.03%
50.80%
G2
$ 11,769,608
$ 8,446,269
35.95%
49.60%
C2
G1
$ 8,769,971
$ 6,561,162
29.81%
42.78%
G2
$ 8,567,005
$ 6,460,461
29.27%
42.18%
C3
G1
$ 5,151,446
$ 4,368,995
8.32%
7.76%
G2
$ 5,364,402
$ 4,474,653
9.40%
9.11%
C1
G1
$ 20,764,974
$ 14,215,614
34.89%
63.73%
G2
$ 19,510,223
$ 13,593,073
33.70%
62.27%
C2
G1
$ 14,136,982
$ 10,200,259
27.72%
54.96%
G2
$ 13,644,070
$ 9,955,702
27.00%
54.08%
C3
G1
$ 7,508,990
$ 6,184,903
8.62%
10.60%
G2
$ 7,777,916
$ 6,318,330
9.52%
12.04%
C1
G1
$ 14,373,920
$ 9,673,285
31.22%
57.89%
G2
$ 13,468,256
$ 9,223,942
30.06%
56.49%
C2
G1
$ 9,501,450
$ 6,721,457
24.07%
49.23%
G2
$ 9,155,840
$ 6,549,983
23.38%
48.39%
C3
G1
$ 4,628,981
$ 3,769,628
6.67%
9.11%
G2
$ 4,843,425
$ 3,876,024
7.51%
10.50%
C1
G1
$ 9,808,882
$ 6,428,765
27.43%
52.33%
G2
$ 9,152,565
$ 6,103,135
26.31%
50.97%
C2
G1
$ 6,190,356
$ 4,236,598
20.26%
43.69%
G2
$ 5,949,963
$ 4,117,327
19.61%
42.91%
C3
G1
$ 2,571,831
$ 2,044,431
4.47%
7.35%
G2
$ 2,747,360
$ 2,131,519
5.24%
8.69%
Table 8 - 2 NPV and MIRR calculations for the 36 scenarios considered.

R&D

Quantity

R1

Q1

Q2

Q3

R2

Q1

Q2

Q3

Competition

Growth

NPV (25%)

NPV (30%)

The resultant best-case, mid-range, and worst-case NPV and MIRR results are shown in
Table 8-3. The best-case values are an average of the three most optimistic projections for NPV
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and MIRR; similarly, the worst-case values are an average of the three most pessimistic
projections.
Best-Case
Mid-Range
Worst-Case
NPV (25%)
$ 23,537,319
$ 10,789,245
$ 3,316,057
NPV (30%)
$ 16,880,714
$ 7,437,517
$ 2,648,526
MIRR - RSCH
40.71%
31.69%
5.46%
62.24%
50.97%
8.38%
MIRR - Sales
Table 8 - 3 Best-case, mid-range, and worst-case NPV and MIRR results.

As stated previously, it is a Company goal to compensate investors for their risk by
achieving MIRRs of at least 50% for research stage investors, and 30% for sales stage investors
(see: Chapter 7, Financial Analysis). As indicated in Table 8-3, this goal is achieved in all but the
worst-case scenario. Pro forma for each of the 36 scenarios studied are included in the Appendix.

II. Sensitivity Analyses
The aforementioned scenarios study the potential impact of incorrectly forecasted R&D
time, quantities sold, competition, or growth. However, all these cases assume a target price of
$150,000 per filtration analysis service. Furthermore, the cases assume a study period (and
company life) of eight years, ending in 2019. It is possible that competition will arise and
challenge OptiFilt earlier than cases C1 through C3, summarized previously, predict. In this case,
OptiFilt may dissolve or be sold earlier than 2019. Sensitivity analyses were performed to
determine the impact of a) price point and b) company life on the profitability of the Company.
For the price sensitivity analysis, we determined NPV (at a 25% discount rate) and MIRR
analyses at ten potential prices for a single filtration analysis service. These analyses were
performed for the best-case, mid-range, and worst-case scenarios determined in the previous
section. We have included the base price chosen previously (see: Pricing), as well as prices
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above and below that value. Results are shown in Table 8-4, along with breakeven prices for the
best-case, mid-range, and worst-case scenarios.

Price/Service
$ 150,000
$ 140,000
$ 130,000
$ 120,000
$ 110,000
$ 100,000
$ 90,000
$ 80,000
$ 70,000
$ 60,000
$ 50,000
Breakeven
Price

Best
$23,537,319
$ 23,268,308
$ 22,206,219
$ 21,144,130
$ 20,082,041
$ 19,019,952
$ 17,957,863
$ 16,895,773
$ 15,833,684
$ 14,771,595
$ 13,709,506
< $50,000

NPV (25%)
Mid-Range
$ 11,769,608
$ 11,189,764
$ 10,609,921
$ 10,030,078
$ 9,450,235
$ 8,870,391
$ 8,290,548
$ 7,710,705
$ 7,130,862
$ 6,551,019
$ 5,971,175
< $50,000

Worst
$ 2,747,360
$ 2,344,117
$ 1,940,874
$ 1,537,631
$ 1,134,388
$ 731,145
$ 327,902
$ (75,341)
$ (478,584)
$ (881,827)
$ (1,285,070)
$
81,868

MIRR - Research Stage
Best
Mid-Range
Worst
0.43%
35.95%
5.24%
43.09%
35.83%
4.67%
43.12%
35.70%
4.04%
43.15%
35.56%
3.33%
43.19%
35.42%
2.54%
43.23%
35.28%
1.64%
43.27%
35.12%
0.60%
43.31%
34.96%
-0.61%
43.35%
34.79%
-2.04%
43.40%
34.61%
-3.80%
43.45%
34.43%
-6.03%

MIRR - Sales Stage
Best
Mid-Range
Worst
62.24%
49.60%
8.69%
60.42%
49.19%
8.22%
59.98%
48.76%
7.69%
59.54%
48.33%
7.09%
59.08%
47.89%
6.42%
58.62%
47.43%
5.64%
58.14%
46.96%
4.72%
57.66%
46.48%
3.64%
57.15%
45.99%
2.33%
56.64%
45.49%
0.70%
56.11%
44.97%
-1.41%

Table 8 - 4 Price sensitivity analysis for best-case, mid-range, and worst-case scenarios.

For the mid-range scenario, OptiFilt’s breakeven price was lower than the $50,000 lower
limit, well below our previously determined $150,000 price point. For the worst-case scenario,
OptiFilt breaks even at a price of $81,868, which is still comfortably below the previously
determined price point. These results confirm that OptiFilt can comfortably charge clients
$150,000 per filtration analysis service—this value is well above the value required for the
Company to remain profitable. Additionally, at this price point, our MIRR goals are achieved for
each investor group. From a demand viewpoint, this value is also reasonable considering the
added profits clients will enjoy as a result of our services (see: Chapter 7, Financial Analysis).
At the same time, however, the Company might consider lowering its price point in an
attempt to expand its consumer base or remain profitable in the midst of competitors. Because
OptiFilt’s price point is comfortably above breakeven points for even the worst-case scenario,
these results confirm that the Company can elect to reduce its price point and remain profitable,
given that the new price point is far enough from the break-even point to maintain acceptable
profits.
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With $150,000 confirmed as the price for one filtration analysis service, we examine the
effects of a shortened company life. As explained previously, unforeseen competition can rise
quickly and force OptiFilt out of business before the end of the previously established study
period, 2019. Such rapid innovation from competitors is unlikely because the OptiFilt
computational models will be proprietary and therefore protected by intellectual property laws.
Even so, given the rapid growth and innovation present in the U.S. biotechnology industry, it is
prudent to prepare for a potential early termination of company life.
NPV and MIRR analyses were performed using a service price of $150,000 for three
early termination scenarios: these cases have OptiFilt dissolving after two, four, and six years of
sales (at EOY 2014, 2016, and 2018, respectively). For comparison, the base case (in which the
terminal stage begins at EOY 2019 is also included. Results are shown in Table 8.5. In each early
termination scenario, the scale-up schedule was kept constant; that is, if the company dissolves at
EOY 2014, 2014 capacity is the same as in the base case.

Years of
Sales

Best

NPV (25%)
Mid-Range

Worst

Best

2
4
6
Base Case

$ 4,812,652
$ 5,339,538
$ 12,598,090
$ 23,537,319

$ 1,113,974
$ 1,401,625
$ 5,364,402
$ 10,789,245

$ (3,388,171)
$ 1,102,187
$ 3,316,057

16.14%
2.56%
12.71%
40.71%

MIRR - Research Stage
Mid-Range Worst
6.67%
-0.46%
9.40%
31.69%

-15.91%
0.46%
5.46%

Best

MIRR - Sales Stage
Mid-Range
Worst

30.40%
1.59%
12.08%
62.24%

17.15%
-1.16%
9.11%
50.97%

Breakeven
< 2 years
< 2 years
3 years
Table 8 - 5 Early termination effects. Note that the worst-case scenario has a maximum company life of five years, and so the
six-year case does not apply in this scenario.

For the mid-range case, the Company breaks even within the first two years of sales,
assuming that capacities in each year are the same as those projected in the base case. After two
years of sales at most, OptiFilt can dissolve without losing investors’ money.12 The Company,
then, only needs to operate into 2014 to prevent a loss on initial investments. For this reason, the
12

Although no money is lost at the breakeven point, neither group of investors will receive their desired rates of
return. Even so, this analysis is a ‘worst-case’ safeguard against loss rather than a profitability analysis. The goal
here is to determine the vulnerability of the Company to financial loss.
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-14.48%
3.45%
8.38%

early termination analysis assures us that OptiFilt is generally well-protected against this type of
financial loss, assuming that the Company operates at least as favorably as the mid-range
scenario predicts.
In the event of worst-case operations, the Company will need to operate for
approximately three years in order to avoid losing investors’ money. Again, because OptiFilt’s
models are proprietary, it will be very difficult for competitors to force OptiFilt out of business
within this short period of time. For this reason, it is unlikely even in this worst case that OptiFilt
will be dissolved before the breakeven point and lose investors’ money. The Company is very
well-protected against loss.

III.

Conclusions

These profitability, scenario, and sensitivity analyses provide strong evidence that OptiFilt
will be financially successful and stable, even in the event of various unlikely but
disadvantageous scenarios. As such, the Company presents a lucrative and responsible
investment opportunity for both angel investors and venture capitalists. In the vast majority of
scenarios studied, investors receive returns comparable to or greater than those seen elsewhere in
the biotechnology industry. Furthermore, early termination analyses have shown that financial
loss is very unlikely even in the worst of scenarios.
Despite our confidence in OptiFilt and the care with which we conducted these analyses, it is
important to note that this study is not perfect. An infinite number of factors can impact
OptiFilt’s profitability moving forward, many of which are external and out of the Company’s
control. Like all financial opportunities, investment in OptiFilt inherently contains some risk.
The most probable and relevant of these risks were included in the foregoing analysis.
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Conclusions
The goal of this project was to create a high-throughput system for testing new
membranes that was both highly scalable and accurate. To accomplish this purpose, OptiFilt
plans to use a mix of bench-side experimentation and semi-empirical models designed in
MATLAB and COMSOL. Biopharmaceutical companies would be able to utilize OptiFilt’s
service to optimize the performance of their membrane-based separation and purification
processes, which, depending on the protein of interest, can cost companies millions of dollars per
year. We have shown our break-even price to be approximately $50,000, with a suggested selling
point of $150,000, which nets OptiFilt a positive NPV valuation. Companies will profit by
saving product that would otherwise be lost in the waste filtrate of a purification process.
It was shown that OptiFilt’s current MATLAB and COMSOL models are internally
consistent, satisfying multiple tests in which the models produced the expected real-world
behavior. The MATLAB model obtained different Kc and Kd values when excluding fouling, and
when using one of the four types of accepted fouling models today. Changing other filtration
conditions also allows OptiFilt to characterize the membrane differently. When these coefficients
of membrane behavior are integrated into the COMSOL model, complex flow geometries and
concentration profiles are obtained, all of which are heavily dependent on Kc and Kd. In the
future, a complete bench to MATLAB to COMSOL analysis may be performed for the purpose
of impressing interested companies.
Competitors in this industry include Sci Log, Fluid Components, and Millipore, all of
which offer a more rigid service, with decreased customizability, at a cheaper price. While
OptiFilt will charge more, OptiFilt offers multiple models of fouling, full concentration profiles
through time, and is fully tuned for scaling. Furthermore, OptiFilt will train technicians to

126

perform pressure correlations and fouling model analyses, thereby condensing the lengthy
process of filtration optimization into one convenient service. Other services lack scalability, in
that a customer of Sci Log would have to purchase multiple FilterTec Plus systems for several
desired geometries. Furthermore, companies typically pay for only the products, and must train
their own personnel to operate them. OptiFilt will be entirely self-contained, and a purchase will
behave as a full subscription to the service for as long as it takes to optimize the purification.
If the current UF-based optimization is popular and successful, OptiFilt will expand to
sterile, viral, and depth filtration in the coming years, thereby increasing its consumer base.
Sterile and viral filtration are not fundamentally different from ultrafiltration; associated filters
simply have pore sizes of different magnitudes. OptiFilt will be able to create MATLAB and
COMSOL models for these purposes as well.
OptiFilt technology will significantly improve the performance of downstream
purification in a multitude of biopharmaceutical processes. In so doing, companies will improve
their product yields, thereby increasing general access to potentially life-saving drugs.
Furthermore, by eliminating the difficulties of one step in the long sequence of drug discovery,
synthesis, and purification, OptiFilt will expedite innovation and drug design. We strongly
believe that this technology will not only prove to be a profitable endeavor, but will also greatly
aid in the availability of crucial pharmaceuticals throughout the world.
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Appendix A: FDA Biologic Impurity Guidelines

[Code of Federal Regulations]
[Title 21, Volume 7]
[Revised as of April 1, 2010]
[CITE: 21CFR610.13]

TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER F--BIOLOGICS
PART 610 -- GENERAL BIOLOGICAL PRODUCTS STANDARDS
Subpart B--General Provisions

Sec. 610.13 Purity.
Products shall be free of extraneous material except that which is
unavoidable in the manufacturing process described in the approved biologics
license application. In addition, products shall be tested as provided in
paragraphs (a) and (b) of this section.
(a)(1)Test for residual moisture. Each lot of dried product shall be tested
for residual moisture and shall meet and not exceed established limits as
specified by an approved method on file in the biologics license application.
The test for residual moisture may be exempted by the Director, Center for
Biologics Evaluation and Research or the Director, Center for Drug Evaluation
and Research, when deemed not necessary for the continued safety, purity, and
potency of the product.
(2)Records. Appropriate records for residual moisture under paragraph (a)(1)
of this section shall be prepared and maintained as required by the
applicable provisions of 211.188 and 211.194 of this chapter.
(b)Test for pyrogenic substances. Each lot of final containers of any product
intended for use by injection shall be tested for pyrogenic substances by
intravenous injection into rabbits as provided in paragraphs (b) (1) and (2)
of this section:Provided, That notwithstanding any other provision of
Subchapter F of this chapter, the test for pyrogenic substances is not
required for the following products: Products containing formed blood
elements; Cryoprecipitate; Plasma; Source Plasma; Normal Horse Serum;
bacterial, viral, and rickettsial vaccines and antigens; toxoids; toxins;
allergenic extracts; venoms; diagnostic substances and trivalent organic
arsenicals.
(1)Test dose. The test dose for each rabbit shall be at least 3 milliliters
per kilogram of body weight of the rabbit and also shall be at least
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equivalent proportionately, on a body weight basis, to the maximum single
human dose recommended, but need not exceed 10 milliliters per kilogram of
body weight of the rabbit, except that: (i) Regardless of the human dose
recommended, the test dose per kilogram of body weight of each rabbit shall
be at least 1 milliliter for immune globulins derived from human blood; (ii)
for Streptokinase, the test dose shall be at least equivalent
proportionately, on a body weight basis, to the maximum single human dose
recommended.
(2)Test procedure, results, and interpretation; standards to be met. The test
for pyrogenic substances shall be performed according to the requirements
specified in United States Pharmacopeia XX.
(3)Retest. If the lot fails to meet the test requirements prescribed in
paragraph (b)(2) of this section, the test may be repeated once using five
other rabbits. The temperature rises recorded for all eight rabbits used in
testing shall be included in determining whether the requirements are met.
The lot meets the requirements for absence of pyrogens if not more than three
of the eight rabbits show individual rises in temperature of 0.6 deg. C or
more, and if the sum of the eight individual maximum temperature rises does
not exceed 3.7 deg. C.
[38 FR 32056, Nov. 20, 1973, as amended at 40 FR 29710, July 15, 1975; 41 FR
10429, Mar. 11, 1976; 41 FR 41424, Sept. 22, 1976; 44 FR 40289, July 10,
1979; 46 FR 62845, Dec. 29, 1981; 49 FR 15187, Apr. 18, 1984; 50 FR 4134,
Jan. 29, 1985; 55 FR 28381, July 11, 1990; 64 FR 56453, Oct. 20, 1999; 67 FR
9587, Mar. 4, 2002; 70 FR 14985, Mar. 24, 2005]
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Appendix B: MATLAB Proprietary Code
Model without fouling
function [go] = go();
M = [1 0 0 0 0 0 0;
0 1 0 0 0 0 0;
0 0 0 0 0 0 0;
0 0 0 0 0 0 0;
0 0 0 0 0 0 0;
0 0 0 0 0 0 0;
0 0 0 0 0 0 0];
options=odeset('Mass',M,'MassSingular','yes','MStateDependence','none');
% Membrane constants
mu=10;
P_tm=100;
Lp=10E-8;
sigma=1;
diff=10E-8;
PhiKC=0.01;
PhiKD=0.02;
L=0.001;
Ac=0.005;
kc=2.33*mu^(1/6)*diff^(1/3);

%
%
%
%
%
%
%
%
%
%

Vr0=5*10^(-6);
Cr0=10;

% Initial retentate volume (m^3)
% Initial retentate concentration (mol/m^3)

Solution viscosity (g/m s)
Transmembrane pressure (mmHg)
Hydraulic permeability (m/s mmHg)
Osmotic reflection coefficient
Solute diffusivity in solvent (m^2/s)
Theta constant
Theta constant
Length of membrane (m)
Cross-sectional area of membrane (m^2)
Mass transfer coefficient (m/s)

z0 = [0.0001; 0.5; 0.02; 0.023; 1];
% fmincon initial guess
optimfval=optimset('Algorithm','interior-point','Display','off');
suppress fsolve output
[z,zval]=fmincon(@IC,z0,[],[],[],[],[0 0 0 0 0 ],[Inf Inf 1 1
Inf],[],optimfval);
function [Q] = IC(g)
% Solves a system of equations to find appropriate initial
% conditions for the DAE system.
q=[Lp*(P_tm-sigma*g(5))-g(1);
(PhiKC*g(1)*L)/(PhiKD*diff)-g(2);
PhiKC/(1-(1-PhiKC)*exp(-g(2)))-g(3);
(g(3)*exp(g(1)/kc))/(1-g(3)+g(3)*exp(g(1)/kc))-g(4);
23.487*exp(0.0116*((Cr0*g(4)/g(3))-(Cr0*g(4))))-g(5)];
Q=abs(norm(q));
end
[t,R]=ode15s(@test_membrane,[0 153],[Vr0 Cr0 z(1) z(2) z(3) z(4)
z(5)],options);
function [fR] = test_membrane(t, R)
% 3/19/2011
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%

% solution vector
fR = zeros(7,1);
% -----------------------------------------% differential equations
% -----------------------------------------% Volume (m^3) IC 0.001-0.005 L or 10^(-6)-5*10^(-6) m^3
fR(1)=-Ac*R(3);
% Cr (g/m^3 solution) IC 84-448 g/L or 84000-448000 g/m^3
fR(2)=(1/R(1))*(-(R(3)*R(6)*R(2)*Ac)-(R(2)*fR(1)));
% Velocity (m/s)
fR(3)=Lp*(P_tm-sigma*R(7))-R(3);
% Peclet number (dimensionless)
fR(4)=(PhiKC*R(3)*L)/(PhiKD*diff)-R(4);
% Theta (dimensionless) IC 0-1
%fR(5)=0.98-R(5);
fR(5)=PhiKC/(1-(1-PhiKC)*exp(-R(4)))-R(5);
% Theta prime (dimensionless) IC 0-1... theta prime > theta
%fR(6)=0.99-R(6);
fR(6)=(R(5)*exp(R(3)/kc))/(1-R(5)+R(5)*exp(R(3)/kc))-R(6);
% Osmotic pressure (mm Hg) IC 48-3840 mmHg
fR(7)=23.487*exp(0.0116*((R(2)*R(6)/R(5))-(R(2)*R(6))))-R(7);
end
subplot(3,4,1)
plot(t,R(:,1))
title('Vr v. t')
subplot(3,4,2)
plot(t,R(:,2))
title('Cr v. t')
subplot(3,4,3)
plot(t,R(:,3))
title('vf v. t')
subplot(3,4,4)
plot(t,R(:,4))
title('Pe v. t')
subplot(3,4,5)
plot(t,R(:,5))
title('theta v. t')
subplot(3,4,6)
plot(t,R(:,6))
title('theta prime v. t')
subplot(3,4,7)
plot(t,R(:,7))
title('osmotic p v. t')
subplot(3,4,8)
plot(t,R(:,2).*R(:,6))
title('Cf v. t')
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subplot(3,4,9)
plot(t,R(:,6).*R(:,2)./R(:,5))
title('Cr,u v. t')
subplot(3,4,10)
plot(t,R(:,2).*R(:,1))
title('mAb mass (retentate) v. t')
subplot(3,4,11)
plot(t,R(:,2)-R(:,6).*R(:,2))
title('Cr-Cf')
subplot(3,4,12)
plot(t, R(:,2).*R(:,6).*(Vr0-R(:,1)))
title('mAb mass (filtrate) v. t')
end
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Model with fouling
function [go] = go();
% Change inputted phi values in go.m (line 44) and in test_membrane.m
% (lines 10-11) when comparing simulated annealing results.
M = [1 0 0 0 0 0 0 0 0;
0 1 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 1 0;
0 0 0 0 0 0 0 0 0];
options=odeset('Mass',M,'MassSingular','yes','MStateDependence','none');
z0 = [0.0001; 0.5; 0.02; 0.023; 1; 0.01];
% fsolve initial guess
optimfval=optimset('Algorithm','interior-point','Display','off');
[z,zval]=fmincon(@IC,z0,[],[],[],[],[0 0 0 0 0 0],...
[Inf Inf 1 1 Inf Inf],[],optimfval);
Vr0=1*10^(-3);
Cr0=1;
Vf0=0;

% Initial retentate volume (m^3)
% Initial retentate concentration (mol/m^3)
% Initial filtrate volume (m^3)

function [Q] = IC(g)
% Solves a system of equations to find appropriate initial
% conditions for the DAE system.
Vr0=1*10^(-3);
% Initial retentate volume (m^3)
Cr0=1;
% Initial retentate concentration (mol/m^3)
Vf0=0;
% Initial filtrate volume (m^3)
mu=10;
% Solution viscosity (g/m s)
diff=10^(-8);
% Solute diffusivity in solvent (m^2/s)
L=0.0001;
% Length of membrane (m)
kc=2.33*mu^(1/6)*diff^(1/3);
% Mass transfer coefficient (m/s)
Ka=3.36*10^(-4);
Kc=5.03*10^(6);

% Fouling model coefficient (s^-1)
% Fouling model coefficient (s/m^2)

P_tm=100;
Lp0=0.0001;
sigma=1;
delPi0=23.97;
Ac=0.005;

%
%
%
%
%

Transmembrane pressure (mmHg)
Initial hydraulic permeability (m/s mmHg)
Osmotic reflection coefficient
Initial osmotic pressure (mmHg)
Cross-sectional area of membrane (m^2)

phiGuess=[0.01 0.02];
J0=Ac*Lp0*(P_tm-sigma*delPi0);

% Initial flux (m/s)

q=[g(6)*(P_tm-sigma*g(5))-g(1);
(phiGuess(1)*g(1)*L)/(phiGuess(2)*diff)-g(2);
phiGuess(1)/(1-(1-phiGuess(1))*exp(-g(2)))-g(3);
(g(3)*exp(g(1)/kc))/(1-g(3)+g(3)*exp(g(1)/kc))-g(4);
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23.487*exp(0.0116*((Cr0*g(4)/g(3))-(Cr0*g(4))))-g(5);
((((1-Ka*5E-8)^(-4))+Kc*J0*Vf0)^(-1))*J0/(P_tm-sigma*g(5))-g(6)];
Q=abs(norm(q));
end
[t,R]=ode15s(@test_membrane,[0:.5:2200],[Vr0 Cr0 z(1) z(2) z(3) z(4) z(5) Vf0
z(6)],options);
subplot(4,4,1)
plot(t,R(:,1)/100*5)
title('Vr (m^3)')
subplot(4,4,2)
plot(t,R(:,2))
title('Cr (g/m^3)')
subplot(4,4,3)
plot(t,R(:,3)/1000)
title('vf or J (m/s)')
subplot(4,4,4)
plot(t,R(:,4))
title('Pe')
subplot(4,4,5)
plot(t,R(:,5))
title('theta')
subplot(4,4,6)
plot(t,R(:,6))
title('theta prime')
subplot(4,4,7)
plot(t,R(:,7))
title('osmotic p (mm Hg)')
subplot(4,4,8)
plot(t,R(:,2).*R(:,6))
title('Cf (g/m^3)')
subplot(4,4,9)
plot(t,R(:,6)./R(:,5).*R(:,2))
title('Cr,u (g/m^3)')
subplot(4,4,10)
plot(t,R(:,8))
title('Vf (m^3)')
subplot(4,4,11)
plot(t,R(:,9)/1000)
title('Lp (m/s mm Hg)')
subplot(4,4,12)
plot(t,R(:,1).*R(:,2)/20)
title('Mass, retentate (g)')
% ignores Cr,u
subplot(4,4,13)
plot(t,R(:,2).*R(:,6).*R(:,8))
title('Mass, filtrate (g)')
subplot(4,4,14)
plot(t,R(:,6)./R(:,5).*R(:,2)-R(:,2).*R(:,6));
title('Cru-Cf (g/m^3)')
end

function [fR] = test_membrane(t, R)
% solution vector
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fR = zeros(9,1);
PhiKC=0.01;
PhiKD=0.02;

% Theta constant
% Theta constant

% constants
mu=10;
diff=10^(-8);
L=0.0001;
kc=2.33*mu^(1/6)*diff^(1/3);

%
%
%
%

Ka=3.36*10^(-4);
Kc=5.03*10^(6);

% Fouling model coefficient (s^-1)
% Fouling model coefficient (s/m^2)

P_tm=100;
Lp0=0.0001;
sigma=1;
delPi0=23.97;
Ac=0.005;

%
%
%
%
%

Solution viscosity (g/m s)
Solute diffusivity in solvent (m^2/s)
Length of membrane (m)
Mass transfer coefficient (m/s)

Transmembrane pressure (mmHg)
Initial hydraulic permeability (m/s mmHg)
Osmotic reflection coefficient
Initial osmotic pressure (mmHg)
Cross-sectional area of membrane (m^2)

J0=Ac*Lp0*(P_tm-sigma*delPi0);
% -----------------------------------------% differential equations
% -----------------------------------------% Volume (m^3) IC 0.001-0.005 L or 10^(-6)-5*10^(-6) m^3
fR(1)=-Ac*R(3);
% Cr (g/m^3 solution) IC 84-448 g/L or 84000-448000 g/m^3
fR(2)=(1/R(1))*(-(R(3)*R(6)*R(2)*Ac)-(R(2)*fR(1)));
% Throughput volume (m^3) IC 0
fR(8)=Ac*R(3);
% -----------------------------------------% algebraic constraints
% -----------------------------------------% Velocity/flux (m/s)
fR(3)=R(9)*(P_tm-sigma*R(7))-R(3);
% Peclet number (dimensionless)
fR(4)=(PhiKC*R(3)*L)/(PhiKD*diff)-R(4);
% Theta (dimensionless) IC 0-1
fR(5)=0.98-R(5);
%fR(5)=PhiKC/(1-(1-PhiKC)*exp(-R(4)))-R(5);
% Theta prime (dimensionless) IC 0-1... theta prime > theta
fR(6)=0.99-R(6);
%fR(6)=(R(5)*exp(R(3)/kc))/(1-R(5)+R(5)*exp(R(3)/kc))-R(6);
% Osmotic pressure (mm Hg) IC 48-3840 mmHg
fR(7)=23.487*exp(0.0116*((R(2)*R(6)/R(5))-(R(2)*R(6))))-R(7);
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% Hydraulic permeability (m/s mm Hg)
%fR(9)=4.96873411768589e-05-R(9);
fR(9)=((((1-Ka*t)^(-4))+(Kc*J0*R(8)))^(-1))*J0/(P_tm-sigma*R(7))-R(9);
end
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Complete model with SA
function [results] = go(data, phi)
% 1. import experimental data, stored in Excel sheet
% 2. run results.m, then go to test_membrane.m and change the PhiKc guess to
results(1), and the PhiKd guess to results(2)
% 3. run compare(data,results) to view side-by-side comparison of SA-based
graph and data graph.
M =[1 0 0 0 0 0 0 0 0;
0 1 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 0 0;
0 0 0 0 0 0 0 1 0;
0 0 0 0 0 0 0 0 0];
options_ode=odeset('Mass',M,'MassSingular','yes','MStateDependence','none','S
tats','off');
%------------------------% Membrane constants
%------------------------mu=10;
diff=10^(-8);
L=0.0001;
kc=2.33*mu^(1/6)*diff^(1/3);

%
%
%
%

Ka=3.36*10^(-4);
Kc=5.03*10^(6);

% Fouling model coefficient (s^-1)
% Fouling model coefficient (s/m^2)

P_tm=100;
Lp0=0.01;
sigma=1;
delPi0=23.97;
Ac=0.005;

%
%
%
%
%

J0=Ac*Lp0*(P_tm-sigma*delPi0);

% Initial flux (m/s)

Vr0=1*10^(-3);
Cr0=1;
Vf0=0;

% Initial retentate volume (m^3)
% Initial retentate concentration (mol/m^3)
% Initial filtrate volume (m^3)

Solution viscosity (g/m s)
Solute diffusivity in solvent (m^2/s)
Length of membrane (m)
Mass transfer coefficient (m/s)

Transmembrane pressure (mmHg)
Initial hydraulic permeability (m/s mmHg)
Osmotic reflection coefficient
Initial osmotic pressure (mmHg)
Cross-sectional area of membrane (m^2)

z0 = [0.0001; 0.5; 0.02; 0.023; 1; 0.01];
% fsolve initial guess
optimfval=optimset('Algorithm','interior-point','Display','off');
[results,fval]=runFit();

% run simulated annealing

% once the optimization is stopped, store in results vector so that
% compare.m is easy to use
[z,zval]=fmincon(@IC,z0,[],[],[],[],[0 0 0 0 0 0],[Inf Inf 1 1 Inf
Inf],[],optimfval);
results(1,3:8)=z(1:6);
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function [x,fval,time] = runFit()
% Runs simulated annealing.
x0 = [phi(1) phi(2)];
lb = [0 0];
ub = [1 1];

% Start iterating from the guess given
% No nonzero phiKc, phiKd

options_sim =
saoptimset('Display','iter','TemperatureFcn',@temperatureexp,...
'DisplayInterval',1,'PlotFcns',{@saplotf,@saplotbestf,...
@saplotstopping,@saplotbestx},'MaxFunEvals',Inf,...
'ObjectiveLimit',1E-10,'InitialTemperature',1,...
'ReannealInterval',100);
[x,fval]=simulannealbnd(@runModel,x0,lb,ub,options_sim);
% finds the minimum value of error in runModel
end
function [error] = runModel(phiGuess)
% Uses fsolve to calculate initial DAE guesses and then solves the
% ODE with those guesses.
% calculate DAE guesses
[z,zval]=fmincon(@IC,z0,[],[],[],[],[0 0 0 0 0 0],...
[Inf Inf 1 1 Inf Inf],[],optimfval);
function [Q] = IC(g)
% Solves a system of equations to find appropriate initial
% conditions for the DAE system.
q=[g(6)*(P_tm-sigma*g(5))-g(1);
(phiGuess(1)*g(1)*L)/(phiGuess(2)*diff)-g(2);
phiGuess(1)/(1-(1-phiGuess(1))*exp(-g(2)))-g(3);
(g(3)*exp(g(1)/kc))/(1-g(3)+g(3)*exp(g(1)/kc))-g(4);
23.487*exp(0.0116*((Cr0*g(4)/g(3))-(Cr0*g(4))))-g(5);
((((1-Ka*5E-8)^(-4))+Kc*J0*Vf0)^(-1))*J0/(P_tm-sigma*g(5))-g(6)];
Q=abs(norm(q));
end
function [fR] = oderesults(t, R)
% Stores all ODEs and algebraic equations of the actual model.
% solution vector
fR = zeros(9,1);
% these two values change after each iteration and must be
% reassigned in oderesults
PhiKC=phiGuess(1);
% Theta constant
PhiKD=phiGuess(2);
% Theta constant
% -----------------------------------------% differential equations
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% -----------------------------------------% Volume (m^3) IC 0.001-0.005 L or 10^(-6)-5*10^(-6) m^3
fR(1)=-Ac*R(3);
% Cr (g/m^3 solution) IC 84-448 g/L or 84000-448000 g/m^3
fR(2)=(1/R(1))*(-(R(3)*R(6)*R(2)*Ac)-(R(2)*fR(1)));
% Throughput volume (m^3) IC 0
fR(8)=Ac*R(3);
% -----------------------------------------% algebraic constraints
% -----------------------------------------% Velocity/flux (m/s)
fR(3)=R(9)*(P_tm-sigma*R(7))-R(3);
% Peclet number (dimensionless)
fR(4)=(PhiKC*R(3)*L)/(PhiKD*diff)-R(4);
% Theta (dimensionless) IC 0-1
fR(5)=PhiKC/(1-(1-PhiKC)*exp(-R(4)))-R(5);
% Theta prime (dimensionless) IC 0-1... theta prime > theta
fR(6)=(R(5)*exp(R(3)/kc))/(1-R(5)+R(5)*exp(R(3)/kc))-R(6);
% Osmotic pressure (mm Hg) IC 48-3840 mmHg
fR(7)=23.487*exp(0.0116*((R(2)*R(6)/R(5))-(R(2)*R(6))))-R(7);
% Hydraulic permeability (m/s mm Hg)
fR(9)=((((1-Ka*t)^(-4))+(Kc*J0*R(8)))^(-1))*J0/(P_tm-sigma*R(7))-R(9);
end
try
% the time span in ode15s must be consistent with the imported data.
[t,R]=ode15s(@oderesults,[0:0.5:560],[Vr0 Cr0 z(1) z(2) z(3) z(4)
z(5) Vf0 z(6)],options_ode); %#ok<ASGLU>
% given the inputted phiKc, phiKd guess, temp stores the
% calculated results' deviation from experimental data
temp(:,1)=data(:,2)-R(:,5);
temp(:,2)=data(:,3)-R(:,6);
error=norm(temp);
catch
error=100;
end

% if the PhiKc, PhiKd guess results
% in inconsistent y0, discard results

end
function [Q] = IC(g)
% Solves a system of equations to find appropriate initial
% conditions for the DAE system.
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q=[g(6)*(P_tm-sigma*g(5))-g(1);
(results(1)*g(1)*L)/(results(2)*diff)-g(2);
results(1)/(1-(1-results(1))*exp(-g(2)))-g(3);
(g(3)*exp(g(1)/kc))/(1-g(3)+g(3)*exp(g(1)/kc))-g(4);
23.487*exp(0.0116*((Cr0*g(4)/g(3))-(Cr0*g(4))))-g(5);
((((1-Ka*5E-8)^(-4))+Kc*J0*Vf0)^(-1))*J0/(P_tm-sigma*g(5))-g(6)];
Q=abs(norm(q));
end
end

142

FilterTec Plus
™

• Simultaneously Compare 3 Filters
• Filterability Studies & Vmax Determination
• Evaluate Filter Combinations
• Monitor/Control Pressure, Feed Rate, Collection Rate, etc.
• Automatic Documentation to Spreadsheet
• Built-In Alarms for Walk-Away Operation
• Compatible with All Manufacturers’ Filters
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3-Filter Testing Station

3-Filter Testing Station

FilterTec™ Plus

P1

3-Filter Testing Station
FilterTec Plus
TM

F1

Parallel Testing
Save time and improve efficiency in Filterability Studies
& Vmax Determinations. The FilterTec™ Plus testing
station gives you the flexibility to evaluate three filters
simultaneously. Plus, you’ll have the freedom to test
filter combinations on your schedule. This allows you to
test any combination of filters from the same or different
manufacturers.

Save Money with Real-time Monitoring
Improve your lab’s productivity and efficiency. With FilterTec™
Plus be assured that your tests will maintain a constant rate
or pressure without supervision. FilterTec™ Plus has five
operational modes and six user-definable alarms that allow
you to work on other projects while doing filter tests.

F3

F2

SCALE 3

SCALE 2

SCALE 1

A constant pressure can be easily maintained, and the
collection rates achieved will be based upon the dynamics
of the filter. If the filters are the same, the Feed Rate will be
roughly spit into thirds.
The second common configuration utilizes 3 pump heads, 3
sets of tubing, all 3 sensors and balances, with everything
running in parallel.
FilterTec Plus
TM

• R/P Stat Mode: Constant Rate/Constant Pressure Filtration
with six user-definable alarms.

P1

• P Stat Mode: Constant Pressure Filtration with six
user-definable alarms.

F1

• R/P Step-Scan Mode: Automated, programmable,
continuous changing of pump rate or pressure with time.
SCALE 1

Save Time with Automated Documentation

P2

Don’t waste time manually documenting filtration information.
SciDoc interface software is sent to you ready to use for realtime verification and documentation of filtration parameters.
Automatic documentation allows for easy comparison of
filters, and you’ll be able to quickly present your data findings.
• SciDoc interface software with custom macros for Excel®
for data compilation.
• Complete process analysis with graphing of data.
• Real-time verification and documentation of process
parameters.
FilterTec™ Plus is shipped to you complete, ready to use as
a 3-Filter Testing Station. This Station consists of 3 balances
with cables, the Serial-3 Balance Interface box, and a stand
and clamp set for holding your 3 filters over the balances. An
optional 6-way Rotary Valve is available and is controlled by
the operational modes.
You can test one, two, or three filters simultaneously.
This system has several different parallel or serial
configurations.
The first of the more common configurations uses one
head to provide solution through a manifold to 3 filters
while monitoring or controlling the pressure with each filter
emptying into its own container on its own balance.

F2

SCALE 2

P3
F3

SCALE 3

This setup puts the control of the feed rate in the hands of
channel 1 with channels 2 and 3 being similar, but not always
identical. To minimize differences, use tubing from the same
manufacturer and lot whenever possible.
Also, while only one of the 3 sensors will be used for control,
each sensor and balance will provide independent alarms
based on the system’s settings. When in Constant Pressure
Mode, the source sensor’s channel is controlled, and the other
channels again will be similar but not identical.

SciLog, Inc. 8845 South Greenview Drive, Suite 4, Middleton, WI 53562 Ph: (800)955-1993 Fx: (608) 824-0509 www.scilog.com

PHARMA REFRACTOMETER
FOR IN-LINE CONCENTRATION
MEASUREMENT

K-PATENTS PHARMA REFRACTOMETER PR-23-AC
SB:PR-23/Pharma

TYPICAL APPLICATIONS
PHARMACEUTICAL CHEMICALS

Acetylsalicylic acid, Calcium gluconate,
Glycerophosphates, Chloral hydrate, Saccharin,
Antihistamines, Tranquilizers, Antifilarials, Diethyl
carbamazine citrate, Antidiabetics and more.

ACTIVE PHARMACEUTICAL INGREDIENTS
Actives, Excipients, Intermediates, Raw material, Fine
chemicals, and Bulk chemicals.

ANTIBIOTICS

Penicillin, Streptomycin, Tetracyclines, Chloramphenicol,
and Antifungals.

BLOOD PRODUCTS

Blood, Plasma, Serum, Infusion liquids, Sodium
chloride, and Glucose.

PROTEINS

Proteins and Protein buffer solutions

SYNTHETIC DRUGS

Sulfa drugs, Antituberculosis drugs, Antileprotic drugs,
Analgesics, Anesthetics, and Antimalarials.

VITAMINS

Ascorbid acid, Ca-arabonate, Riboflavin, Vitamin-B,
Vitamin-C Sodium Pantonate. and more.

SYNTHETIC HORMONES
SYRUPS

Concentrated aqueous solutions of sucrose.

DRUGS OF VEGETABLE ORIGIN

Quinine, Strychnine and Brucine, Emetine, and Digitalis
Glycosides, and Herbal extracts.

VACCINES AND SERA
SURGICAL SUTURES
Glue for human tissue.

ACIDS, BASES AND SOLVENTS

K-PATENTS PHARMA REFRACTOMETER PR-23-AC

REGULATORY
COMPLIANCE
Food and Drug Administration's (FDA's)
regulations require documented act of
demonstrating that a specific procedure,
process, and activity will consistently lead
to the expected results. This is called
validation.
K-Patents Process Refractometer PR-23
is ideal real-time instrument that meets
the pharmaceutical industry standards
and guidelines including PAT, GMP, CIP/
SIP, 21 CFR Part 11 and validation. The
ability to understand and continuously
control parameters such as Refractive
Index nD contributes significantly to the
development of effective drugs and efficient manufacturing processes.

EQUIPMENT QUALIFICATION
These steps are common for a K-Patents Pharma Refractometer PR-23-AC qualification process:

1A. LAB TEST WITH STATIC
SAMPLE

Laboratory test for manual sampling in
a laboratory cuvette consisting of an
agitator with stirrer and connections for
thermostat controlled water.

K-Patents Pharma Refractometer PR23-AC fulfills the pharmaceutical drug
production regulations for process wetted part materials, sealing, and surface
roughnesses. No animal originated
media are used in the machining and
polishing processes.
K-Patents refractometers are designed,
manufactured and serviced under ISO
9001 quality system and procedures that
guarantee the accuracy and repeatability
of the measurement results. Each sensor
is provided with a calibration certificate
comparing a set of standard liquids to
the actual sensor output. Therefore, the
calibration and accuracy can be routinely
verified with the traceable standard refractive index liquids.
Validation often includes the qualification of systems and equipment. It is a
requirement for Good Manufacturing
Practices (GMPs) and other regulatory
requirements.
K-Patents provides a qualification procedure and equipment that help the user to
prove the suitability of the refractometer
for its designated function. This includes
a set up for tests with refractometer in a
laboratory or in a pilot process in making
small quantities of the drug.

2. TEST IN PILOT SCALE

Installation in a pilot process using
a pharma mini flow cell.

3. INSTALLATION AT FULL
PRODUCTION SCALE

1B. LAB TEST WITH
CONTINUOUS SAMPLE

Laboratory test for continuous sampling
in a laboratory cuvette consisting of connections for a sample inlet and outlet and
for thermostat controlled water.

DRUG FORMULATION

Step one of the equipment qualification
process is also an applicable procedure
for creating proprietary chemical curves
for different drug recipies on the user's
own manufacturing facility. This makes
the drug formulation and validation
easier in considerably less time.

DIGITAL MEASUREMENT
PRINCIPLE
Optical
image

Prism

Light
source

Critical
angle

Process
medium
The light source sends light against the
interface between a prism and the process solution, where the rays meet the
surface at different angles.
Prism

Reflected light

Cr

itic

al

an

gl

e

Light source

The angle corresponding to the shadow
line is called the Critical Angle of Total
Reflection. The Critical Angle is a function of the refractive index and therefore
the concentration of the solution.

Solution

Refracted light

Depending on the angle, some rays are
totally reflected. And, some rays are only
partially reflected, most of the light is
refracted into the process solution.

A digital CCD-camera detects the optical
image and the shadow line. The camera
transforms the optical image point-bypoint to an electrical signal. The exact
shadow line position is located and the
refractive index nD is determined.
A built-in temperature sensor meas-ures
the temperature T on the interface of the
process liquid. The indicating transmitter
converts the refractive index nD and temperature T to concentration units.
The diagnostics program ensures that the
measurement is reliable.

Thus an optical image with a dark sector
and a light sector is created.

FDA 21 CFR
PART 11
ADHERENCE
The K-Patents Refractometer includes
an Ethernet communication solution.
Together with the user's own procedural and administrative user controls
it facilitates electronic data records for
FDA 21 CFR Part 11 adherence. The
transmitter uses the UDP/IP protocol to
communicate over the Ethernet to any
type of computer. This eliminates human error and allows for refractometer
generated measurement and diagnostic
data capture for storage, analysis and
reporting.
Any computer with a standard Ethernet
connection can be configured to view
and download data from the sensor by
using a standard web browser.
Access to the refractometer and to the
refractometer generated data can be
restricted to authorized personnel only
using a password protection.

DESIGN
Air cooling fins
Processor card
Thermal conductor
Thermal isolation

CCD-camera
Light source
Prism
Temperature sensor

CORE-Optics
All measuring components (light source, prism,
temperature sensor and CCD-camera) are in one
solid CORE-optics module.
The patented CORE-optics is mechanically isolated
from the influence of external forces and vibrations.
The CORE-optics contains no mechanical
adjustments.
(US Patent No. 6067151)

SPECIFICATIONS
Compact sensor PR-23-AC:
[5.047]
128.2

[1.181]
30.0

[4.724]
120.0

[0.551]
14.0

2.5” SANITARY CLAMP
M16 CABLE GLAND

Laboratory test cuvette LTC for off-line
laboratory testing:
Mixer
O-ring 16x2 EPDM
O-ring 21x2 EPDM
Sample
chamber

O-ring 20.2x3 Kalrez

Cooling/
heating
jacket

1,57
40
Cooling/heating
water outlet
8mm (0.35")
Cooling/heating
water inlet
8mm (0.35")
10,13
257

2.5" sanitary clamp

Mini flow cell PMFC for low volume pilot
processes:

Refractive Index range:

Standard: Full range, nD = 1.3200...1.5300 (corresponds to 0...100 % b.w.)

Accuracy:

Refractive index nD ±0.0002 (corresponds typically to ± 0.1% by weight)
Repeatability nD ±0.0001 (corresponds typically to ±0.05% by weight)

Speed of response:

1 s undamped, damping time selectable up to 5 min

Calibration:

With Cargille standard R.I. liquids over full range of nD 1.3200...1.5300

CORE-Optics:

No mechanical adjustments (US Patent No. US6067151)

Digital measurement:

3648 pixel CCD element

Light source:

Light emitting diode (LED), 589 nm wavelength, sodium D-line

Temperature sensor:

Built-in Pt-1000, linearization according to IEC 751

Temperature compensation:

Automatic, digital compensation

Instrument verification:

According to ISO 9000 quality system: NIST traceable with standard R.I. liquids
and Transmitter's menu guided procedure and report for printing

Ambient temperature:

Sensor: max. 45°C (113°F), min. -20°C (-4°F)
Indicating transmitter: max. 50°C (122°F), min. 0°C (32°F)

SENSOR PR-23-AC:
Process connection:

Sanitary 3A-clamp 2.5"

Process temperature:

-20°C...130°C (-4°F...266°F)

Surface roughness, option:

Ra 0.4μm (15μ inch)

Process wetted parts, standard:

AISI 316L stainless steel, prism spinel, prism gaskets PTFE (teflon), EPDM

Sensor protection class:

IP67, Nema 4X

Sensor weight:

2 kg (4.4 lbs)

Laboratory test cuvette LTC
for off-line laboratory testing:

AISI 316 L stainless steel laboratory test cuvette for manual and static sampling.
Contains an agitator with PTFE (teflon) stirrer, and connections for sample inlet
and outlet, and 1/4" tube connections for thermostat controlled water.

Pharma mini flow cell PMFC:

For in-line testing of low volume samples in pilot conditions, process connection
Sanitary 3A-clamp 1,5", electropolished wetted parts material with surface
roughness of Ra 0.4μm (15μ inch)

1,25
31,8
1,25
31,8

10
1, 28

0,16
4

Indicating transmitter DTR in stainless steel
enclosure:
9,99
254

6,04
153

Display:

320x240 pixel graphical LCD with LED backlight

Keypad:

18 membrane keys

Current output:

Two independent current outputs, 4-20 mA, max. load 1000 Ohm, galvanic
isolation 1500 VDC or AC (peak), hold function during prism wash

Ethernet connection:

10/100 Mbit/s, data acquisition over UDP/IP Protocol with K-Patents data logging
software

Power:

AC input 100-240 VAC/50-60 Hz, optional 24 VDC, 30 VA

Alarms/Wash relays:

Two built-in signal relays, max. 250 V/3 A

Sensor connectivity:

One or two sensors can be connected to the DTR. Sensors independent of
each other: own parameter sets and usable in different applications. Two
current outputs configurable independently to indicate process concentration or
temperature of either sensor.

Transmitter protection class:

Enclosure IP66, Nema 4X

Enclosure material:

Standard: Polycarbonate, optional: AISI 304 stainless steel

Indicating transmitter weight:

4.5 kg (10 lbs)

11,95
304

INTERCONNECTING CABLE: IEC 61158-2 compliant two-wire cable

K-PATENTS OY
P.O. BOX 77
ELANNONTIE 5
FI-01511 VANTAA, FINLAND
PHONE: INT.+358-207-291 570
FAX: INT.+358-207-291 577
info@kpatents.com
WWW.KPATENTS.COM

Interconnecting cable length:

Standard 10 m (33 ft), max. 200 m (660 ft)

ORDERING INFORMATION:

- Sensor type and flow cell option(s)
- Desired scale
- Properties of process solution
- Process temperature range
- Surface roughness

- Process pipe size
- Process flow rate
- Supply voltage and frequency
- Material certificates
- Options

K-PATENTS, INC.
1804 CENTRE POINT CIRCLE, SUITE 106
NAPERVILLE, IL 60563
U.S.A.
PHONE: (630) 955 1545
FAX: (630) 955 1585
info@kpatents-usa.com

WWW.KPATENTS.COM

We reserve the right to technical alterations.

Done Information Oy / Keili
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INDICATING TRANSMITTER DTR:

R1 Q1 C1 G1

Appendix D: Pro Forma for Scenario Analyses
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,935,800)
$
$ (2,624,438)
$ 1,049,775

$ 6,937,500
$ (496,914)
$ (3,154,550)
$ (39,480)
$ 3,246,557
$ (1,298,623)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (63,646)
$ 8,913,534
$ (3,565,414)

$ 20,812,500
$ (494,520)
$ (5,652,050)
$ (38,666)
$ 14,627,264
$ (5,850,905)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,200)
$ 21,580,230
$ (8,632,092)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,016)
$ 21,580,414
$ (8,632,166)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (11,646)
$ 21,591,784
$ (8,636,714)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$
(138)
$ 21,603,292
$ (8,641,317)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (570,205)
$
(270)
$
$
7,500
$ (562,975)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (933,376)

$ 2,422,044

$ 4,841,561

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 25,516,587
$ 18,507,527

RSCH Stage MIRR
Sales Stage MIRR

44%
62%

25%

50%

$ (933,376)
$
-

$ 951,370
$ 1,470,674

$ 8,244,819

$ 12,401,133

$ 12,971,264

$ 12,966,716

$ 12,962,113

75%
100%
100%
Divided Free Cash Flows
$ 1,901,748
$ 3,238,535
$ 4,871,120
$ 2,939,814
$ 5,006,284
$ 7,530,013

100%

100%

$ 5,095,065
$ 7,876,199

$ 5,093,279
$ 7,873,438

R1 Q1 C1 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,935,800)
$
$ (2,624,438)
$ 1,049,775

$ 6,937,500
$ (496,914)
$ (3,154,550)
$ (39,480)
$ 3,246,557
$ (1,298,623)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (63,646)
$ 8,913,534
$ (3,565,414)

$ 20,812,500
$ (494,520)
$ (5,652,050)
$ (38,666)
$ 14,627,264
$ (5,850,905)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,200)
$ 21,580,230
$ (8,632,092)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,016)
$ 21,580,414
$ (8,632,166)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (11,646)
$ 21,591,784
$ (8,636,714)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$
(138)
$ 21,603,292
$ (8,641,317)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (570,205)
$
(270)
$
$
7,500
$ (562,975)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (933,376)

$ 2,422,044

$ 4,841,561

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 24,330,397
$ 17,919,001

RSCH Stage MIRR
Sales Stage MIRR

43%
61%

25%

50%

$ (933,376)
$
-

$ 951,370
$ 1,470,674

$ 8,244,819

$ 12,401,133

$ 12,971,264

$ 12,966,716

$ 12,962,113

75%
100%
100%
Divided Free Cash Flows
$ 1,901,748
$ 3,238,535
$ 4,871,120
$ 2,939,814
$ 5,006,284
$ 7,530,013

100%

100%

$ 5,095,065
$ 7,876,199

$ 5,093,279
$ 7,873,438

R1 Q1 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,935,800)
$
$ (2,624,438)
$ 1,049,775

$ 6,937,500
$ (496,914)
$ (3,154,550)
$ (39,480)
$ 3,246,557
$ (1,298,623)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (63,646)
$ 8,913,534
$ (3,565,414)

$ 20,812,500
$ (494,520)
$ (5,652,050)
$ (38,666)
$ 14,627,264
$ (5,850,905)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,200)
$ 21,580,230
$ (8,632,092)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,016)
$ 21,580,414
$ (8,632,166)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (11,646)
$ 21,591,784
$ (8,636,714)

$ 13,875,000
$ (494,520)
$ (5,652,050)
$
(138)
$ 7,728,292
$ (3,091,317)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (570,205)
$
(270)
$
$
7,500
$ (562,975)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (933,376)

$ 2,422,044

$ 4,841,561

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 18,888,595
$ 14,492,171

RSCH Stage MIRR
Sales Stage MIRR

37%
54%

25%

50%

$ (933,376)
$
-

$ 951,370
$ 1,470,674

$ 8,244,819

$ 12,401,133

$ 12,971,264

$ 12,966,716

$ 4,637,113

75%
100%
100%
Divided Free Cash Flows
$ 1,901,748
$ 3,238,535
$ 4,871,120
$ 2,939,814
$ 5,006,284
$ 7,530,013

100%

100%

$ 5,095,065
$ 7,876,199

$ 5,093,279
$ 7,873,438

R1 Q1 C2 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,935,800)
$
$ (2,624,438)
$ 1,049,775

$ 6,937,500
$ (496,914)
$ (3,154,550)
$ (39,480)
$ 3,246,557
$ (1,298,623)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (63,646)
$ 8,913,534
$ (3,565,414)

$ 20,812,500
$ (494,520)
$ (5,652,050)
$ (38,666)
$ 14,627,264
$ (5,850,905)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,200)
$ 21,580,230
$ (8,632,092)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,016)
$ 21,580,414
$ (8,632,166)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (11,646)
$ 21,591,784
$ (8,636,714)

$ 13,875,000
$ (494,520)
$ (5,652,050)
$
(138)
$ 7,728,292
$ (3,091,317)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (570,205)
$
(270)
$
$
7,500
$ (562,975)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (933,376)

$ 2,422,044

$ 4,841,561

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 18,464,244
$ 14,281,630

RSCH Stage MIRR
Sales Stage MIRR

36%
53%

25%

50%

$ (933,376)
$
-

$ 951,370
$ 1,470,674

$ 8,244,819

$ 12,401,133

$ 12,971,264

$ 12,966,716

$ 4,637,113

75%
100%
100%
Divided Free Cash Flows
$ 1,901,748
$ 3,238,535
$ 4,871,120
$ 2,939,814
$ 5,006,284
$ 7,530,013

100%

100%

$ 5,095,065
$ 7,876,199

$ 5,093,279
$ 7,873,438

R1 Q1 C3 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,935,800)
$
$ (2,624,438)
$ 1,049,775

$ 6,937,500
$ (496,914)
$ (3,154,550)
$ (39,480)
$ 3,246,557
$ (1,298,623)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (63,646)
$ 8,913,534
$ (3,565,414)

$ 20,812,500
$ (494,520)
$ (5,652,050)
$ (38,666)
$ 14,627,264
$ (5,850,905)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,200)
$ 21,580,230
$ (8,632,092)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,016)
$ 21,580,414
$ (8,632,166)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (11,646)
$ 21,591,784
$ (8,636,714)

$
$ (494,520)
$ (5,652,050)
$
(138)
$ (6,146,708)
$ 2,458,683

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (570,205)
$
(270)
$
$
7,500
$ (562,975)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (933,376)

$ 2,422,044

$ 4,841,561

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 12,260,604
$ 10,476,816

RSCH Stage MIRR
Sales Stage MIRR

12%
11%

25%

50%

$ (933,376)
$
-

$ 951,370
$ 1,470,674

$ 8,244,819

$ 12,401,133

$ 12,971,264

$ 12,966,716

$ (3,687,887)

75%
100%
100%
Divided Free Cash Flows
$ 1,901,748
$ 3,238,535
$ 4,871,120
$ 2,939,814
$ 5,006,284
$ 7,530,013

100%

100%

$ 5,095,065
$ 7,876,199

$ 5,093,279
$ 7,873,438

R1 Q1 C3 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,935,800)
$
$ (2,624,438)
$ 1,049,775

$ 6,937,500
$ (496,914)
$ (3,154,550)
$ (39,480)
$ 3,246,557
$ (1,298,623)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (63,646)
$ 8,913,534
$ (3,565,414)

$ 20,812,500
$ (494,520)
$ (5,652,050)
$ (38,666)
$ 14,627,264
$ (5,850,905)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,200)
$ 21,580,230
$ (8,632,092)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (23,016)
$ 21,580,414
$ (8,632,166)

$ 27,750,000
$ (494,520)
$ (5,652,050)
$ (11,646)
$ 21,591,784
$ (8,636,714)

$
$ (494,520)
$ (5,652,050)
$
(138)
$ (6,146,708)
$ 2,458,683

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (570,205)
$
(270)
$
$
7,500
$ (562,975)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (933,376)

$ 2,422,044

$ 4,841,561

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 12,598,090
$ 10,644,259

RSCH Stage MIRR
Sales Stage MIRR

13%
12%

25%

50%

$ (933,376)
$
-

$ 951,370
$ 1,470,674

$ 8,244,819

$ 12,401,133

$ 12,971,264

$ 12,966,716

$ (3,687,887)

75%
100%
100%
Divided Free Cash Flows
$ 1,901,748
$ 3,238,535
$ 4,871,120
$ 2,939,814
$ 5,006,284
$ 7,530,013

100%

100%

$ 5,095,065
$ 7,876,199

$ 5,093,279
$ 7,873,438

R1 Q2 C1 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,605,050)
$
$ (2,293,688)
$ 917,475

$ 5,100,000
$ (496,914)
$ (2,493,050)
$ (39,480)
$ 2,070,557
$ (828,223)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (63,646)
$ 6,230,784
$ (2,492,314)

$ 15,300,000
$ (494,520)
$ (4,329,050)
$ (38,666)
$ 10,437,764
$ (4,175,105)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,200)
$ 15,553,230
$ (6,221,292)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,016)
$ 15,553,414
$ (6,221,366)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (11,646)
$ 15,564,784
$ (6,225,914)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$
(138)
$ 15,576,292
$ (6,230,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (419,178)
$
(270)
$
$
7,500
$ (411,948)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (734,926)

$ 1,867,472

$ 3,382,938

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 17,858,534
$ 12,817,578

RSCH Stage MIRR
Sales Stage MIRR

41%
56%

25%

50%

$ (734,926)
$
-

$ 733,536
$ 1,133,936

$ 5,882,147

$ 8,935,960

$ 9,355,064

$ 9,350,516

$ 9,345,913

75%
100%
100%
Divided Free Cash Flows
$ 1,328,806
$ 2,310,486
$ 3,510,012
$ 2,054,133
$ 3,571,661
$ 5,425,947

100%

100%

$ 3,674,635
$ 5,680,429

$ 3,672,849
$ 5,677,668

R1 Q2 C1 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,605,050)
$
$ (2,293,688)
$ 917,475

$ 5,100,000
$ (496,914)
$ (2,493,050)
$ (39,480)
$ 2,070,557
$ (828,223)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (63,646)
$ 6,230,784
$ (2,492,314)

$ 15,300,000
$ (494,520)
$ (4,329,050)
$ (38,666)
$ 10,437,764
$ (4,175,105)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,200)
$ 15,553,230
$ (6,221,292)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,016)
$ 15,553,414
$ (6,221,366)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (11,646)
$ 15,564,784
$ (6,225,914)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$
(138)
$ 15,576,292
$ (6,230,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (419,178)
$
(270)
$
$
7,500
$ (411,948)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (734,926)

$ 1,867,472

$ 3,382,938

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 17,003,270
$ 12,393,241

RSCH Stage MIRR
Sales Stage MIRR

40%
55%

25%

50%

$ (734,926)
$
-

$ 733,536
$ 1,133,936

$ 5,882,147

$ 8,935,960

$ 9,355,064

$ 9,350,516

$ 9,345,913

75%
100%
100%
Divided Free Cash Flows
$ 1,328,806
$ 2,310,486
$ 3,510,012
$ 2,054,133
$ 3,571,661
$ 5,425,947

100%

100%

$ 3,674,635
$ 5,680,429

$ 3,672,849
$ 5,677,668

R1 Q2 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,605,050)
$
$ (2,293,688)
$ 917,475

$ 5,100,000
$ (496,914)
$ (2,493,050)
$ (39,480)
$ 2,070,557
$ (828,223)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (63,646)
$ 6,230,784
$ (2,492,314)

$ 15,300,000
$ (494,520)
$ (4,329,050)
$ (38,666)
$ 10,437,764
$ (4,175,105)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,200)
$ 15,553,230
$ (6,221,292)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,016)
$ 15,553,414
$ (6,221,366)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (11,646)
$ 15,564,784
$ (6,225,914)

$ 10,200,000
$ (494,520)
$ (4,329,050)
$
(138)
$ 5,376,292
$ (2,150,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (419,178)
$
(270)
$
$
7,500
$ (411,948)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (734,926)

$ 1,867,472

$ 3,382,938

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 12,986,064
$ 9,865,749

RSCH Stage MIRR
Sales Stage MIRR

34%
48%

25%

50%

$ (734,926)
$
-

$ 733,536
$ 1,133,936

$ 5,882,147

$ 8,935,960

$ 9,355,064

$ 9,350,516

$ 3,225,913

75%
100%
100%
Divided Free Cash Flows
$ 1,328,806
$ 2,310,486
$ 3,510,012
$ 2,054,133
$ 3,571,661
$ 5,425,947

100%

100%

$ 3,674,635
$ 5,680,429

$ 3,672,849
$ 5,677,668

R1 Q2 C2 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,605,050)
$
$ (2,293,688)
$ 917,475

$ 5,100,000
$ (496,914)
$ (2,493,050)
$ (39,480)
$ 2,070,557
$ (828,223)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (63,646)
$ 6,230,784
$ (2,492,314)

$ 15,300,000
$ (494,520)
$ (4,329,050)
$ (38,666)
$ 10,437,764
$ (4,175,105)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,200)
$ 15,553,230
$ (6,221,292)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,016)
$ 15,553,414
$ (6,221,366)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (11,646)
$ 15,564,784
$ (6,225,914)

$ 10,200,000
$ (494,520)
$ (4,329,050)
$
(138)
$ 5,376,292
$ (2,150,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (419,178)
$
(270)
$
$
7,500
$ (411,948)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (734,926)

$ 1,867,472

$ 3,382,938

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 12,690,854
$ 9,719,281

RSCH Stage MIRR
Sales Stage MIRR

33%
48%

25%

50%

$ (734,926)
$
-

$ 733,536
$ 1,133,936

$ 5,882,147

$ 8,935,960

$ 9,355,064

$ 9,350,516

$ 3,225,913

75%
100%
100%
Divided Free Cash Flows
$ 1,328,806
$ 2,310,486
$ 3,510,012
$ 2,054,133
$ 3,571,661
$ 5,425,947

100%

100%

$ 3,674,635
$ 5,680,429

$ 3,672,849
$ 5,677,668

R1 Q2 C3 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,605,050)
$
$ (2,293,688)
$ 917,475

$ 5,100,000
$ (496,914)
$ (2,493,050)
$ (39,480)
$ 2,070,557
$ (828,223)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (63,646)
$ 6,230,784
$ (2,492,314)

$ 15,300,000
$ (494,520)
$ (4,329,050)
$ (38,666)
$ 10,437,764
$ (4,175,105)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,200)
$ 15,553,230
$ (6,221,292)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,016)
$ 15,553,414
$ (6,221,366)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (11,646)
$ 15,564,784
$ (6,225,914)

$
$ (494,520)
$ (4,329,050)
$
(138)
$ (4,823,708)
$ 1,929,483

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (419,178)
$
(270)
$
$
7,500
$ (411,948)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

$ 1,867,472

$ 3,382,938

970,341

Free Cash Flow

$ (734,926)

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 8,113,595
$ 6,913,920

RSCH Stage MIRR
Sales Stage MIRR

39,480

10%
9%

25%

50%

$ (734,926)
$
-

$ 733,536
$ 1,133,936

$ 5,882,147

$ 8,935,960

$ 9,355,064

$ 9,350,516

$ (2,894,087)

75%
100%
100%
Divided Free Cash Flows
$ 1,328,806
$ 2,310,486
$ 3,510,012
$ 2,054,133
$ 3,571,661
$ 5,425,947

100%

100%

$ 3,674,635
$ 5,680,429

$ 3,672,849
$ 5,677,668

R1 Q2 C3 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,605,050)
$
$ (2,293,688)
$ 917,475

$ 5,100,000
$ (496,914)
$ (2,493,050)
$ (39,480)
$ 2,070,557
$ (828,223)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (63,646)
$ 6,230,784
$ (2,492,314)

$ 15,300,000
$ (494,520)
$ (4,329,050)
$ (38,666)
$ 10,437,764
$ (4,175,105)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,200)
$ 15,553,230
$ (6,221,292)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (23,016)
$ 15,553,414
$ (6,221,366)

$ 20,400,000
$ (494,520)
$ (4,329,050)
$ (11,646)
$ 15,564,784
$ (6,225,914)

$
$ (494,520)
$ (4,329,050)
$
(138)
$ (4,823,708)
$ 1,929,483

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (419,178)
$
(270)
$
$
7,500
$ (411,948)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

$ 1,867,472

$ 3,382,938

970,341

Free Cash Flow

$ (734,926)

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 8,378,439
$ 7,045,322

RSCH Stage MIRR
Sales Stage MIRR

39,480

11%
11%

25%

50%

$ (734,926)
$
-

$ 733,536
$ 1,133,936

$ 5,882,147

$ 8,935,960

$ 9,355,064

$ 9,350,516

$ (2,894,087)

75%
100%
100%
Divided Free Cash Flows
$ 1,328,806
$ 2,310,486
$ 3,510,012
$ 2,054,133
$ 3,571,661
$ 5,425,947

100%

100%

$ 3,674,635
$ 5,680,429

$ 3,672,849
$ 5,677,668

R1 Q3 C1 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,368,800)
$
$ (2,057,438)
$ 822,975

$ 3,787,500
$ (496,914)
$ (2,020,550)
$ (39,480)
$ 1,230,557
$ (492,223)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (63,646)
$ 4,314,534
$ (1,725,814)

$ 11,362,500
$ (494,520)
$ (3,384,050)
$ (38,666)
$ 7,445,264
$ (2,978,105)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,200)
$ 11,248,230
$ (4,499,292)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,016)
$ 11,248,414
$ (4,499,366)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (11,646)
$ 11,259,784
$ (4,503,914)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$
(138)
$ 11,271,292
$ (4,508,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (311,301)
$
(270)
$
$
7,500
$ (304,071)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (593,176)

$ 1,471,349

$ 2,341,065

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 12,388,496
$ 8,753,329

RSCH Stage MIRR
Sales Stage MIRR

37%
51%

25%
$ (593,176)
$
-

50%
$
$

577,940
893,408

$ 4,194,523

$ 6,460,837

$ 6,772,064

$ 6,767,516

$ 6,762,913

75%
100%
100%
Divided Free Cash Flows
$ 919,562
$ 1,647,593
$ 2,537,793
$ 1,421,503
$ 2,546,930
$ 3,923,044

100%

100%

$ 2,660,042
$ 4,112,022

$ 2,658,256
$ 4,109,261

R1 Q3 C1 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,368,800)
$
$ (2,057,438)
$ 822,975

$ 3,787,500
$ (496,914)
$ (2,020,550)
$ (39,480)
$ 1,230,557
$ (492,223)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (63,646)
$ 4,314,534
$ (1,725,814)

$ 11,362,500
$ (494,520)
$ (3,384,050)
$ (38,666)
$ 7,445,264
$ (2,978,105)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,200)
$ 11,248,230
$ (4,499,292)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,016)
$ 11,248,414
$ (4,499,366)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (11,646)
$ 11,259,784
$ (4,503,914)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$
(138)
$ 11,271,292
$ (4,508,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

39,480

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (311,301)
$
(270)
$
$
7,500
$ (304,071)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

970,341

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

Free Cash Flow

$ (593,176)

$ 1,471,349

$ 2,341,065

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 11,769,608
$ 8,446,269

RSCH Stage MIRR
Sales Stage MIRR

36%
50%

25%
$ (593,176)
$
-

50%
$
$

577,940
893,408

$ 4,194,523

$ 6,460,837

$ 6,772,064

$ 6,767,516

$ 6,762,913

75%
100%
100%
Divided Free Cash Flows
$ 919,562
$ 1,647,593
$ 2,537,793
$ 1,421,503
$ 2,546,930
$ 3,923,044

100%

100%

$ 2,660,042
$ 4,112,022

$ 2,658,256
$ 4,109,261

R1 Q3 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,368,800)
$
$ (2,057,438)
$ 822,975

$ 3,787,500
$ (496,914)
$ (2,020,550)
$ (39,480)
$ 1,230,557
$ (492,223)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (63,646)
$ 4,314,534
$ (1,725,814)

$ 11,362,500
$ (494,520)
$ (3,384,050)
$ (38,666)
$ 7,445,264
$ (2,978,105)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,200)
$ 11,248,230
$ (4,499,292)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,016)
$ 11,248,414
$ (4,499,366)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (11,646)
$ 11,259,784
$ (4,503,914)

$ 7,575,000
$ (494,520)
$ (3,384,050)
$
(138)
$ 3,696,292
$ (1,478,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (311,301)
$
(270)
$
$
7,500
$ (304,071)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

$ 1,471,349

$ 2,341,065

970,341

Free Cash Flow

$ (593,176)

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 8,769,971
$ 6,561,162

RSCH Stage MIRR
Sales Stage MIRR

39,480

30%
43%

25%
$ (593,176)
$
-

50%
$
$

577,940
893,408

$ 4,194,523

$ 6,460,837

$ 6,772,064

$ 6,767,516

75%
100%
100%
Divided Free Cash Flows
$ 919,562
$ 1,647,593
$ 2,537,793
$ 1,421,503
$ 2,546,930
$ 3,923,044

100%
$ 2,660,042
$ 4,112,022

$ 2,217,913
100%
$ 2,658,256
$ 4,109,261

R1 Q3 C2 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,368,800)
$
$ (2,057,438)
$ 822,975

$ 3,787,500
$ (496,914)
$ (2,020,550)
$ (39,480)
$ 1,230,557
$ (492,223)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (63,646)
$ 4,314,534
$ (1,725,814)

$ 11,362,500
$ (494,520)
$ (3,384,050)
$ (38,666)
$ 7,445,264
$ (2,978,105)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,200)
$ 11,248,230
$ (4,499,292)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,016)
$ 11,248,414
$ (4,499,366)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (11,646)
$ 11,259,784
$ (4,503,914)

$ 7,575,000
$ (494,520)
$ (3,384,050)
$
(138)
$ 3,696,292
$ (1,478,517)

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (311,301)
$
(270)
$
$
7,500
$ (304,071)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

$ 1,471,349

$ 2,341,065

970,341

Free Cash Flow

$ (593,176)

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 8,567,005
$ 6,460,461

RSCH Stage MIRR
Sales Stage MIRR

39,480

29%
42%

25%
$ (593,176)
$
-

50%
$
$

577,940
893,408

$ 4,194,523

$ 6,460,837

$ 6,772,064

$ 6,767,516

75%
100%
100%
Divided Free Cash Flows
$ 919,562
$ 1,647,593
$ 2,537,793
$ 1,421,503
$ 2,546,930
$ 3,923,044

100%
$ 2,660,042
$ 4,112,022

$ 2,217,913
100%
$ 2,658,256
$ 4,109,261

R1 Q3 C3 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,368,800)
$
$ (2,057,438)
$ 822,975

$ 3,787,500
$ (496,914)
$ (2,020,550)
$ (39,480)
$ 1,230,557
$ (492,223)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (63,646)
$ 4,314,534
$ (1,725,814)

$ 11,362,500
$ (494,520)
$ (3,384,050)
$ (38,666)
$ 7,445,264
$ (2,978,105)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,200)
$ 11,248,230
$ (4,499,292)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,016)
$ 11,248,414
$ (4,499,366)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (11,646)
$ 11,259,784
$ (4,503,914)

$
$ (494,520)
$ (3,384,050)
$
(138)
$ (3,878,708)
$ 1,551,483

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (311,301)
$
(270)
$
$
7,500
$ (304,071)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

$ 1,471,349

$ 2,341,065

970,341

Free Cash Flow

$ (593,176)

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 5,151,446
$ 4,368,995

RSCH Stage MIRR
Sales Stage MIRR

39,480

8%
8%

25%
$ (593,176)
$
-

50%
$
$

577,940
893,408

$ 4,194,523

$ 6,460,837

$ 6,772,064

$ 6,767,516

$ (2,327,087)

75%
100%
100%
Divided Free Cash Flows
$ 919,562
$ 1,647,593
$ 2,537,793
$ 1,421,503
$ 2,546,930
$ 3,923,044

100%

100%

$ 2,660,042
$ 4,112,022

$ 2,658,256
$ 4,109,261

R1 Q3 C3 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (1,368,800)
$
$ (2,057,438)
$ 822,975

$ 3,787,500
$ (496,914)
$ (2,020,550)
$ (39,480)
$ 1,230,557
$ (492,223)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (63,646)
$ 4,314,534
$ (1,725,814)

$ 11,362,500
$ (494,520)
$ (3,384,050)
$ (38,666)
$ 7,445,264
$ (2,978,105)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,200)
$ 11,248,230
$ (4,499,292)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (23,016)
$ 11,248,414
$ (4,499,366)

$ 15,150,000
$ (494,520)
$ (3,384,050)
$ (11,646)
$ 11,259,784
$ (4,503,914)

$
$ (494,520)
$ (3,384,050)
$
(138)
$ (3,878,708)
$ 1,551,483

$

$

$

$

$

23,200

$

23,016

$

11,646

$

138

-

63,646

38,666

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$ (311,301)
$
(270)
$
$
7,500
$ (304,071)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

-

$

-

$

-

$

-

$

-

$

-

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$

-

$ 1,471,349

$ 2,341,065

970,341

Free Cash Flow

$ (593,176)

% Design Capacity
RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

NPV at 25%
NPV at 30%

$ 5,364,402
$ 4,474,653

RSCH Stage MIRR
Sales Stage MIRR

39,480

9%
9%

25%
$ (593,176)
$
-

50%
$
$

577,940
893,408

$ 4,194,523

$ 6,460,837

$ 6,772,064

$ 6,767,516

$ (2,327,087)

75%
100%
100%
Divided Free Cash Flows
$ 919,562
$ 1,647,593
$ 2,537,793
$ 1,421,503
$ 2,546,930
$ 3,923,044

100%

100%

$ 2,660,042
$ 4,112,022

$ 2,658,256
$ 4,109,261

R2 Q1 C1 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,905,800)
$ (39,480)
$ (2,442,193)
$ 976,877

$ 6,937,500
$ (494,520)
$ (3,154,550)
$ (63,646)
$ 3,224,784
$ (1,289,914)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (38,666)
$ 8,938,514
$ (3,575,405)

$ 20,812,500
$ (494,520)
$ (4,403,300)
$ (23,200)
$ 15,891,480
$ (6,356,592)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (23,016)
$ 22,829,164
$ (9,131,666)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (11,646)
$ 22,840,534
$ (9,136,214)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$
$ 22,852,180
$ (9,140,872)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 2,428,311

$ 4,831,569

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,421,000)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,421,000)
$
-

NPV at 25%
NPV at 30%

$ 20,764,974
$ 14,215,614

RSCH Stage MIRR
Sales Stage MIRR

35%
64%

38,666

23,200

$ 8,987,883

$ 13,150,309

$ 13,715,966

$ 13,711,308

75%
100%
100%
Divided Free Cash Flows
$ 731,689
$ 1,455,830
$ 2,708,195
$ 1,696,622
$ 3,375,739
$ 6,279,688

100%

0%

$ 3,962,401
$ 9,187,908

$ 4,132,843
$ 9,583,124

R2 Q1 C1 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,905,800)
$ (39,480)
$ (2,442,193)
$ 976,877

$ 6,937,500
$ (494,520)
$ (3,154,550)
$ (63,646)
$ 3,224,784
$ (1,289,914)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (38,666)
$ 8,938,514
$ (3,575,405)

$ 20,812,500
$ (494,520)
$ (4,403,300)
$ (23,200)
$ 15,891,480
$ (6,356,592)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (23,016)
$ 22,829,164
$ (9,131,666)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (11,646)
$ 22,840,534
$ (9,136,214)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$
$ 22,852,180
$ (9,140,872)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 2,428,311

$ 4,831,569

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,421,000)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,421,000)
$
-

NPV at 25%
NPV at 30%

$ 19,510,223
$ 13,593,073

RSCH Stage MIRR
Sales Stage MIRR

34%
62%

38,666

23,200

$ 8,987,883

$ 13,150,309

$ 13,715,966

$ 13,711,308

75%
100%
100%
Divided Free Cash Flows
$ 731,689
$ 1,455,830
$ 2,708,195
$ 1,696,622
$ 3,375,739
$ 6,279,688

100%

0%

$ 3,962,401
$ 9,187,908

$ 4,132,843
$ 9,583,124

R2 Q1 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,905,800)
$ (39,480)
$ (2,442,193)
$ 976,877

$ 6,937,500
$ (494,520)
$ (3,154,550)
$ (63,646)
$ 3,224,784
$ (1,289,914)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (38,666)
$ 8,938,514
$ (3,575,405)

$ 20,812,500
$ (494,520)
$ (4,403,300)
$ (23,200)
$ 15,891,480
$ (6,356,592)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (23,016)
$ 22,829,164
$ (9,131,666)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (11,646)
$ 22,840,534
$ (9,136,214)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$
$ 8,977,180
$ (3,590,872)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 2,428,311

$ 4,831,569

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,421,000)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,421,000)
$
-

NPV at 25%
NPV at 30%

$ 14,136,982
$ 10,200,259

RSCH Stage MIRR
Sales Stage MIRR

28%
55%

38,666

23,200

$ 8,987,883

$ 13,150,309

$ 13,715,966

$ 5,386,308

75%
100%
100%
Divided Free Cash Flows
$ 731,689
$ 1,455,830
$ 2,708,195
$ 1,696,622
$ 3,375,739
$ 6,279,688

100%

0%

$ 3,962,401
$ 9,187,908

$ 4,132,843
$ 9,583,124

R2 Q1 C2 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,905,800)
$ (39,480)
$ (2,442,193)
$ 976,877

$ 6,937,500
$ (494,520)
$ (3,154,550)
$ (63,646)
$ 3,224,784
$ (1,289,914)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (38,666)
$ 8,938,514
$ (3,575,405)

$ 20,812,500
$ (494,520)
$ (4,403,300)
$ (23,200)
$ 15,891,480
$ (6,356,592)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (23,016)
$ 22,829,164
$ (9,131,666)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (11,646)
$ 22,840,534
$ (9,136,214)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$
$ 8,977,180
$ (3,590,872)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 2,428,311

$ 4,831,569

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,421,000)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,421,000)
$
-

NPV at 25%
NPV at 30%

$ 13,644,070
$ 9,955,702

RSCH Stage MIRR
Sales Stage MIRR

27%
54%

38,666

23,200

$ 8,987,883

$ 13,150,309

$ 13,715,966

$ 5,386,308

75%
100%
100%
Divided Free Cash Flows
$ 731,689
$ 1,455,830
$ 2,708,195
$ 1,696,622
$ 3,375,739
$ 6,279,688

100%

0%

$ 3,962,401
$ 9,187,908

$ 4,132,843
$ 9,583,124

R2 Q1 C3 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,905,800)
$ (39,480)
$ (2,442,193)
$ 976,877

$ 6,937,500
$ (494,520)
$ (3,154,550)
$ (63,646)
$ 3,224,784
$ (1,289,914)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (38,666)
$ 8,938,514
$ (3,575,405)

$ 20,812,500
$ (494,520)
$ (4,403,300)
$ (23,200)
$ 15,891,480
$ (6,356,592)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (23,016)
$ 22,829,164
$ (9,131,666)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (11,646)
$ 22,840,534
$ (9,136,214)

$
$ (494,520)
$ (4,403,300)
$
$ (4,897,820)
$ 1,959,128

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 2,428,311

$ 4,831,569

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,421,000)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,421,000)
$
-

NPV at 25%
NPV at 30%

$ 7,508,990
$ 6,184,903

RSCH Stage MIRR
Sales Stage MIRR

9%
11%

38,666

23,200

$ 8,987,883

$ 13,150,309

$ 13,715,966

$ (2,938,692)

75%
100%
100%
Divided Free Cash Flows
$ 731,689
$ 1,455,830
$ 2,708,195
$ 1,696,622
$ 3,375,739
$ 6,279,688

100%

0%

$ 3,962,401
$ 9,187,908

$ 4,132,843
$ 9,583,124

R2 Q1 C3 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,905,800)
$ (39,480)
$ (2,442,193)
$ 976,877

$ 6,937,500
$ (494,520)
$ (3,154,550)
$ (63,646)
$ 3,224,784
$ (1,289,914)

$ 13,875,000
$ (494,520)
$ (4,403,300)
$ (38,666)
$ 8,938,514
$ (3,575,405)

$ 20,812,500
$ (494,520)
$ (4,403,300)
$ (23,200)
$ 15,891,480
$ (6,356,592)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (23,016)
$ 22,829,164
$ (9,131,666)

$ 27,750,000
$ (494,520)
$ (4,403,300)
$ (11,646)
$ 22,840,534
$ (9,136,214)

$
$ (494,520)
$ (4,403,300)
$
$ (4,897,820)
$ 1,959,128

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$ (570,205)
$
$
$
$ (570,205)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 2,428,311

$ 4,831,569

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,421,000)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,421,000)
$
-

NPV at 25%
NPV at 30%

$ 7,777,916
$ 6,318,330

RSCH Stage MIRR
Sales Stage MIRR

10%
12%

38,666

23,200

$ 8,987,883

$ 13,150,309

$ 13,715,966

$ (2,938,692)

75%
100%
100%
Divided Free Cash Flows
$ 731,689
$ 1,455,830
$ 2,708,195
$ 1,696,622
$ 3,375,739
$ 6,279,688

100%

0%

$ 3,962,401
$ 9,187,908

$ 4,132,843
$ 9,583,124

R2 Q2 C1 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,575,050)
$ (39,480)
$ (2,111,443)
$ 844,577

$ 5,100,000
$ (494,520)
$ (2,493,050)
$ (63,646)
$ 2,048,784
$ (819,514)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (38,666)
$ 6,255,764
$ (2,502,305)

$ 15,300,000
$ (494,520)
$ (3,411,050)
$ (23,200)
$ 11,371,230
$ (4,548,492)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (23,016)
$ 16,471,414
$ (6,588,566)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (11,646)
$ 16,482,784
$ (6,593,114)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$
$ 16,494,430
$ (6,597,772)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,873,738

$ 3,372,947

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,222,550)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,222,550)
$
-

NPV at 25%
NPV at 30%

$ 14,373,920
$ 9,673,285

RSCH Stage MIRR
Sales Stage MIRR

31%
58%

38,666

23,200

$ 6,426,760

$ 9,486,686

$ 9,901,316

$ 9,896,658

75%
100%
100%
Divided Free Cash Flows
$ 564,588
$ 1,016,323
$ 1,936,487
$ 1,309,151
$ 2,356,623
$ 4,490,273

100%

0%

$ 2,858,492
$ 6,628,194

$ 2,983,427
$ 6,917,889

R2 Q2 C1 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,575,050)
$ (39,480)
$ (2,111,443)
$ 844,577

$ 5,100,000
$ (494,520)
$ (2,493,050)
$ (63,646)
$ 2,048,784
$ (819,514)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (38,666)
$ 6,255,764
$ (2,502,305)

$ 15,300,000
$ (494,520)
$ (3,411,050)
$ (23,200)
$ 11,371,230
$ (4,548,492)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (23,016)
$ 16,471,414
$ (6,588,566)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (11,646)
$ 16,482,784
$ (6,593,114)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$
$ 16,494,430
$ (6,597,772)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,873,738

$ 3,372,947

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,222,550)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,222,550)
$
-

NPV at 25%
NPV at 30%

$ 13,468,256
$ 9,223,942

RSCH Stage MIRR
Sales Stage MIRR

30%
56%

38,666

23,200

$ 6,426,760

$ 9,486,686

$ 9,901,316

$ 9,896,658

75%
100%
100%
Divided Free Cash Flows
$ 564,588
$ 1,016,323
$ 1,936,487
$ 1,309,151
$ 2,356,623
$ 4,490,273

100%

0%

$ 2,858,492
$ 6,628,194

$ 2,983,427
$ 6,917,889

R2 Q2 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,575,050)
$ (39,480)
$ (2,111,443)
$ 844,577

$ 5,100,000
$ (494,520)
$ (2,493,050)
$ (63,646)
$ 2,048,784
$ (819,514)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (38,666)
$ 6,255,764
$ (2,502,305)

$ 15,300,000
$ (494,520)
$ (3,411,050)
$ (23,200)
$ 11,371,230
$ (4,548,492)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (23,016)
$ 16,471,414
$ (6,588,566)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (11,646)
$ 16,482,784
$ (6,593,114)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$
$ 6,294,430
$ (2,517,772)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,873,738

$ 3,372,947

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,222,550)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,222,550)
$
-

NPV at 25%
NPV at 30%

$ 9,501,450
$ 6,721,457

RSCH Stage MIRR
Sales Stage MIRR

24%
49%

38,666

23,200

$ 6,426,760

$ 9,486,686

$ 9,901,316

$ 3,776,658

75%
100%
100%
Divided Free Cash Flows
$ 564,588
$ 1,016,323
$ 1,936,487
$ 1,309,151
$ 2,356,623
$ 4,490,273

100%

0%

$ 2,858,492
$ 6,628,194

$ 2,983,427
$ 6,917,889

R2 Q2 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,575,050)
$ (39,480)
$ (2,111,443)
$ 844,577

$ 5,100,000
$ (494,520)
$ (2,493,050)
$ (63,646)
$ 2,048,784
$ (819,514)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (38,666)
$ 6,255,764
$ (2,502,305)

$ 15,300,000
$ (494,520)
$ (3,411,050)
$ (23,200)
$ 11,371,230
$ (4,548,492)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (23,016)
$ 16,471,414
$ (6,588,566)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (11,646)
$ 16,482,784
$ (6,593,114)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$
$ 6,294,430
$ (2,517,772)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,873,738

$ 3,372,947

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,222,550)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,222,550)
$
-

NPV at 25%
NPV at 30%

$ 9,155,840
$ 6,549,983

RSCH Stage MIRR
Sales Stage MIRR

23%
48%

38,666

23,200

$ 6,426,760

$ 9,486,686

$ 9,901,316

$ 3,776,658

75%
100%
100%
Divided Free Cash Flows
$ 564,588
$ 1,016,323
$ 1,936,487
$ 1,309,151
$ 2,356,623
$ 4,490,273

100%

0%

$ 2,858,492
$ 6,628,194

$ 2,983,427
$ 6,917,889

R2 Q2 C3 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,575,050)
$ (39,480)
$ (2,111,443)
$ 844,577

$ 5,100,000
$ (494,520)
$ (2,493,050)
$ (63,646)
$ 2,048,784
$ (819,514)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (38,666)
$ 6,255,764
$ (2,502,305)

$ 15,300,000
$ (494,520)
$ (3,411,050)
$ (23,200)
$ 11,371,230
$ (4,548,492)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (23,016)
$ 16,471,414
$ (6,588,566)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (11,646)
$ 16,482,784
$ (6,593,114)

$
$ (494,520)
$ (3,411,050)
$
$ (3,905,570)
$ 1,562,228

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,873,738

$ 3,372,947

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,222,550)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,222,550)
$
-

NPV at 25%
NPV at 30%

$ 4,628,981
$ 3,769,628

RSCH Stage MIRR
Sales Stage MIRR

7%
9%

38,666

23,200

$ 6,426,760

$ 9,486,686

$ 9,901,316

$ (2,343,342)

75%
100%
100%
Divided Free Cash Flows
$ 564,588
$ 1,016,323
$ 1,936,487
$ 1,309,151
$ 2,356,623
$ 4,490,273

100%

0%

$ 2,858,492
$ 6,628,194

$ 2,983,427
$ 6,917,889

R2 Q2 C3 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,575,050)
$ (39,480)
$ (2,111,443)
$ 844,577

$ 5,100,000
$ (494,520)
$ (2,493,050)
$ (63,646)
$ 2,048,784
$ (819,514)

$ 10,200,000
$ (494,520)
$ (3,411,050)
$ (38,666)
$ 6,255,764
$ (2,502,305)

$ 15,300,000
$ (494,520)
$ (3,411,050)
$ (23,200)
$ 11,371,230
$ (4,548,492)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (23,016)
$ 16,471,414
$ (6,588,566)

$ 20,400,000
$ (494,520)
$ (3,411,050)
$ (11,646)
$ 16,482,784
$ (6,593,114)

$
$ (494,520)
$ (3,411,050)
$
$ (3,905,570)
$ 1,562,228

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$ (419,178)
$
$
$
$ (419,178)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,873,738

$ 3,372,947

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,222,550)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,222,550)
$
-

NPV at 25%
NPV at 30%

$ 4,843,425
$ 3,876,024

RSCH Stage MIRR
Sales Stage MIRR

8%
11%

38,666

23,200

$ 6,426,760

$ 9,486,686

$ 9,901,316

$ (2,343,342)

75%
100%
100%
Divided Free Cash Flows
$ 564,588
$ 1,016,323
$ 1,936,487
$ 1,309,151
$ 2,356,623
$ 4,490,273

100%

0%

$ 2,858,492
$ 6,628,194

$ 2,983,427
$ 6,917,889

R2 Q3 C1 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,338,800)
$ (39,480)
$ (1,875,193)
$ 750,077

$ 3,787,500
$ (494,520)
$ (2,020,550)
$ (63,646)
$ 1,208,784
$ (483,514)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (38,666)
$ 4,339,514
$ (1,735,805)

$ 11,362,500
$ (494,520)
$ (2,702,300)
$ (23,200)
$ 8,142,480
$ (3,256,992)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (23,016)
$ 11,930,164
$ (4,772,066)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (11,646)
$ 11,941,534
$ (4,776,614)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$
$ 11,953,180
$ (4,781,272)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,477,615

$ 2,331,073

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,080,800)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,080,800)
$
-

NPV at 25%
NPV at 30%

$ 9,808,882
$ 6,428,765

RSCH Stage MIRR
Sales Stage MIRR

27%
52%

38,666

23,200

$ 4,597,387

$ 6,869,813

$ 7,176,566

$ 7,171,908

75%
100%
100%
Divided Free Cash Flows
$ 445,229
$ 702,390
$ 1,385,267
$ 1,032,386
$ 1,628,683
$ 3,212,120

100%

0%

$ 2,069,986
$ 4,799,827

$ 2,162,416
$ 5,014,151

R2 Q3 C1 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,338,800)
$ (39,480)
$ (1,875,193)
$ 750,077

$ 3,787,500
$ (494,520)
$ (2,020,550)
$ (63,646)
$ 1,208,784
$ (483,514)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (38,666)
$ 4,339,514
$ (1,735,805)

$ 11,362,500
$ (494,520)
$ (2,702,300)
$ (23,200)
$ 8,142,480
$ (3,256,992)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (23,016)
$ 11,930,164
$ (4,772,066)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (11,646)
$ 11,941,534
$ (4,776,614)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$
$ 11,953,180
$ (4,781,272)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,477,615

$ 2,331,073

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,080,800)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,080,800)
$
-

NPV at 25%
NPV at 30%

$ 9,152,565
$ 6,103,135

RSCH Stage MIRR
Sales Stage MIRR

26%
51%

38,666

23,200

$ 4,597,387

$ 6,869,813

$ 7,176,566

$ 7,171,908

75%
100%
100%
Divided Free Cash Flows
$ 445,229
$ 702,390
$ 1,385,267
$ 1,032,386
$ 1,628,683
$ 3,212,120

100%

0%

$ 2,069,986
$ 4,799,827

$ 2,162,416
$ 5,014,151

R2 Q3 C2 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,338,800)
$ (39,480)
$ (1,875,193)
$ 750,077

$ 3,787,500
$ (494,520)
$ (2,020,550)
$ (63,646)
$ 1,208,784
$ (483,514)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (38,666)
$ 4,339,514
$ (1,735,805)

$ 11,362,500
$ (494,520)
$ (2,702,300)
$ (23,200)
$ 8,142,480
$ (3,256,992)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (23,016)
$ 11,930,164
$ (4,772,066)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (11,646)
$ 11,941,534
$ (4,776,614)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$
$ 4,378,180
$ (1,751,272)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,477,615

$ 2,331,073

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,080,800)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,080,800)
$
-

NPV at 25%
NPV at 30%

$ 6,190,356
$ 4,236,598

RSCH Stage MIRR
Sales Stage MIRR

20%
44%

38,666

23,200

$ 4,597,387

$ 6,869,813

$ 7,176,566

75%
100%
100%
Divided Free Cash Flows
$ 445,229
$ 702,390
$ 1,385,267
$ 1,032,386
$ 1,628,683
$ 3,212,120

100%
$ 2,069,986
$ 4,799,827

$ 2,626,908
0%
$ 2,162,416
$ 5,014,151

R2 Q3 C2 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,338,800)
$ (39,480)
$ (1,875,193)
$ 750,077

$ 3,787,500
$ (494,520)
$ (2,020,550)
$ (63,646)
$ 1,208,784
$ (483,514)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (38,666)
$ 4,339,514
$ (1,735,805)

$ 11,362,500
$ (494,520)
$ (2,702,300)
$ (23,200)
$ 8,142,480
$ (3,256,992)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (23,016)
$ 11,930,164
$ (4,772,066)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (11,646)
$ 11,941,534
$ (4,776,614)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$
$ 4,378,180
$ (1,751,272)

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,477,615

$ 2,331,073

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,080,800)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,080,800)
$
-

NPV at 25%
NPV at 30%

$ 5,949,963
$ 4,117,327

RSCH Stage MIRR
Sales Stage MIRR

20%
43%

38,666

23,200

$ 4,597,387

$ 6,869,813

$ 7,176,566

75%
100%
100%
Divided Free Cash Flows
$ 445,229
$ 702,390
$ 1,385,267
$ 1,032,386
$ 1,628,683
$ 3,212,120

100%
$ 2,069,986
$ 4,799,827

$ 2,626,908
0%
$ 2,162,416
$ 5,014,151

R2 Q3 C3 G1
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,338,800)
$ (39,480)
$ (1,875,193)
$ 750,077

$ 3,787,500
$ (494,520)
$ (2,020,550)
$ (63,646)
$ 1,208,784
$ (483,514)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (38,666)
$ 4,339,514
$ (1,735,805)

$ 11,362,500
$ (494,520)
$ (2,702,300)
$ (23,200)
$ 8,142,480
$ (3,256,992)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (23,016)
$ 11,930,164
$ (4,772,066)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (11,646)
$ 11,941,534
$ (4,776,614)

$
$ (494,520)
$ (2,702,300)
$
$ (3,196,820)
$ 1,278,728

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,477,615

$ 2,331,073

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,080,800)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,080,800)
$
-

NPV at 25%
NPV at 30%

$ 2,571,831
$ 2,044,431

RSCH Stage MIRR
Sales Stage MIRR

4%
7%

38,666

23,200

$ 4,597,387

$ 6,869,813

$ 7,176,566

$ (1,918,092)

75%
100%
100%
Divided Free Cash Flows
$ 445,229
$ 702,390
$ 1,385,267
$ 1,032,386
$ 1,628,683
$ 3,212,120

100%

0%

$ 2,069,986
$ 4,799,827

$ 2,162,416
$ 5,014,151

R2 Q3 C3 G2
Year
Income Statement
Revenue
Cost of Sales
Operating Costs, SG&A
Depreciation
Pre-Tax Income
Taxes (40%)
Net Income
Cash Flow Statement
Cash from Operating Activities
Plus: Depreciation
WC Change
(+)/- A/R
(+)/- Inventory
(+)/- A/P
(+)/- C/R
Total WC Change
Cash From Investing Activities
(Purchase)/Selling of Equipment
Cash From Financing Activities
Issuance of Common Stock

2012

2013

2014

2015

2016

2017

2018

2019

$
$ (688,638)
$ (687,050)
$
$ (1,375,688)
$ 550,275

$
$ (496,914)
$ (1,338,800)
$ (39,480)
$ (1,875,193)
$ 750,077

$ 3,787,500
$ (494,520)
$ (2,020,550)
$ (63,646)
$ 1,208,784
$ (483,514)

$ 7,575,000
$ (494,520)
$ (2,702,300)
$ (38,666)
$ 4,339,514
$ (1,735,805)

$ 11,362,500
$ (494,520)
$ (2,702,300)
$ (23,200)
$ 8,142,480
$ (3,256,992)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (23,016)
$ 11,930,164
$ (4,772,066)

$ 15,150,000
$ (494,520)
$ (2,702,300)
$ (11,646)
$ 11,941,534
$ (4,776,614)

$
$ (494,520)
$ (2,702,300)
$
$ (3,196,820)
$ 1,278,728

$

$

39,480

$

$

$

$

23,016

$

11,646

$

-

$
$
(135)
$
40,241
$ (171,763)
$ (131,656)

$
$
$
$
$

(270)
7,500
7,230

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$ (311,301)
$
$
$
$ (311,301)

$
$
$
$
$

-

$
$
$
$
$

-

$ (197,398)

$

(2,394)

$

$

-

$

-

$

-

$

-

$

-

$

$

$ 1,000,000

$

-

$

-

$

-

$

-

$

-

$ 1,477,615

$ 2,331,073

-

970,341

-

63,646

-

Free Cash Flow

$ (184,126)

$ (1,080,800)

% Design Capacity

25%

50%

RSCH Stage Investors (39.3% Equity)
Sales Stage Investors (60.7% Equity)

0%
Investment
$ (970,341)
$ (1,000,000)

$ (184,126)
$
-

$ (1,080,800)
$
-

NPV at 25%
NPV at 30%

$ 2,747,360
$ 2,131,519

RSCH Stage MIRR
Sales Stage MIRR

5%
9%

38,666

23,200

$ 4,597,387

$ 6,869,813

$ 7,176,566

$ (1,918,092)

75%
100%
100%
Divided Free Cash Flows
$ 445,229
$ 702,390
$ 1,385,267
$ 1,032,386
$ 1,628,683
$ 3,212,120

100%

0%

$ 2,069,986
$ 4,799,827

$ 2,162,416
$ 5,014,151
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